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Chronic obstructive pulmonary disease (COPD) is the third leading cause of death 
in the United States. Cigarette smoke (CS) is the leading cause of emphysema, a 
component of COPD, which is characterized by airway inflammation and destruction of 
alveolar sacs and gas exchange impairment. The pathogenesis of emphysema remains to 
be elucidated, but CS-induced endothelial cell (EC) apoptosis is an established 
mechanism that is both necessary and sufficient to cause emphysematous remodeling. 
Fallica et al have previously shown that expression of the cytokine macrophage migration 
inhibitory factor (MIF) is altered in patients with COPD and is significantly attenuated in 
advanced stage COPD. Preclinical data reveals that chronic CS exposure antagonizes 
MIF gene expression in vivo. Furthermore, MIF deficient mice have increased ROS 
production, DNA damage and exacerbated emphysematous tissue remodeling. Damico et 
al have also previously shown that EC apoptosis is enhanced in the absence MIF in the 
context of CS. Taken together, these provide evidence for MIF’s cytoprotective role in 
the context of CS-induced oxidative stress.  MIF has also been shown to antagonize 
oxidant-mediated injury in other models, which may be linked to its capacity to impact 
the antioxidant regulator and transcription factor, nuclear factor erythroid 2-related factor 
2 (Nrf2). The goal of this thesis is to elucidate the mechanisms by which MIF is 
impacting antioxidant responses during CS-induced oxidative stress.  
Our results reported here demonstrate that MIF is a necessary mediator of Nrf2-
dependent transcription in vivo in a model of CS-induced oxidative injury and 
emphysematous remodeling. We then demonstrated in primary EC in vitro that 
exogenous MIF was sufficient to drive antioxidant response element (ARE)-driven 
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transcriptional activity and stabilize Nrf2 protein via a proteasomal-dependent 
mechanism. There are two recognized regulators of Nrf2 stability. The Kelch-like ECH-
associated protein 1 (KEAP1)-Cullin3 (CUL3) ligase complex dynamically regulates 
Nrf2 by targeting it for proteasomal-mediated degradation under basal conditions. In 
contrast, DJ-1 has been demonstrated to directly and indirectly promote Nrf2 stability in 
select models. Given that MIF capacity to interfer with Nrf2’s proteasomal-mediated 
degradation, we sought to understand MIF’s effects on the members and regulators of the 
KEAP1-CUL3 ligase complex, as well as DJ-1. 
The CUL3 component of the KEAP1-CUL3 complex is regulated by two 
established mechanisms 1) post-translational modification (PTM) of CUL3 and 2) via 
inhibitory protein-protein interactions with CAND1. The recognized PTM of CUL3 
involves the cyclic addition and removal of a small ubiquitin-like molecule, NEDD8, 
through a process known as neddylation and deneddylation, respectively. We found that 
chronic CS exposure in vivo was associated with increased CUL3 neddylation in the lung. 
This observation is lost in MIF deficient animals exposed to CS, implicating MIF as a 
regulator of CUL3 PTM in the context of CS-induced oxidative injury. To test the 
hypothesis that the observed CUL3 neddylation status was sufficient to alter Nrf2 
activity, we altered the PTM of CUL3 by ectopic expression of the neddylase, UBC12. 
This was sufficient to enhance CUL3 neddylation and, importantly, drive Nrf2 expression 
and ARE activity, supporting a model in which MIF stabilizes Nrf2 in the context of CS 
in vivo via alterations in CUL3 neddylation status. MIF however, was neither necessary 
nor sufficient to alter CUL3 neddylation in vitro, suggesting that the mechanism was 
indirect or contextual. We then investigated the effects of MIF on the known CUL3 
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inhibitor, CAND1 and determined that MIF is a novel positive regulator of CAND1 
expression. Further, over expression of CAND1 was sufficient to stabilized Nrf2 in ECs 
in vitro.  
 In addition to negative Nrf2 regulators, we also explored MIF’s effects on the DJ-
1. DJ-1 is a redox-sensitive molecule that is important in mediating antioxidant responses 
and antagonizing ROS in neuronal cells. We tested the hypothesis that MIF-mediated 
Nrf2 stability via a DJ-1-dependent mechanism. Despite reports of DJ-1 regulating Nrf2 
in pulmonary epthelial cells (EpiCs) in vitro, we found that DJ-1 was not sufficient for 
Nrf2 stabilization in EC in vitro, suggesting that the molecular mechanisms of Nrf2 
stabilization may differ between pulmonary EC and EpiCs. In conclusion, we provide 
evidence that MIF’s ability to enhance Nrf2 stability as a novel positive regulator of 
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1. Chronic Obstructive Pulmonary Disease (COPD) 
 
1.1 Definition 
Chronic obstructive pulmonary disease (COPD) is a progressive and largely 
irreversible disease that remains to be a major public health problem. It is a 
heterogeneous disease with many comorbidities that is comprised of chronic bronchitis, 
emphysema and non-reversible asthma (Izumi 2003). COPD is a term that describes a 
group of pulmonary diseases, characterized by slow progression of flow airflow 
obstruction, gas exchange impairment, air trapping and mucus hyper-secretion (Hogg and 
Timens 2009). Emphysema and chronic bronchitis are the two main types of COPD. 
Chronic bronchitis is defined as the presence of a productive cough on most days for 
three months in two consecutive years independent of other causes of chronic cough such 
as tuberculosis and heart failure. The pathological features of chronic bronchitis include, 
goblet cell hyperplasia, inflammation and hypertrophy, which ultimately lead to fibrosis 
of the upper airways (Hoidal 1994, Nelson and Mason 2000). Emphysema is defined 
histologically and is characterized by progressive and irreversible enlargement of 
airspace due to the destruction of alveolar sacs (reviewed in (Fischer, Pavlisko et al. 
2011). Patients can exhibit a mix of different characteristic features of both emphysema 
and chronic bronchitis, but ultimately all display airway obstruction.  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was 
launched in 1997 to raise awareness about chronic COPD and set a criterion for 
classification. It utilizes evidence-based documents to set guidelines for detection, 
treatment and management. According to GOLD, COPD is defined as the following: 
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“a preventable and treatable disease characterized by persistent airflow limitation that is 
usually progressive and associated with enhanced chronic inflammatory response in the 
airways and the lung to hazardous particles and gases. Exacerbations and comorbidities 
contribute to the severity in individual patients.” 
The GOLD criteria have been established as a way of classifying disease severity base on 
airflow limitation. The GOLD criteria use spirometry as an assessment of pulmonary 
function. It classifies disease severity as a ratio of forced expiratory volume in 1 second 
(FEV1) to forced vital capacity (FVC). An FEV1/FVC of less than 0.7 indicates airway 
obstruction. The GOLD definition has been adopted by both, the American Thoracic 
Society (ATS) as well as the European Respiratory Society (ERS) (Holman, 1966).  
 
1.2 Emphysema Definition 
 Emphysema is a component of COPD that is characterized by the permanent 
enlargement of the air spaces distal to the terminal bronchioles due to the progressive 
destruction of the alveolar walls as a consequence of damage to the connective tissue, 
ultimately leading to impaired gas exchange (reviewed in (Cantin and Crystal, 1985)). It 
is a disease of the distal to terminal bronchioles that is defined as: “a condition of the 
lung characterized by permanent abnormal enlargement of the respiratory airspaces, 
accompanied by destruction of their walls without obvious fibrosis” (American Thoracic 
Society, 1962). 
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 1.3 Epidemiology & Global Burden of Disease  
The epidemiology of COPD has been difficult to characterize due to disease 
heterogeneity and misclassification. It is established that COPD is one of the leading 
causes of death in both low and high-income countries (Celli, MacNee et al. 2004). 
According to the National Institute of Health, COPD was the third leading cause of death 
in 2014 (Mannino and Buist 2007) and estimated 15.7 million (6.4%) Americans have 
reported being diagnosed with it (Raherison and Girodet 2009). It is also the fifth leading 
cause of years lost to mortality or disability-adjusted life years. The estimated prevalence 
of COPD in the US, based on spirometry (FEV1<60-65% of predicted value) was about 
4–6% and 1–3% of adult white males and females, respectively (National Center for 
Health Statistics, (2016)). The prevalence of COPD is double in males as compared to 
females, it is expected that this discrepancy will diminish. This is due to the fact that 
more women have taken up smoking in developed countries. An increase in biomass 
exposure in non-smoking women will also reduce the gender-driven differences of COPD 
prevalence (Mannino and Buist 2007). The World Health Organization estimated that 
COPD accounted for about 30 million deaths, globally and 3 million deaths in North 
America. The estimated prevalence of COPD is 5-15% (Higgins and Thom, 1989).     
 There are many comorbidities associated with COPD that impact multiple organ 
systems, such as the cardiovascular and musculoskeletal system, which further 
complicate disease management and drive economic burden (Barnes and Celli 2009, 
Barnes, Calverley et al. 2013). Currently, management and treatment of COPD is about 
$36 billion, with projected directed costs being about $49 billion by 2020. Furthermore, 
COPD contributed to about 16.4 million workdays costing about $3.9 billion lost in 
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absenteeism in 2014 (Center for Disease Control, 2014 (Murray and Lopez 1997)). In 
conclusion, COPD is a costly disease that accounts for increased health expenses and 
time lost in the workplace.                          
 
1.4 Causes & Risk Factors 
 
 While smoking remains to be the number one risk factor for COPD, as it 
contributes to about 80-90% of COPD in the US (US Department of Health and Human 
Services, 2002), the presence of disease in non/never smokers indicates other risk factors 
that are responsible for disease manifestation. COPD is a multifactorial disease that is the 
result of interplay between genetics and environmental factors (Eisner, Anthonisen et al 
2011). 
 
1.3.1 Environmental Risk Factors 
Chronic exposure to CS remains the number one risk factor for developing 
emphysema. Cigarettes are comprised of 600 ingredients that release complex mixture of 
over 4,000 chemicals when burned to produce CS (Department of Health and Human 
Services, 1964).  CS is a heterogeneous and potent source of oxidants that represent about 
twenty-two different classes of compounds (Borgerding and Klus 2005). It is comprised 
of a particulate phase, which is condensed liquid particles suspended in a volatile/semi-
volatile gaseous phase (Church and Pryor 1985). Each puff of mainstream CS results in 
the inhalation of about 10
15
 free radicals (Valavanidis, Vlachogianni et al. 2009). The 
exact mechanism by which CS induces lung damage is still unclear, but its capacity to 
promote chronic inflammation has been well established as a major contributor in COPD 
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pathogenesis (Macnee 2007). Incidences of COPD in never-smoked individuals provide 
evidence for other risk factors that play a role the development of disease (Zeng, Sun et 
al. 2012).  
According to the Third National Health and Nutrition Examination Survey, never 
smokers represented 23% of burden of disease in the US (Celli, Halbert et al. 2005). The 
effects of first-hand smoking on the development of disease differ according to regions 
and studies. The range by which smoking serves as the major contributor of COPD is 9.7-
97.9%, which provides evidence for the effects of environmental and other risk factors 
(reviewed in (Eisner, Anthonisen et al. 2010)). There is a lot of evidence of 
environmental exposures serving as risk factors for COPD development and it is not a 
new concept. Phillips first identified the role of occupational and industrial exposure in 
chronic bronchitis in 1963. He not only shed light on the effects of air pollution on 
bronchitis exacerbation, but he also introduced the idea that environmental exposures can 
be a cause of respiratory disease (Phillips 1963). Other environmental causes of COPD 
independent of smoking include: indoor air pollution (Salvi and Barnes, 2010 (Gunen, 
Hacievliyagil et al. 2008), outdoor air pollution (Kunzli, Kaiser et al. 2000, Schikowski, 
Sugiri et al. 2005), socioeconomic status and chronic asthma (Husman, Koskenvuo et al. 
1987, Kogevinas, Anto et al. 1998).  
 
1.3.2 Genetic Risk Factors 
 Genetics plays an important role in the development of COPD. While smoking is 
the leading cause of COPD, only about 15-20% of smokers develop disease, which 
suggests that there are differences in susceptibility which are genetic in nature 
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(Louhelainen, Rytila et al. 2009). Larson et al showed that COPD tends to aggregate in 
families (Larson, Barman et al. 1970). Furthermore, a monozygotic twin study had shown 
the potential influence of genetics on pulmonary function (Man and Zamel 1976). While 
linkage studies show aggregation of the disease among families, they are limited in their 
capacity to separate genetics from shared familial environments. The genes that play a 
role in the development of COPD are ones that affect the proteases and anti-proteases, 
inflammation, metabolism of CS-derived toxins as well as the mucocilliary clearance 
system in the lung. 
An established gene, whose mutation or deficiency does contribute to the 
manifestation of COPD is the SERPINA1 gene, which encodes for alpha-1 antitrypsin 
(AAT) (Webb, Hyde et al. 1973), an anti-protease. Imbalance of proteases and anti-
proteases drives parenchymal lung damage, ultimately resulting in emphysematous 
remodeling. SERPINA1 is activated under conditions of oxidative stress. Laurell and 
Eriksson first identified the protein in an electrophoresis experiment in 1963 and noted 
that its loss is associated with early-onset COPD (Laurell and Erickson, 1963, American 
Thoracic Society/European Respiratory Society, 2003). AAT is a glycoprotein (52 kDal) 
that is secreted by many different cell types (Geboes, Ray et al. 1982). Once secreted, it 
goes into circulation where it can inhibit a number of proteases, including excess 
neutrophil elastases, pancreatic trypsin, granzyme-B and many other circulating proteases 
(Bergin, Reeves et al. 2010). 
In addition to pulmonary tissue remodeling, the effective metabolism of noxious 
chemicals, like those derived from CS or air pollution is an important mechanism that 
protects the lungs from CS-induced. Furthermore, COPD is also the result of an 
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imbalance of oxidants and antioxidants that lead to alterations of the redox status in the 
lung. Therefore, compromised or inefficient xenobiotic metabolism can lead to increased 
ROS production and oxidative injury (reviewed in (MacNee 2000, Sandford and Pare 
2000)). Inherited deficiencies in the xenobiotic metabolizing enzymes such as, 
glutathione S-transferases (GSTs) (Ishii, Matsuse et al. 1999) and cytochrome p450s 
(Cantlay, Lamb et al. 1995) can increase individual susceptibility to the development of 
COPD. These enzymes are critical in remediating the effects of free radicals and 
electrophillic compounds, such as those found in CS (Sheehan, Meade et al. 2001). GSTs 
are highly polymorphic therefore their detoxifying capacity is heavily dependent on the 
inherited genotype. Dey et al. found that the GSTM1 null genotype is significantly linked 
to COPD susceptibility and demonstrated that it is a risk factor for smokers who live in 
close proximity to coal mines (Dey, Gogoi et al. 2014). Other drug metabolizing enzymes 
that can potentially influence the susceptibility of COPD are cytochrome p450 family of 
enzymes. Like GSTs, these enzymes are highly polymorphic and a meta-analysis by 
Wang et al., found that polymorphic variants of CYP1A1 may contribute to differences in 
COPD susceptibility (Wang, Chen et al. 2015). These provide evidence for the 
importance of roles of genetic polymorphism in modulating individual susceptibility to 
the development of COPD.  
Ultimately, only a fraction of smokers develop COPD. This indicates that genetic 
polymorphisms play an important role in modulating an individual’s risk in developing 
disease. Genetic variation in the activities and expression of genes that play roles in 
oxidative stress, detoxification, inflammation and remodeling are important in 
understanding disease susceptibility.   
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1.5 Cellular and Molecular Events in the Pathogenesis of Emphysema 
 
 Emphysema is a complex, multifactorial disease. Pathologically, it caused by 
two major processes, narrowing and remodeling of the small airways and destruction of 
the lung parenchyma with subsequent alveolar destruction (Hogg, Chu et al. 2004). 
Chronic exposures to sources of oxidative stress like those found in cigarette smoke and 
environmental pollutants can initiate disease, which is then perpetuated by abnormal 
immune responses, alterations in lung tissue repair and attenuated antioxidant responses. 
There are three cellular and molecular events that form a triad, which drives disease 
pathogenesis. These include increased oxidative stress, which causes an imbalance 
between oxidants and antioxidants, chronic inflammation and protease/anti-protease 
imbalance. These events are all inter-related and interconnected as they can all cause and 
promote one another. Collectively, they lead to increased apoptosis, which perpetuates 
disease in the context of emphysema. This dissertation will focus on the effects of 
oxidative stress and the ultimate effects on cell apoptosis as driver for emphysematous 
remodeling.  
 
 1.5.1 Oxidative Stress and Initiation of Disease  
 Oxidant toxicity in the lung is the result of prolonged exposure to noxious 
chemicals such as those found in cigarette smoke and other environmental exposures that 
perpetuate the state of increased oxidative stress. There is mounting evidence that 
markers of oxidative stress are elevated in patients with COPD as compared to their 
healthy counterparts. These markers of oxidative stress have been characterized in the 
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setting of increased oxidative burden among smokers that can be obtained from blood, 
sputum and bronchoalveolar lavage fluid (BAL). These include markers of DNA damage, 
concentration of oxidized proteins, lipid peroxidation and generation of ROS (Liu, 
Sandrini et al. 2007). Exhaled breath condensate is another method employed to assess 
the concentrations of limited free radicals such as reactive nitrogen species (RNS), 
hydrogen peroxide and 8-isprostane can be observed in exhaled breath condensate (EBC) 
of individuals with COPD (Dekhuijzen, Aben et al. 1996, Montuschi, Collins et al. 2000, 
Corradi, Montuschi et al. 2001).  
 COPD initiation (and progression) is the result of chronic exposure to oxidants 
that overwhelm antioxidant capacity in the lung. Oxidant exposures, like CS can 
penetrate the epithelial lining fluid, an important barrier to protect the lungs from the 
environment and direct injure underlying epithelial cells (EpiCs). Interestingly, once the 
disease is initiated, progression persists even after the cessation of CS exposure, 
implicating the perpetuation of ROS and free radical formation in the absence of CS. 
Although the reasons by the pathogenesis continue in spite of the removal of the 
environmental insult remain unclear, some evidence suggests that particles in the lung are 
not cleared completely and thus continue driving ROS (Louhelainen, Rytila et al. 2009). 
CS induces systematic changes by promoting vascular dysfunction. CS also activates 
signaling pathways and kinases, leading to the release of mediators ultimately, driving 
inflammation (Rahman 2005). In addition to directly measuring ROS and their effects on 
biological molecules, quantifying antioxidant capacity and activity provide important 
information on the lung’s ability to neutralize the effects of ROS.  
 The lung is equipped with antioxidant machinery that can antagonize the effects 
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of oxidants like those found in CS. However, disease occurs when this 
oxidant/antioxidant homeostasis is imbalanced, which can cause significant cellular 
damage, activation of immune cells and promotion of inflammation (reviewed in (Lee 
and Thomas 2009)). The lung contains both enzymatic and non-enzymatic antioxidant 
that neutralize the effects of free radicals. Oxidants activate and stabilize, nuclear factor 
erythroid 2–related factor 2 (Nrf2), which then translocates to the nucleus where it can 
activate genes encoding antioxidants. One gene that is upregulated by Nrf2, is reduced 
glutathione (GSH), which is a non-enzymatic antioxidant that becomes oxidized to its 
dimeric form, thereby dampening free radicals (Smith, Houston et al. 1993). There is 
evidence that CS can deplete both the concentration and the activity of antioxidants. Not 
only do patients with COPD have altered levels of antioxidants (Tavilani, Nadi et al. 
2012), but some individuals have genetic polymorphisms encode for suboptimal protein 
function and are associated with reduced lung function. Splice variants of the enzyme 
SOD3 have been associated with decreased FEV1 and increased susceptibility to oxidant-
mediated lung injury (Bowler, Nicks et al. 2004, Reinhard, Meyer et al. 2005).  
 
1.6 Cellular Apoptosis & Emphysema Pathogenesis  
 
 The “microvascular hypothesis” of COPD has been gaining attention as a 
mechanism of disease pathogenesis. The pulmonary microvasculature is necessary in 
maintaining the integrity of alveolar septa (Liebow 1959). This hypothesis states that 
progressive loss of alveolar structure is caused by direct insults to lung microvasculature, 
which drives emphysematous tissue remodeling (Barnes 2009, Mackay, Dodd et al. 
2013). Histological observations in the emphysematous lung showed significantly 
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decreased pulmonary capillaries of the alveolar septa and thin alveolar walls, which led to 
the development of this hypothesis (Liebow 1959). It serves as an alternative to the 
classical inflammation, protease-antiprotease imbalance hypothesis (Shapiro, 2000), 
which fails to fully address all of the causes of progressive lung tissue loss in 
emphysema. More recent clinical, translational and preclinical data have all provided 
evidence for the loss of pulmonary vasculature in emphysematous destruction. Further, 
enhanced apoptosis is an established cause of the disappearance of the alveolar septa 
(Tuder, Zhen et al. 2003).    
   
 
 1.6.1 The Role of Apoptosis in Emphysematous Remodeling 
 There is a growing body of evidence that demonstrates apoptosis as an important 
contributor in emphysematous destruction (Schmidt and Tuder 2010). By definition 
apoptosis is a highly regulated process that describes the collapse of cell due to activation 
of the of an intracellular death program. Morphologically, it is characterized by cell 
shrinkage, cytoskeletal collapse, membrane blebbing and DNA fragmentation (Kerr, 
Wyllie et al. 1972). Both EC and EpiC apoptosis are enhanced in emphysematous 
remodeling (Kasahara, Tuder et al. 2001). In addition to apoptosis of structural cells that 
are importance in the maintenance of the integrity of the alveolar septa, immune cells 
have also been demonstrated to undergo cell death (Hodge, Hodge et al. 2005). Apoptosis 
initiates damage in a number of ways. EC and EpiC cell death contributes to 
compromised alveolar structure and function. Concurrent impairment of efficient 
phagocytosis by neutrophils and monocytes leads to release of pro-inflammatory 
mediators from apoptotic cells. Inefficient mechanisms of cell clearance also prevent 
 13 
normal cell replacement (Vandivier, Henson et al. 2006).  
 CS can initiate cell apoptosis through its capacity to induce double-stranded 
breaks (DSBs). Increased DSBs lead to the activation of the kinase, ataxia telangiectasia 
mutated (ATM). ATM directly phosphorylates the histone 2S (HA)X (ϒH2AX), 
ultimately leading to the recruitment and activation of pro-apoptotic downstream effector 
molecules such as p53 (Canman, Lim et al. 1998, Huang, Halicka et al. 2004). The 
presence of the DSBs, as indicated by ϒH2AX foci in alveolar EpiC and ECs was 
enhanced in the lung of COPD patients as compared to the non-COPD smokers and non-
smokers. Amplified DSBs was also associated with increased apoptosis in these lungs 
(Aoshiba, Zhou et al. 2012). Increased levels of caspase-cleaved cytokeratin-18, a 
product of apoptotic process have also been correlated with COPD progression (Hacker, 
Lambers et al. 2009).  
 The importance of EC in the maintenance of lung homeostasis has been widely 
demonstrated in the context of COPD, as ECs play a critical role in not only regulating 
vascular function, but also in maintaining the integrity of the alveolar septa. The 
microvasculature, which is composed mainly of ECs is responsible for maintain proper 
alveoli function and is indispensable for EpiC survival (Kasahara, Tuder et al. 2001). 
There are different models of emphysema that demonstrate the importance of EC 
homeostasis in the context of emphysematous remodeling.  
 EC apoptosis in the pathogenesis of emphysema was demonstrated by Giordano 
and colleagues. They selectively targeted capillary ECs for apoptosis via a peptide-
mediated method and induced emphysematous-like tissue destruction in the murine lung 
(Giordano, Lahdenranta et al. 2008). Another study showed that induced EC apoptosis by 
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blocking the vascular endothelial growth factor (VEGF) receptor 2 with the 
pharmacological inhibitor, SU5416 promoted alveolar cell apoptosis and emphysematous 
tissue damage. Furthermore, inhibiting apoptosis with a caspase inhibitor, antagonized 
emphysematous tissue destruction, implicating that apoptosis is the specific mechanism 
that is contributing to remodeling (Kasahara, Tuder et al. 2000). VEGF is critical in EC 
survival, as it regulates the Akt pathway and downstream anti-apoptotic proteins (Gerber, 
McMurtrey et al. 1998). It is highly expressed in the lungs and has been differentially 
expressed in patients with COPD. They demonstrated diminished expression of this 
angiogenic molecule (Marwick, Stevenson et al. 2006). Additionally, CS exposure 
suppresses VEGF expression in murine lungs (Wright, Tai et al. 2002). Expression of 
endothelial nitrous oxide synthase (eNOS) is another marker of has been identified to be 
diminished in COPD patients (Nana-Sinkam, Lee et al. 2007). Circulating EC progenitor 
cells (CD34+ cells), which are crucial in maintaining lung repair mechanisms, show a 3-
fold decrease in COPD patients as compared to their healthy counterparts. Although it is 
still unclear if it is a causal phenomenon or the result of disease, it provides evidence for 
altered vascular homeostasis and maintenance in the context of disease (Palange, Testa et 
al. 2006). Toru and Kubo have also noted the role of circulating microparticles as 
markers for disease pathogenesis. Microparticles are the result of membrane budding 
released when different cell types including red blood cells, leukocytes and ECs undergo 
apoptosis in response to inflammation or injury (Rubin, Canellini et al. 2012). Patients 
with COPD displayed significantly elevated endothelial cell MP (EMPs) levels as 
compared to former smokers (Takahashi, Kobayashi et al. 2012). Another larger study 
stratified patients with COPD according to the GOLD stage progression and has found 
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that certain types of EMPs correlate with disease severity, implicating EC apoptosis as a 
marker for disease (Thomashow, Shimbo et al. 2013). Ultimately, these provide evidence 
for ECs as having an indispensable role in maintaining lung homeostasis. Furthermore, 
inducing EC apoptosis is sufficient to damage the lung parenchyma, ultimately propelling 
















2. Macrophage Migration Inhibitory Factor (MIF) 
 
 Macrophage migration inhibitory factor (MIF) is a pleitropic cytokine that is 
involved in many different cellular functions. In humans, it is encoded by a single Mif 
gene, located on Chromosome 22. It was initially discovered as a lymphocytic cytokine 
that inhibited macrophages, but growing literature has demonstrated that MIF is 
expressed and secreted by most cell types in response to stress (Bernhagen, Calandra et 
al. 1993). The literature surrounding this cytokine has evolved to elucidate its function as 
an unconventional cytokine as it has hormonal activities and enzymatic activities in 
addition to its proinflammatory capacity.  
 
2.1 Structure & Function  
 
  MIF is 12.5-kDa protein that consists of 115 amino acid. It was one of the first 
cytokines discovered in a delayed-type hypersensitivity study as an inhibitor of 
macrophages secreted from T lymphocyte (Bloom and Bennett 1966). Its functions were 
made clearer in the 1990’s when it was identified as an immune-regulatory cytokine that 
was secreted and expressed by many different cell types. It was found to inhibit the 
immunosuppressive effects of glucocorticoids, released in response to many different 
types of stimuli including lipopolysaccharides, endotoxins and malaria parasite (Donnelly 
and Bucala 1997, Dobson, Augustijn et al. 2009). MIF can exist as a monomer, 
homodimer or as a homotrimer. Its homotrimeric structure consists of six α-helices 
surrounded by three β-sheets forming a barrel–shaped protein. Interestingly, MIF is one 
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of few proteins that contain a channel that spans the length of the entire protein. The 
channel has a region of positive electrostatic potential, potentially facilitating its 
interaction with negatively charged proteins or DNA (Sun, Bernhagen et al. 1996). While 
MIF exists as a homotrimer, under normal solution conditions, it has the potential to exist 
as a monomer and homodimer depending on the solvent and concentration (Philo, Yang 
et al. 2004). Monomer MIF contains two α-helices and six β-sheets (Sun, Bernhagen et 
al. 1996). MIF binds to its receptor CD74 in its trimeric form (Leng, Metz et al. 2003, 
Fan, Rajasekaran et al. 2013). Furthermore, Reidy et al showed that the oligomeric state 
of MIF drives its function and ability to induce inflammatory responses. They showed 
that trimeric MIF is functionally active and mediates host defense inflammation in 
response to bacterial infection (Reidy, Rittenberg et al. 2013).  
 
2.1.1 MIF’s Cysteine Residues Confer its Oxidoreductase/Enzymatic Capacity  
 MIF contains three critical cysteine residues (Cys57, Cy60 and Cys80) that exist as 
free thiol groups (Sun, Bernhagen et al. 1996). In a cross-linkage experiment completed 
by Mischke colleagues, they found that Cys60 is necessary for MIF’s oligomerization, as 
its substitution with Ser significantly decreased the proportion of homodimers and 
homotrimers (Mischke, Kleemann et al. 1998). Additionally, these cysteine residues 
confer MIF’s oxidoreducatse activity. Mutational studies have revealed that Cys60 being 
essential for MIF’s oxidoreductase activity, while Cy57 is partially responsible for 
mediating its proper function (Kleemann, Kapurniotu et al. 1999). MIF contains the 
conserved Cys57-Ala-Leu-Cys60 (CALC or CXXC) motif that is found in other thiol-
oxidoreductase proteins such as thioredoxin (Trx). It has been shown the MIF’s CALC 
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motif can catalyze the reduction of small molecules such as insulin and 2-
hydroxyethyldisulfide. Furthermore, these two residues play a critical role in regulating 
MIF’s macrophage-activating capacity (Kleemann, Kapurniotu et al. 1998). There is 
some evidence to suggest that this motif can also regulate intramolecular disulfide bond 
formation (Sun, Bernhagen et al. 1996). The role of MIF in mediating oxidant injuries 
has been elucidated in the context of ischemic reperfusion models. MIF
-/- 
mice have 
increased susceptibility to I/R-induce cardiac injury, which is mediated by an increase in 
oxidative stress burden, implicating MIF’s role in mediating blunting the effects of ROS 
(Koga, Kenessey et al. 2011). In addition to mediating oxidation-reduction reactions, 
there is some evidence to suggest that MIF’s CALC motif is important in mediating other 
physiological functions, such as regulating MIF’s glucocorticoid inhibitory capacity, 
potentially through modulation of protein-receptor interaction (Nguyen, Beck et al. 
2003). It may however, also impact p53 activity by directly and indirectly regulating the 
redox status of the cell and reducing intercellular oxidative stress (Nguyen, Lue et al. 
2003).  
 MIF does not behave like a conventional cytokine, in that its enzymatic 
capabilities are functionally homologous to those found in TPOR superfamily of proteins. 
In addition to its oxidoreductase ability, it also has tautoisomerase activity. Melanin 
biosynthesis requires the conversion of the non-physiological compound 2-carboxy-2,3-
dihydroindole-5,6-quinone (dopachrome) into 5,6-di- hydroxyindole-2-carboxylic acid 
(DHICA), which was discovered to be catalyzed by MIF (Rosengren, Bucala et al. 1996). 
It also catalyzes the tautomerization of phenylpyruvate, which is also believed to be 
biologically insignificant because of its intracellular location and concentration 
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(Rosengren, Aman et al. 1997). Mutational studies have revealed that Pro1 is necessary 
for this activity (Swope, Sun et al. 1998). While targeting MIF’s enzymatic capacity may 
serve as an attractive therapeutic target, the physiological significance of this enzymatic 
activity is still unclear. 
2.1.2 Post-translational Modification & Activity  
MIF’s third cysteine residue, Cys81 is important in mediating MIF’s post-
translational modification and its interaction (Luedike, Hendgen-Cotta et al. 2012) with 
the tumor suppressing transcription factor, p53. Cys81 is necessary for MIF’s interaction 
with p53, mutation of this residue to serine interrupts MIF’s binding ability to p53 (Jung, 
Seong et al. 2008). Cys81 also has the capacity to regulate MIF’s oxidoreductase activity, 
indirectly. This residue can be post-translationally modified by the addition of an s-
nitrosylation group (S-NO). MIF
-/- 
mice display enhanced ischemic/reperfusion (I/R)-
induced injury in the heart. The treatment of these mice with recombinant MIF (rMIF) 
attenuated the effects of IR-induced injury. The cardioprotection is lost in Cys81Ser-MIF 
mutant-treated mice, demonstrating the importance of S-NO-mediated cardiac protection 
in the context of I/R (Luedike, Hendgen-Cotta et al. 2012).  
 
2.1.3 Secretion & Expression 
MIF is constitutively expressed by many different cell types. It is an important 
mediator of inflammation and is thus expressed by different types of immune cells 
including monocytes, macrophages, mast cells and dendritic cells. It is also expressed by 
structural cells such as, EC, EpiCs and fibroblasts (reviewed in (Calandra, Bernhagen et 
al. 1994, Calandra and Roger 2003)). It has been shown to bind to the CD74 receptor, 
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activating ERK signaling pathways ultimately, overriding the anti-inflammatory 
functions of glucocorticoids (Mitchell, Metz et al. 1999, Leng, Metz et al. 2003). MIF 
may also mediate its biological effects via endocytosis, a receptor-independent 
mechanism (Kleemann, Hausser et al. 2000). Given MIF’s critical role in modulating 
immune responses it is ubiquitously expressed throughout most organs tissues of the 
body, but highly expressed in tissues that interface with the environment, such as the 
lungs and gut and expressed in organs that are important regulating immunity, including 
the spleen, lymph nodes, thymus and bone (The Human Protein Atlas, accessed June 
2017).  
MIF’s role as a potent regulator of inflammation and immune responses to 
varying microbial toxins, infections, other proinflammatory cytokines and 
glucocorticoids has been well-established (Calandra, Bernhagen et al. 1995, Bacher, 
Meinhardt et al. 1997). It is rapidly released in the setting of infections as it regulates 
innate, acquired and autoimmune responses. Upon activation and secretion, MIF exhibits 
both paracrine and autocrine functions in the context of inflammation. It goes into 
circulation where it leads to the expression of the pro-inflammatory cytokines tumor 
necrosis factor-α (TNF- α, IFN-γ, IL-1β and IL-6). It can activate macrophages and T 
cells and inhibit apoptosis (Lue, Kleemann et al. 2002, Bucala and Donnelly 2007).  
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2.2 MIF, Apoptosis & Emphysematous Remodeling  
 
MIF’s role in inhibiting apoptosis has gained attention in the context of 
emphysema/COPD. Circulating plasma levels of MIF are decreased in smokers with 
COPD as compared to smokers without COPD (Sauler et al.  2013). Furthermore, this 
phenomenon is inversely correlated with disease severity as patients with advanced stage 
COPD (GOLD Stage V) had the lowest levels of circulating MIF (Fallica et al. 2014). 
While it is unclear if dampened plasma MIF level is a causal factor of disease or merely 
an epiphenomenon, preclinical data suggests a causal relationship. Preclinical data has 
further elucidated MIF’s role in emphysema pathobiology. MIF is differentially 
expressed in the context of CS exposure. Under conditions of acute exposure, MIF 
expression is upregulated in the BAL and murine lung (Sauler et al, 2013). Chronic CS 
exposure, however suppresses MIF expression, which is coincident with emphysematous 
tissue destruction in vivo (Fallica et al, 2014, Sauler et al, 2013). The knockout of MIF in 
vivo also further sensitizes mice to the effects CS. These mice have enhanced airway 
remodeling, characterized by greater air space enlargement (Fallica Boyer et al, 2014, 
Sauler et al, 2013). Further, these animals have increased expression of γH2AX, ROS 
production and CS-induced apoptosis, demonstrating MIF’s role in antagonizing these 
events (Fallica, Boyer et al. 2014; Fallica Varela et al, 2016).   
While both EpiCs and ECs are susceptible to CS-induced apoptosis, Fallica et al 
found that MIF deficiency preferentially enhances CS-induced apoptosis in ECs (Fallica 
et al, 2014). EC apoptosis has been determined to be both a necessary and sufficient 
process that drives the progression of emphysematous tissue remodeling and COPD, 
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which is characterized by increased cell apoptosis that outpaces repair (Liu, Ding et al. 
2014, Strulovici-Barel, Staudt et al. 2016). MIF’s role in regulating EC homeostasis has 
been previously demonstrated in other studies. Munat and colleagues showed that MIF 
and VEGF levels are strongly correlated in the context of glioblastoma cells (Munaut et 
al. 2002). The effects of MIF on EC apoptosis were first identified by Damico et al. They 
showed that the loss of MIF results in the loss of EC resistance to lipopolysaccharide 
(LPS)-induced apoptosis, implicating its role as a necessary regulator of EC survival. 
They also showed that MIF regulates its cytoprotection through FLICE-like inhibitor 
protein (FLIP), an antagonist of the death receptor-mediated apoptosis (Damico, Chesley 
et al. 2008). MIF’s ability to antagonize ECs apoptosis was also demonstrated in the 
context of CS in vitro, via inhibition of p53 activation (Damico et al. 2010). p53 is a 
tumor suppressor that induces cell cycle arrest and apoptosis in response to genotoxic 
stimuli (Nigro, Baker et al. 1989). CS exposure induces EC apoptosis in a p53-dependent 
manner. This was evidenced by the siRNA-mediated knockdown of p53 in vitro, which 
conferred apoptotic resistance in ECs exposed to CS. Furthermore, MIF deficiency in 
these cells led to p53 upregulation and exacerbated sensitivity of EC’s to CS. Rescue 
experiments that demonstrated the pharmacological inhibition of p53, demonstrated 
MIF’s ability to antagonize CS-induced is p53-dependent (Damico, Simms et al. 2011). 
Additionally, MIF’s role in antagonizing p53-mediated EC apoptosis is through its ability 
to directly inhibit activity of apoptosis signal kinase 1 (ASK1) and downstream activation 
of the p38 mitogen activated kinase (MAPK) pathway (Fallica, Varela et al. 2016).  
Activity of the ROS-generating enzyme, xanthine oxidoreductase (XOR) is 
elevated in lungs of mice exposed to CS (Kim et al. 2013). ASK1 drives XOR activity 
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and MIF has been shown to antagonize this. MIF
-/-
 mice have exacerbated XOR during 
CS exposure. The increased activity of XOR is associated with increased ROS production 
in the murine lung. Furthermore, in vitro data reveals that MIF antagonizes ASK1-
dependent phosphorylation of p38, subsequent XOR activation, increased ROS 
accumulation and DNA damage-induced p53 activation (Fallica, Boyer et al. 2014). In 
conclusion these provide evidence for antagonizing the effects of CS-induced 
emphysematous remodeling via its ability to maintain EC homeostasis and confer 
apoptotic resistance in the context of ROS.  
 
2.3 The Emerging Role of MIF as a Positive Regulator of Antioxidant Responses 
 
 MIF’s complex role as an antagonist of apoptosis has been partially elucidated by 
a growing body of literature that demonstrated its ability to regulate antioxidant 
responses. It has been established that MIF’s oxidoreductase activity can directly regulate 
cellular redox status. It has been shown to confer cytoprotection through its ability to 
mitigate the effects increased oxidative burden, ultimately antagonizing DNA damage 
and p53 activation. MIF protects HeLa cells from the effects of oxidant-induced 
apoptosis via its Cys60 residue. Further, it positively regulates antioxidants and induces 
intercellular levels of glutathione and glutathione S-transferase (Takahashi, Nishihira et 
al. 2001, Nguyen, Beck et al. 2003).  
Upregulation of antioxidants is crucial in promoting cytoprotection in the context 
of oxidative stress. Nrf2, a critical regulator of the antioxidant response element (ARE), 
is critical for the regulation of a variety of antioxidant genes (Moi, Chan et al. 1994). 
MIF’s ability to regulate the ARE was first identified by Kimura and colleagues. They 
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showed that the novel cardioprotective drug 1,3-benzothiazin-4-one (BTZO-1) inhibits 
cardiac myocyte apoptosis in the context of heart disease via direct binding to MIF 
(Kimura, Sato et al. 2010) BTZO-1 promotes cell survival by upregulating ARE-
dependent gene expression. Treatment of cardiomyocytes with exogenous MIF inhibited 
nitric oxide-induced apoptosis. Furthermore co-stimulation of the drug and exogenous 
MIF, increased ARE activity and upregulated the ARE-dependent transcript, 
hemeoxygenase-1 (HO-1), implicating a MIF-dependent mechanism for optimal 
cytoprotective function of BTZO-1 (Kimura, Sato et al. 2010). In addition to modulating 
ARE activity, MIF has been shown to impact Nrf2 expression. MIF deficiency 
potentiates susceptibility to radiation-induced lung injury (RILI) in an age-related 
manner. MIF deficient mice had worse lung injury, attenuated antioxidant capacity as 
well as, Nrf2 protein expression in the lung. Treatment of MIF-/- mice with antioxidants 
protected them from RILI, implicating that enhanced susceptibility in these is due to 
altered Nrf2-antioxidant responses. MIF loss in vitro decreased nuclear translocation of 
Nrf2 in ECs challenges with hydrogen peroxide (H2O2). These data provide evidence for 
MIF’s function upstream of the ARE and highlight MIF’s alternative cytoprotective role 
in inhibiting apoptosis and mitigating oxidative responses via induction of antioxidant-









3. Oxidants and Antioxidant Responses   
 
3.1 Oxidative Stress, Antioxidants  
 
 Oxidative stress is a state in which the effects of oxidants overwhelm the 
antioxidant capacity in a given cellular milieu or organ system. Oxygen is integral to 
aerobic energy production, which is far more efficient than anaerobic respiration. 
However the use of oxygen during aerobic respiration can lead to the production of 
chemically reactive compounds known as reactive oxygen species (ROS) (reviewed from 
((Bowler, Barnes et al. 2004)). Free radicals, which include ROS and can perpetuate 
oxidative stress, are defined as an atom or molecule with an unpaired electron 
(Cheeseman 1993).  
ROS and other types of free radicals are highly unstable and reactive and can 
attack most organic biological macromolecules if kept unchecked by a cell’s antioxidant 
defense system. Gutteridge defined an antioxidant:  
“any substance that, when present in low concentrations compared to that of an 
oxidizable substrate, significantly delays or inhibits the oxidation of that substrate” 
(Gutteridge 1995). 
 He further subdivided antioxidants in three broad categories based on their 
functions: antioxidant enzymes, chain breaking antioxidants and transition metal binding 
proteins (Halliwell and Gutteridge, 2006). Antioxidant enzymes can either donate an 
electron or receive an electron, becoming oxidized or reduced, respectively (Halliwell, 
1995). Chain breaking antioxidants are non-enzymatic antioxidants that are particularly 
important in the prevention of chemical chains that form as a result of a reactive molecule 
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interacting with an organic macromolecule (i.e. lipid peroxidation). Finally, transition-
binding proteins sequester metals such as copper or iron to inhibit the formation of 
radicals (reviewed in (Young and Woodside 2001, Bowler, Barnes et al. 2004)). 
The imbalance between oxidants and antioxidants diseases leads to oxidative 
stress and is the underlying cause of many diseases, including pulmonary and airway 
diseases. The lungs are particularly susceptible to the effects of ROS due to their large 
surface area and incessant exposure to both endogenous and endogenous sources of 
oxidants and pro-oxidants in approximately 8,000 liters of air, daily. There are 
established acute and long-term effects on pulmonary function in response to 
environmental sources of ROS (Bernstein, Alexis et al. 2004). Acute exposure to 
oxidants can cause reversible decrements in lung function (Hollingsworth, Maruoka et al. 
2007), but chronic exposure can lead to irreversible remodeling and decreased pulmonary 
function (Bernstein, Alexis et al. 2004). There is mounting evidence that show oxidative 
stress is involved in the pathogenesis of many chronic pulmonary conditions. Markers of 
oxidative stress are significantly elevated in patients with chronic conditions like COPD 
(Calikoglu, Unlu et al. 2002, Corradi, Rubinstein et al. 2003). Furthermore, oxidants have 
the capacity to enhance inflammation, promoting disease and pulmonary dysfunction 
therefore addressing the oxidant/antioxidant imbalance is critical in different therapeutic 
approaches (MacNee 2001, Hoshino and Mishima 2008).  
 
3.1.1 Sources of ROS and their Effects on Cellular Function  
ROS is vital to cellular function, but its excess can quickly induce damage. While 
it is essential for the maintenance of normal physiological functions, overexposure to 
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ROS can promote disease and lead to detrimental health outcomes. ROS can be broadly 
divided into two basic categories, endogenous and exogenous sources of ROS. 
Endogenous sources of ROS arise from organelles or processes that occur within the cell. 
The mitochondria is the site of aerobic respiration and a potent intracellular ROS-
generating source (Loschen, Flohe et al. 1971, Boveris, Oshino et al. 1972). In moderate 
concentrations, free radicals are important in cell-to-cell communication via perpetuation 
of signal transduction pathways (Thannickal and Fanburg 2000). ROS and free radicals 
are also employed by the immune system in host defense mechanisms and cytokine 
activation (Lo, Wong et al. 1996, Droge 2002).  
Exogenous sources of ROS, pro-oxidants reactive nitrogen species include 
ambient air pollution, occupational exposures (industrial solvents), biomass burning and 
CS exposure (reviewed in (Sies, Berndt et al. 2017). Excessive exposure to can quickly 
tip the homeostatic balance and lead to oxidative stress. Under these conditions, free 
radicals can rapidly react with cellular molecules. A consequence of oxidative stress is 
lipid peroxidation, which is caused by a chain reaction of poly-unsaturated lipids 
ultimately, leading to permanent cell membrane damage and cell death (Chen, Arjomandi 
et al. 2007). DNA damage is another consequence of excess ROS exposure and plays an 
central role in many pathologies (Jena 2012). Free radicals can be carcinogenic as they 
can cause DNA strand breaks, backbone lesions and base modifications, potentially 
inducing DNA mutations, transformation and potentiation of cancer (Balasubramanian, 
Pogozelski et al. 1998). Finally, ROS can attack protein and disrupting or inhibiting their 
function. Oxidation of proteins can lead to protein-protein cross-linkages, proteolytic 
degradation and effect protein turnover (Davies 1986). In conclusion, excess ROS 
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damages intracellular macromolecules, induces cellular dysfunction ultimately leading to 
inflammation and disease.  
 
3.2 Antagonism of ROS Effects by the Antioxidant Response Element (ARE) 
 
Antioxidant responses are due the upregulation of cytoprotective genes during 
oxidative stress due to the activation of the antioxidant response element (ARE) (Tsuji, 
Ayaki et al. 2000). The ARE are cis-acting enhancer sequences found in the promoter 
regions of many antioxidant genes. These genes encode for proteins that protect the cell 
from oxidative stress (Li and Jaiswal 1992, Nguyen, Sherratt et al. 2003). The ARE was 
first identified in rats, originally termed β- naphthoflavone- responsive element between. 
This inducible response element is located between nucleotides -722 and -682 in the 5’-
flanking region of the rat glutathione S-transferase Ya subunit gene (Rushmore, King et 
al. 1990). Rushmore and Pickett found that it is distinguishable from other xenobiotic 
response elements by its responsiveness to phenolic antioxidants; hence it was termed 
antioxidant response element or ARE (Rushmore and Pickett 1990). They have shown 
that this element can be induced by P-naphthoflavone and t-butylhydroquinone, thereby, 
activating Ya subunit gene. It is activated by a number of different compounds that share 
common characteristics. These compound or chemicals can undergo redox cycling, or 







4. Nuclear factor (erythroid-derived)–like 2 (Nrf2)  
 
4.1 Discovery of Nrf2 
 
Nrf2 is a member of the cap’n’collar (CnC) subfamily of proteins of the family. 
CnCs belong to a superfamily of proteins known as the basic-region leucine zipper 
(bZIP) (Mohler, Vani et al. 1991). CnC family of proteins consists transcription factors 
that are conserved among different species. It consists of BACH 1 and 2 as well as, NF-
E2 p45, Nrf1, Nrf2, and Nrf3 (Oyake, Itoh et al. 1996). They have a characteristic 43-
amino acid CnC domain (Bowerman, Eaton et al. 1992). These transcription factors play 
important roles in development, as well as stress responses including oxidative stress 
(Chan, Cheung et al. 1995). Cells are thus equipped with mechanisms to both sense 
(Cullinan, Gordan et al. 2004) and manage oxidative stress. The CnC member, Nrf2 
serves as critical transcription factor in activating a host of antioxidants in response to 
oxidant-induced stress. 
Initially, Nrf2 was discovered as a binding partner of activating protein (AP)-1 
and nuclear factor-erythroid 2 (NF-E2) (Moi, Chan et al. 1994). The function of Nrf2 was 
largely unknown, as the absence of the Nrf2 gene in a murine model did not have any 
development effects, nor did it disrupt physiology (Chan, Lu et al. 1996). The function of 
Nrf2 was later elucidated by Ito and colleagues in a study that investigated the effects of a 
former food additive, butylated hydroxyanisole (BHA) on the induction of detoxifying 
enzymes, GST and NQO-1 in Nrf2-deficient mice. It was found that the absence of Nrf2 
greatly diminished expression of both GST and NQO-1, demonstrating its role in 
upregulating antioxidant gene transcription (Itoh, Chiba et al. 1997).  
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4.2 Nrf2 Structure: The Seven Domains of Nrf2 
  
Nrf2 is a member of the bZIP family of proteins and as such contains two 
important motifs critical for its function: a DNA binding motif and a positively charged 
leucine zipper. The leucine zipper interacts with the major grooves of DNA at the N-
terminal (Alber 1992, Ellenberger 1994). The bZIP region is characterized by a thirty 
amino acid sequence that is rich in the basic residues and a the leucine zipper, which 30-
40 amino acids in length (Vinson, Sigler et al. 1989). Human Nrf2 (hNrf2) is comprised 
of 605 amino acids, which form seven domains known as the Nrf2_ECH homology (Neh) 
domains (Ellenberger 1994). The Neh1 domain contains the CNC-b-ZIP region at the C-
terminal half, which contains the leucine zipper motif and is crucial for binding to the 
ARE (Itoh, Wakabayashi et al. 1999). In addition to its role in DNA binding, the CnC 
domain of Nrf2 interacts with bZIP motifs of member of the small masculoaponeurotic 
fibrosarcoma (Maf) family of proteins (Motohashi, Katsuoka et al. 2004). 
Heterodimerization with these proteins facilitates Nrf2 binding to the ARE and are 
essential for optimal induction of ARE-dependent genes (Katsuoka, Motohashi et al. 
2005).  
Domains Neh2 and Neh6 are important in the negative regulation of Nrf2. Neh2 
interacts with the repressor of Nrf2, Keap1 via two highly conserved motifs, DLG and 
ETGE (Tong, Katoh et al. 2006, Chowdhry, Zhang et al. 2013). KEAP1 forms a 
homodimer with Nrf2, with each monomer binding with low affinity to DLG high 
affinity to ETGE (Tong, Kobayashi et al. 2006). The DLG (or DIDLID) element spans 
amino acids 17-32 and is necessary for KEAP1-induced degradation of Nrf2. The ETEG 
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domain (amino acids 79-82) facilitates KEAP1-Nrf2 interaction under basal homeostatic 
conditions (McMahon, Thomas et al. 2004). The addition of a poly-ubiquitin chain to 
Nrf2 occurs at lysine residues within the Neh2 domain is about 10-30 amino acids away 
from the N-terminal of ETGE motif (Zhang, Lo et al. 2004). Phosphorylation of the 
threonine residue 80 of the ETGE domain is sufficient to perturb the interaction between 
KEAP1 and Nrf2 by impeding the ETGE motif from appropriately fitting into the binding 
pocket of KEAP1 (Kong, Owuor et al. 2001, Lo, Li et al. 2006).  
Unlike Neh2, Neh6 negatively regulates Nrf2 independent of KEAP1. Neh6 
contains the DSGIS motif, which is a redox-insensitive degron and ensures rapid Nrf2 
turnover under conditions of oxidative stress (McMahon, Thomas et al. 2004). It is 
converted to a phosphodegron by the enzymes enzyme glycogen synthase kinase-3 
(GSK-3), which targets it for phosphorylation and subsequent activation (Salazar, Rojo et 
al. 2006, Rada, Rojo et al. 2011). This then allows for the recruitment of the protein β-
transduction repeat containing protein (β-TrCP) via the Neg6 domain motifs, DSGIS 
(338) and DSAPGS (378) (Salazar, Rojo et al. 2006). The interaction between Nrf2 and 
β-TrCP is significantly enhanced when DSGIS is phosphorylated (Chowdhry, Zhang et 
al. 2013). The adaptor molecule S-phase kinase-associated protein 1 (Skp1) adaptor 
protein interacts with the F-box domain of β-TrCP. This adaptor molecule connects Neh6 
of Nrf2 to the Cul1-Rbx1 core E3 complex, providing another mechanism for Nrf2 
ubiquitination. Neh6 has been demonstrated to destabilize Nrf2 in redox-independent 
manner, thereby enhancing Nrf2 degradation under conditions of oxidative stress 
(McMahon, Thomas et al. 2004, Rada, Rojo et al. 2011). Chowdhry et al. found that 
deleting Neh2 and two motifs of the Neh6, SDS1 and PEST, significantly increased Nrf2 
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activity (Chowdhry, Zhang et al. 2013). Another domain involved in the negative 
regulation of Nrf2 is the Neh7 domain. Amino acids 209–316 of human Nrf2 comprise 
Neh7 and it is the site of interaction with retinoic X receptor alpha (RXRα), a repressor of 
the protein. The knockdown of RXR via siRNA enhanced ARE-dependent gene 
transcription under basal conditions and stimulation with tert-Butylhydroquinone 
(TBHQ) (Wang, Liu et al. 2013).  
Neh3 is located at the C-terminal domain half of the protein and has been shown 
to play an important role in regulating transcriptional activation of Nrf2. The Neh3 
domain allows for proper binding to chromodomain helicase DNA-binding protein 6 
(CHD6), via its VFLVPK motif. Mutation of this hydrophobic motif not only reduces 
protein-protein interaction with CHD6 but also the decrease Nrf2 activity, conferring its 
importance in the transcriptional activation of Nrf2. Also, the deletion of the final 16 
amino acids of Nrf2 renders the protein transcriptionally inactive, although it may still 
localize in the nucleus and bind to DNA (Nioi, Nguyen et al. 2005). Neh4 and Neh5 are 
important for optimal transcriptional activation of Nrf2. Katoh et al. demonstrated that 
deletion of Neh4 and Neh5 significantly abrogated Nrf2-dependent ARE-activity (Katoh, 
Itoh et al. 2001) and deletion of latter lead to a significant attenuation of Nrf2-dependent 
transcription of HO-1 (heme oxygenase 1), NQO1 (NAD(P) H:quinone oxidoreductase 1) 
and GCLM (glutamate cysteine ligase modulatory subunit) (Zhang, Hosoya et al. 2007). 
Furthermore, these two domains can bind independently and cooperatively to CREB 
(cAMP Responsive Element Binding protein) Binding Protein (CBP) (Katoh, Itoh et al. 
2001). Not only does CBP functions act as a co-activator of many other molecules, but it 
also has an intrinsic histone acetylase activity important in chromatin remodeling and 
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enhancement of gene transcription (Bannister and Kouzarides 1996, Goodman and 
Smolik 2000). Inhibition of CBP markedly reduces ARE-activity. Additionally, Wang et 
al. demonstrated that overexpressing RXR may disrupt the binding of CBP to Neh4 and 
Neh5 and subsequently decreased transcription by Nrf2 (Wang, Liu et al. 2013). In 
addition to facilitating the recruitment of CBP, Neh5 has been shown to interact with 
Brahma-related gene-1 (BRG), which is plays an important role in ATP-dependent 
chromatin remodeling (Ramirez-Carrozzi, Nazarian et al. 2006). Under conditions of 
oxidative stress, Nrf-2 recruits BRG1 and subsequently, RNA polymerase II to the 
promoter of HO-1 (Zhang, Ohta et al. 2006), which is enhanced by the Neh5 domain 
(Zhang, Hosoya et al. 2007). In summary, Nrf2’s domains function to both positively and 
negatively regulate Nrf2 protein to ensure its efficient turnover under varying cellular 
redox conditions.  
 
4.3 Regulation of Nrf2  
 
4.3.1 Transcriptional Regulation  
There are several ways in which Nrf2 is regulated at the transcriptional level. Nrf2 
is encoded by the NFE2L2 gene and is regulated a number of different ways (Moi, Chan 
et al. 1994). It has been determined that the aryl hydrocarbon receptor (AHR)-xenobiotic 
response element signaling pathway directly affects Nrf2 gene expression (Radjendirane 
and Jaiswal 1999, Miao, Hu et al. 2005). The AHR is a ligand-activated transcription 
factor that is responsible for activating phase I and II genes in the presence of planar 
aromatic hydrocarbons. AHR forms a complex with aryl hydrocarbon receptor nuclear 
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translocator (Arnt) and binds to the promoter of the xenbiotic response element (XRE) 
(Rushmore and Kong 2002). It was initially believed that the ARE and XRE pathways 
are distinct, Jaiswal et al showed that there is in fact crosstalk and regulation between the 
two. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a known inducer of the XRE pathway 
was also shown to induce the ARE-dependent gene expression of NQO-1 (Radjendirane 
and Jaiswal 1999, Ma, Kinneer et al. 2004). Additionally, Miao showed that TCDD 
directly increases Nrf2 gene expression and that this effect is absent in AHR-deficient tao 
cells. They also studies the effects of TCDD on Nrf2 gene in CYP1A1-deficient cell line 
c37 and found that Nrf2 is upregulated independent of CYP1A1 (Radjendirane and 
Jaiswal 1999). In addition to AHR regulation of Nrf2 gene expression, epigenetics plays a 
role in the suppression of Nrf2. Hypermethylation of specific CpG sites in the Nrf2 gene 
promoter represses Nrf2 gene expression and its downstream antioxidant gene targets 
(Yu, Khor et al. 2010).  
 
4.3.2 Post-Translational Regulation-Degradation of Nrf2 
Nrf2 may be post-translationally modified and subsequently regulated in a 
number of ways. Nrf2 levels are maintained under homeostatic conditions by the adaptor 
molecule KEAP1. KEAP1 serves as the substrate of Cullin3-E3 ubiquitin ligase complex 
that ultimately connect the poly-ubiquitin chain to Nrf2, targeting it for degradation. Nrf2 
may also be modified by phosphorylation. This thesis will focus on the degradation 
pathway of Nrf2 by KEAP1.  
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 4.3.2.1 Keap1: The Key Suppressor of Nrf2 
Kelch-like ECH-associated protein 1 (KEAP1) is dominant suppressor of Nrf2 
protein. In the absence of oxidative stress, Keap1 sequesters Nrf2 in the cytoplasm and 
targets Nrf2 for proteosomal-mediated ubiquitination (Zhang, Lo et al. 2004). Oxidative 
stress leads to the disassociation of Nrf2 from and Keap1 and subsequent translocation to 
the nucleus. The structure of KEAP1 is critical for its function as it has the capacity to 
sense redox alterations in the cell (Canning, Sorrell et al. 2015). It serves as an adaptor 
molecule that binds to the scaffold protein, Cullin 3 to form the Cullin-RING E3 ligase 
(CRL3) complex, which is required for the poly-ubiquitination and degradation of Nrf2 
(Cullinan, Gordan et al. 2004).  
 
4.3.2.2 Structure and Function of KEAP1  
KEAP1 is a cysteine-rich molecule that is comprised of 625 amino acids 
(Tkachev, Menshchikova et al. 2011). It consists of five domains: (I) N-terminal (amino 
acids 1-60) (II) the broad complex, tramtrack and bric-a-brac domain (amino acids 61-
179), (III) the intervening region (IVR) (amino acids 180-314), (IV) the Kelch repeat (or 
double glycine repeats (DGR)) (six Kelch repeats amino acids 315–359, 361–410, 412–
457, 459–504, 506–551, and 553–598), (V) and the C-terminal region (CTR) (amino 
acids 599–624) (Adams, Kelso et al. 2000, Dinkova-Kostova, Holtzclaw et al. 2002). It is 
a member of the Broad-complex, Tramtrack and Bric-à-brac/poxvirus and zinc finger 
(BTB/POZ) family of proteins. The evolutionarily conserved BTB motif is about ~120 
amino acids in length and is crucial in facilitating protein-protein interactions, forming 
homo and heterodimers (Bardwell and Treisman 1994), regulating gene transcription 
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(Stogios, Downs et al. 2005), scaffolding to the cytoskeleton (Kang, Kobayashi et al. 
2004) and substrate recognition for proteasomal-mediated degradation (Furukawa, He et 
al. 2003). In the case of KEAP1, the BTB domain is responsible for the recognition and 
recruitment of Cullin 3 (CUL3) a member of Cullin–RING (really interesting new gene) 
family of ligases (Cullinan, Gordan et al. 2004, Hudson and Cooley 2010). It also plays a 
critical role in KEAP1 homodimerization and a point mutation of its highly conserved 
Ser104 residue leads to impaired homodimerization and Nrf2-binding (Zipper and 
Mulcahy 2002).  
The BTB/POZ family of proteins is sub-divided into different subclasses and 
KEAP1 is a member of the BTB-Kelch subclass, which consist of 49 members that are 
characterized by the presence of the BTB domain at the N-terminal and Kelch domain at 
the C-terminal (Stogios and Prive 2004). The crystal structure of the Kelch domain in 
KEAP1 reveals a four-beta anti-parallel sheet arrangement, forming a six-bladed β-
propeller. All of six blades that form the β-propeller interact with Nrf2 and while these 
blades vary in amino acid length, they all contain a conserved 7-residue sequence. The 
longer, blade II is crucial for the KEAP1-Nrf2 interaction (Li, Zhang et al. 2004). The 
Kelch domain of KEAP1 binds two Nrf2 molecules, simultaneously via Nrf2’s conserved 
ETGE motif with the Neh2 domain. Phosphorylation of this motif significantly hinders 
KEAP1 bind capacity to Nrf2. In addition to the DGR domain, the C-terminal has also 
been shown to be critical in mediating KEAP1-Nrf2 interactions (Padmanabhan, Tong et 
al. 2006).  
 KEAP is a cysteine-rich molecule that contains 25 and 27 cysteine residues in 
murine and human KEAP1, respectively. These residues are crucial in detecting changes 
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in the redox status of a cell and they facilitate KEAP1-Nrf2 interaction. Furthermore, the 
cysteine residues are concentrated within the IVR of the molecule, which contains 8 Cys 
over the span of about 100 amino acids. The most reactive Cys residues identified by 
Dinkova et al. are Cys257, Cys273, Cys288, and Cys297, via exposure to an established 
inducer of Phase II enzymes, dexamethasone (Dinkova-Kostova, Holtzclaw et al. 2002). 
Cys151, Cys257 and Cys288 are the residues critical in the interaction between Nrf2 and 
KEAP1 and are involved in the proteasomal-mediated degradation of Nrf2. Point 
mutations of these cysteine residues to serine led to the accumulation of Nrf2 in COS2 
cells exposed to tBHQ. Cys151 however, is responsible for the stabilization and redox-
induced release of Nrf2 and mutation of this residue led to the constitutive repression of 
Nrf2 (Zhang and Hannink 2003). The physiological importance of the Cys151, Cys273 and 
Cys288 in the IVR was established in KEAP1 null mice that transgenically expressed 
mutant Keap1 (C273A) and/or Keap1 (C288A) failed to inhibit constitutive Nrf2 activity 
(Yamamoto, Suzuki et al. 2008). These specific Cys residues are responsible for redox 
sensing and responding to oxidative stress (Takaya, Suzuki et al. 2012, Saito, Suzuki et 
al. 2015). 
 
4.3.2.3 Proposed Models of KEAP1 and Nrf2 Release 
KEAP1’s function is two-fold, first it senses changes in the redox status of the 
cell and it tightly regulates Nrf2 expression through the facilitation of its ubiquitination. 
The interaction between these two molecules is perturbed by the presence of 
electrophiles. There are several proposed models of KEAP1 interaction with Nrf2. The 
chief two models are KEAP1-cullin3 (CUL3) disruption model (Eggler, Small et al. 
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2009) and the “two-substrate recognition model” (also known as the “hinge latch model”) 
(McMahon, Thomas et al. 2006, Tong, Katoh et al. 2006). The latter has become the 
more widely accepted prevailing model.  
 The KEAP-CUL3 disruption model proposes that the modification of Cys151 of 
KEAP1’s BTB domain causes a conformational change and disrupts the interaction 
between KEAP1 and CUL3. This disruption then inhibits the poly-ubiquitination and 
degradation of Nrf2 (Rachakonda, Xiong et al. 2008, Eggler, Small et al. 2009). KEAP1 
serves as an adaptor molecule that facilitates the transfer of ubiquitin from cullin3 
(CUL3)/Rbx1 ligase complex to the lysine resides of the Neh2 domain of Nrf2 
(Kobayashi, Kang et al. 2004). Zhang et al demonstrated that KEAP1 forms a ternary 
complex with the scaffold protein, CUL3 and Rbx1, which is mediated by the BTB 
domain. Furthermore, mutations of specific residues within the BTB domain reduced 
KEAP1’s interaction with CUL3-Rbx1 complex in a co-immunoprecipitation experiment 
(Zhang, Lo et al. 2004). It was then shown that Cys151 is not only important in sensing 
redox changes, but also plays a role in regulating KEAP1 and CRL3 interaction. 
Substitution of Cys151 to the bulkier amino acid, tryptophan disrupted the KEAP1’s 
binding with CUL3 and enhanced ARE activity. The tryptophan substitution caused steric 
clash with residues K131 and R135 between the alpha helix they reside on and the alpha 
helix that Cy151 resides on, ultimating shifting the residues that interact with CUL3 and 
disruption KEAP1-CUL3 interaction (Eggler, Small et al. 2009).  
The prevailing more widely accepted model is the “hinge and latch” model. This 
model demonstrates KEAPs binding to the two motifs of the Nrf2’s Neh2 domain, ETGE 
and DLG (Tong, Katoh et al. 2006). KEAP1 form a homodimer and interacts with these 
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two binding sites with different affinities. KEAP1 binds to the ETGE motif with about 
two orders of magnitude higher affinity than the DLG motif (McMahon, Thomas et al. 
2006). The “hinge” in this model is the interaction of the Kelch domain of Keap1 with 
the ETGE motif of Nrf2’s Neh2 domain and the “latch” is the interaction of KEAP1 with 
the DLG motif. The hinge anchors Keap1 onto Nrf2 and the lesser affinity DLG acts a 
“latch” by changing the position of Nrf2 depending on the cell’s redox state (Tong, 
Kobayashi et al. 2006). One KEAP1 molecule of the homodimer binds to each motif 
separately. McMahon and colleagues showed that deletion of the DLG motif inhibits the 
ubiquitination of Nrf2, but does not impact KEAP1’s binding via the ETGE motif, 
implicating its role as a mediator of ubiquitination (McMahon, Thomas et al. 2006). 
Under conditions of oxidative stress cysteine residues become oxidized leading to 
a conformational change, misalignment of the lysine residues (Kansanen, Kuosmanen et 
al. 2013) and subsequent release the DLG motif “latch.” In this manner, Nrf2 is released 
from KEAP1 and no longer targeted for proteasomal-mediated degradation. It therefore, 
accumulates in the cytoplasm or translocates to the nucleus. This model suggests that 
Nrf2 may still be stabilized while still bound to KEAP1, but not targeted for degradation 
so that newly translated Nrf2 bypasses KEAP1, altogether. Interestingly, the type of 
electrophilic inducer may play a role in directly impacting Nrf2-KEAP1 interactions and 
promote the disassociation of Nrf2 from KEAP1 (Tong, Katoh et al. 2006, Tong, 
Kobayashi et al. 2006, He, Lin et al. 2007). While the exact mechanism by KEAP1 
relinquishes Nrf2 has yet to be determined, mounting evidence suggests that the “hinge-
latch” model best explains KEAP1-Nrf2 disruption in the context of oxidative stress.  
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5. Cullin E3 RING Ligases & their Role in the Polyubiquination of Nrf2 
 
KEAP1 does not directly poly-ubiquitinate Nrf2, instead it merely serves as an 
adaptor of the Cullin3-E3 ligase complex that connects ubiquitin chain to Nrf2. 
Ubiquitination leads to the formation of poly-UB that is recognized by the 26S 
proteasome (De Mot, Nagy et al. 1998). It begins with the activation of a highly 
conserved 76-amino acid ubiquitin (Ub) molecule (Komander 2009) molecule by 
ubiquitin-activating enzyme (E1). Activation entails the thio-ester bond formation 
between the C-terminal of a Ub molecule and a Cys residue of the E1’s active site 
(Schulman and Harper 2009). This activated Ub molecule is then transferred to a ub-
conjugating enzyme (E2) (Olsen and Lima 2013) and finally to protein ligase (E3) 
(Komander 2009).  
There are two main families of E3 ligase, Homologous to E6-AP Carboxy 
Terminus (HECT) and Really Interesting New Genes (RING), which facilitate 
ubiquitination via different mechanisms. HECT E3 ligases form an intermediate thioester 
bond with Ub before ubiquitinating the target substrate (Rotin and Kumar 2009, Metzger, 
Hristova et al. 2012). RING E3 ligases function differently and serve critical roles in 
substrate recognition (Lydeard, Schulman et al. 2013). RING family of E3 ligases 
represents the largest family of E3 ubiquitin ligases. They are responsible for the 
ubiquitination and clearance of about 20% of proteins (Soucy, Smith et al. 2009). 
Humans express eight members of the Cullin family: CUL1, CUL2, CUL3, CUL4a, 
CUL4b, CUL3, CUL5, CUL7 and CUL9 (Petroski and Deshaies 2005, Cui, Xiong et al. 
2016). The basic anatomy of CRLs is: a cullin that serves as the central scaffold, Ring-
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finger protein (RING), such as RBX1 or RBX2, an adaptor molecule and a substrate 
(Cui, Xiong et al. 2016). The diversity of the CRLs is due to the presence of multiple 
cullin molecules that recognize various protein substrate motifs. The N-terminal domain 
(NTD) binds to the adaptor molecule, which serves to recognize the substrate and connect 
it to the CRL. The C-terminal domain (CTD) binds to the RING member protein and is 
the site of post-translational modification (PTM) via the addition and removal of a Nedd8 
molecule (Duda, Borg et al. 2008). This process of cyclic neddylation and deneddylation 
regulates CRL activity (Kawakami, Chiba et al. 2001).  
 
5.1 The Role of CRL3 Subclass in Nrf2 Regulation 
  
Cullins are critical for organizing the CRL’s into functional units, as they serve as 
the central scaffolds that bind to E3 at C-terminal. CUL3 plays an indispensable role in 
murine embryogenesis and its knockout confers embryonic lethality (Singer, Gurian-
West et al. 1999). CUL3’s importance in cell cycle regulation, meiosis (Pintard, Kurz et 
al. 2003) and mitosis have been demonstrated in C. elegans and mammalian cells 
(Sumara, Quadroni et al. 2007). This complex also plays important roles in cell apoptosis 
(Lee, Yuan et al. 2010) and transcriptional stress responses through the recognition and 
binding of the BTB protein, KEAP1 (Eggler, Small et al. 2009).  
Cullins are capable of ubiquitinating the target molecule directly or indirectly, 
facilitated by an adaptor molecule bound to the NTD. The In the case of CRL3, CUL3 
binds the redox sensor and adaptor molecule, KEAP1 and polyubiquitinates Nrf2 
(Kleiger, Saha et al. 2009). CLR3 specifically assembles around the CUL3, which 
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uniquely recognizes the Kelch β-propeller domain of BTB/POZ motif (Ahmad, Engel et 
al. 1998, Canning, Cooper et al. 2013). This family of protein contains about 50 members 
Kelch-like 1–42 (KLHL1–42) and Kelch and BTB domain-containing 1–14 (KBTBD1–
14). KEAP1 is a member of this family and is an established CUL3 adaptor molecule 
(Dhanoa, Cogliati et al. 2013). KEAP1 forms dimer with two CUL3 molecules, thereby 
forming a dimeric CLR3, which is essential for Nrf2 recruitment and degradation. CRLs 
can target a wide range of proteins for degradation and CRL-mediated ubiquitination 
represents a necessary contributor of many cellular processes.  
 
5.2 Regulation of CRL’s 
 
5.2.1 Neddylation and Activation of Cullins: Role of UBC12 
CRL’s are postranslationally modified by the cyclic addition and removal of the 
small ubiquitin-like protein (UBL), neural precursor cell expressed developmentally 
downregulated protein 8 (NEDD8). Neddylation is critical in many cellular functions, 
including cell cycle progression in mammals (Kumar, Yoshida et al. 1993, Tateishi, 
Omata et al. 2001), cell signaling (Zuo, Huang et al. 2013) and transcriptional stress 
responses (Xirodimas, Saville et al. 2004). Like ubiquitin, NEDD8 is activated, 
conjugated to a ligating enzyme and finally transferred to an E3 enzyme. Unlike 
ubiquitin, however it is proteolytically cleaved to reveal a glycine 76 residue at the C-
terminal, which is necessary for the covalent attachment to substrates. NEDD8 can be 
cleaved by two enzymes, ubiquitin C-terminal hydrolase isozyme 3 (UCHL3) (Wada, 
Kito et al. 1998) and deneddylase 1 (DEN1) (Gan-Erdene, Nagamalleswari et al. 2003). 
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NEDD8 is activated by the NEDD8 E1 activating enzyme (NAE) in an ATP-dependent 
manner, forming an thioester intermediate (Walden, Podgorski et al. 2003). NAE is 
heterodimer comprised of APP-BP1 and UBA3 that interacts with NEDD8 at Arg72, as 
mutation of this residue to alanine has revealed its necessary role for NEDD8-E1 
interaction (Gong and Yeh 1999, Souphron, Waddell et al. 2008). The E1-S-NEDD8 
intermediate is then transferred to a conjugating enzyme, E2. There are two known E2 
enzymes, UBC12 (as known as UBE2M) and UBE2F, which bind to E3-Rbx1 and E3-
Rbx2, respectively (Huang, Ayrault et al. 2009). UBC12 binds to cullin 1-4 and UBE2F 
binds and activates cullin 5 (Osaka, Kawasaki et al. 1998, Huang, Ayrault et al. 2009). 
Rbx1 and Rbx2 are RING E3 molecules that interact directly with E2 to promote the 
neddylation of specific lysine of cullins CTD (Zheng, Schulman et al. 2002, Petroski and 
Deshaies 2005). Neddylation leads to conformational changes of the CRL, which then 
causes activation, complex assembly and ultimately, the transfer of ubiquitin from E2 to 
the target molecule (Hori, Osaka et al. 1999, Podust, Brownell et al. 2000). Deneddylated 
cullins exist in closed conformations, which are also considered to be in an “off” state. 
Neddylation changes the conformation of the cullins so that they are in an open state, able 
to accept a substrate-bound adaptor molecule (Duda, Borg et al. 2008). In summary, 
neddylation is a tightly regulated and reversible process that controls CRL activity via 
modulation of its conformational states. 
 
5.2.2. JAB1 and CRL Dennedylation 
Neddylation is a reversible modification and deneddylation is catalyzed by a fifth 
member of the COP9 signalsome (CSN) also known as, Jun-activating binding domain 
protein 1 (JAB1 or CSN5). The CSN is a large ~450 kDa molecular weight complex that 
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contains eight different subunits. It was initially discovered in Arabidopsis and is highly 
conserved between plants and animals (Wei, Chamovitz et al. 1994). JAB1 is the most 
well characterized subunit of the complex and it serves many biological functions. JAB1 
functions both as a member of the complex conferring its catalytic activity and can 
function independent of the complex (Tran, Allen et al. 2003). JAB1 was initially 
identified as a co-activator of the transcription, AP-1 (Claret, Hibi et al. 1996), which 
plays a role in a wide range of biological processes including stress response, cell growth, 
proliferation and apoptosis. JAB1 interacts with AP-1 to increase specificity of 
downstream target genes. Furthermore, given AP-1’s broad function, as well as JAB1’s 
promiscuity in interacting with other modulators of the cell cycle (i.e. p53 and p27), 
JAB1 upregulation is often seen in various cancers (reviewed in (Berg, Zhou et al. 2007, 
Shackleford and Claret 2010)). Like other constituents of the CSN, JAB1 contains the 
MPR1 and PAD1 N-terminal domain (MPN). JAB1’s MPN is differs from other 
members because it contains MPN domain metalloenzyme (JAMM motif). This motif 
confers JAB1’s ispopeptidase capacity (Tran, Allen et al. 2003), which is critical in 
regulating CRL activity. In the absence of a substrate molecule, JAB1 can cleave 
NEDD8 from cullins allowing for efficient cyclic neddylation and deneddylation 
(Cope, Suh et al. 2002, Ambroggio, Rees et al. 2004). Mouromoto and colleagues 
identified JAB1’s isopeptidase in the context of interferon receptor stabilization. They 
showed that JAB1 antagonizes the neddylation of the receptor, thereby promoting its 
stabilization (Muromoto, Nakajima et al. 2013). Interestingly, JAB1’s function is 
paradoxical in nature. While dennedylation is inhibitory leading to CRL inactivity, it is 
necessary for its proper CRL function. Neddylation is inherently destabilizing as it 
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promotes autoubiquitination, however by switching off neddylation, components of the 
CRL are protected from degradation (Bornstein, Ganoth et al. 2006). This demonstrates 
JAB1’s necessary role in mediating proper CRL activity, as well as stabilizing CRL 
components in the absence of substrate.  
 
5.2.3 Inhibition of Neddylation-Role of CAND1 
Once a CRL is deneddylated it becomes available to interact with Cullin-
Associated and NEDD8-Disassociated1 (CAND1 or TIP120A). CAND1 is a negative 
regulator of Cul-neddylation. CAND1 is 120-kDa protein that preferentially binds to 
deneddylated Cullins. CAND1 is critical for CRL regulation as its binding inhibits 
neddylation and subsequent complex assembly (Oshikawa, Matsumoto et al. 2003, 
Goldenberg, Cascio et al. 2004). Like JAB1, CAND1 is critical for efficient CRL 
function (Schmidt, McQuary et al. 2009). CAND1’s functions as a necessary CRL 
mediator were demonstrated in vitro. Ectopic overexpression of CAND1 competed with 
KEAP1 for CUL3 binding, which disrupts KEAP1-CUL3 interaction and induces Nrf2 
stabilization. Conversely, knock down of CAND1 led also led to the stabilization of Nrf2, 
but via indirect effects on CRL3. While CAND1 deficiency potentiated KEAP1-CUL3 
association, KEAP1’s ability to efficiently target Nrf2 for ubiquitination was 
compromised in CAND1-deficient cells, ultimately leading to increased Nrf2 levels (Lo 
and Hannink 2006). In summary, CAND1 is an established negative regulator of the 
CRL, but also functions to maintain efficient CRL activity. Further, Nrf2 increases in the 
context of its loss and gain of function in the in vitro reflects CAND1 ability in 
modulating different aspects of the CRL.  
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5.2.3.1 Structure and Function of CAND1 
CAND1 consists of 27 huntingtin-elongation-A subunit-TOR (HEAT) repeats. 
Each repeat is approximately 40 residues in length and are arranged such that the 
superhelical solenoid structure is formed. CAND1 wraps CAND1 wraps around cullins in 
a head-to-toe manner, in which CAND1’s NTD wraps around the cullins’ CTD. 
Therefore, CAND1’s interaction with cullins extends throughout the entire length of the 
cullin ultimately, forming a ternary complex. CAND1 directly blocks neddylation by 
binding to the lysine residue critical for neddylation, (Lys720 in CUL1), effectively 
blocking neddylation of the scaffold. Furthermore, CAND1 also binds to the region 
where RING proteins dock, ultimately inhibiting their binding and maintaining the 
complex in a disassembled state (Goldenberg, Cascio et al. 2004). The addition of 
NEDD8 molecule disrupts the interaction between the cullin and CAND1, thereby 











6. DJ-1 & Regulation of Antioxidant Responses  
 
 DJ-1 is a 20-kDa multifunctional protein that is 189 amino acid in size that is 
encoded by the PARK7 gene. DJ-1 was initially discovered by Nagakubo et al, as an 
oncogene that promotes cell growth and proliferation. This group found that co-
transfection of DJ-1 with ras was sufficient to transform mouse NIH3T3 cells. DJ-1 is 
expressed ubiquitously by most tissues including the lung and brain, but is preferentially 
expressed in the testis (Nagakubo, Taira et al. 1997). Intracellular DJ-1 exists in the 
cytoplasm, nucleus and mitochondria (Canet-Aviles, Wilson et al. 2004). DJ-1 may also 
be secreted into cerebrospinal fluids of patients with Parkinson’s disease (PD) (Waragai, 
Wei et al. 2006). While the function of DJ-1 remains largely unknown, evidence suggests 
that it is a redox-sensitive molecular chaperone. Its other roles include:, sensing and 
antagonism of oxidative stress (Ariga, Takahashi-Niki et al. 2013), male sterility 
(Honbou, Suzuki et al. 2003), neuroprotection (Bonifati, Rizzu et al. 2003, Yanagida, 
Kitamura et al. 2009), enhancing RNA-protein interactions, as well as pro-oncogenic 
functions (Cao, Lou et al. 2015).  
 
6.1 Structure of DJ-1 
 
Crystal structure of DJ-1 reveals a resemblance to heat shock protein 31 (HSP31) 
in bacteria (Wilson, Collins et al. 2003). Monomeric DJ-1 has a core comprised of a beta 
sheet, which is flanked by α-helices. In total, DJ-1 is a homodimer that consists of seven 
β-strands and nine α-helices (Nagakubo, Taira et al. 1997, Wilson, Collins et al. 2003). 
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The alpha and beta sheets are arranged to form a structure similar to that of a Rossman 
fold, which exists in glutamine amidotransferase (GAT) family of proteins (Horvath and 
Grishin 2001). DJ-1 is also structurally similar to the diverse members of the DJ-
1/ThiJ/PfpI superfamily of proteins (Du, Choi et al. 2000). These families of chaperones, 
proteases, catalase and kinases contain a conserved ThiJ domain, whose function is 
largely unknown (Mizote, Tsuda et al. 1999).  
It consists of three cysteine residues, Cys46, Cys53 and Cys106 (Canet-Aviles, 
Wilson et al. 2004, Ito, Ariga et al. 2006), which confer its redox-sensing capacity. Ito et 
al. have found that cysteine residues Cys46 and Cys53 are susceptible to s-nitrosylation, 
while Cys106 is not (Ito, Ariga et al. 2006). Furthermore, Cys46 is critical for the 
dimerization of DJ-1. Although the function of dimerized DJ-1 is largely unknown, some 
evidence suggests that it may exist and interact with other molecules as an obligate dimer 
(Lee, Kim et al. 2003). The missense mutation leading to the substitution of Leu166 for 
proline in DJ-1 leads to not only to its inability to form dimers, but its complete loss of 
function, which also has implications for the manifestation of PD (Bonifati, Rizzu et al. 
2003, Moore, Zhang et al. 2003). The crystal structure solved by Lee et al. showed that 
dimerization of DJ-1 is facilitated by alpha helices α1, α7, α8 and beta sheet β4 (Kinumi, 
Kimata et al. 2004). While all three cysteine residues are liable to oxidation, Cys106 is 
particularly sensitive to the effects of oxidative stress (Du, Choi et al. 2000, Kinumi, 
Kimata et al. 2004) and is critical for the cytoprotective function of DJ-1 (Canet-Aviles, 
Wilson et al. 2004). Furthermore, oxidized Cys106 is used as biomarker of PD (Saito 
2014). It is oxidized to three species (Cys-SOH), cysteine sulfinic acid (Cys-SO2H), and 
cysteine sulfonic acid (Cys-SO3H). Cys-SO2H is the most stable and confers biologically 
 49 
active DJ-1. Cys106 is the most conserved residue of DJ-1 across different DJ-1 
homologues (Canet-Aviles, Wilson et al. 2004). Mutations of this residue have 
demonstrated its vital role in the mediation of oxidation stress. In addition to sensing 
cellular redox changes, DJ-1 has the capacity to attenuate oxidative stress both via Nr2 
and independent of the pathway.  
 
6.2 The Cytopotective Roles of DJ-1  
 
 Among its many other functions, DJ-1 confers cytoprotection of different models 
by activating antioxidant response pathways, promoting cell survivorship, inhibiting 
apoptosis and maintaining mitochondrial function (Larsen, Ambrosi et al. 2011, Abdel-
Aleem, Khaleel et al. 2016, Wang and Gao 2016). It is for these reasons that DJ-1 
upregulation in the context of cancer is detrimental and its loss-of-function promotes the 
pathogenesis of PD (Hague, Rogaeva et al. 2003). In spite of the controversy regarding 
the roles of DJ-1, its function in oxidative stress has become widely accepted. DJ-1 is 
loss is associated with increased sensitivity to the effects of sources of ROS (Martinat, 
Shendelman et al. 2004). Moreover, the converse, or overexpression of DJ-1 protects 
cells against the ROS-mediated apoptosis.  
 
6.2.1 DJ-1 & the Inhibition of Oxidative Stress 
DJ-1’s function have been most well characterized in the context of PD, a 
neurological disorder that is driven by exacerbated protein misfolding and enhanced ROS 
(Bonifati, Rizzu et al. 2003, Bonifati, Oostra et al. 2004). In addition to the brain, DJ-1’s 
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biological significance has been demonstrated in multiple organ systems including the 
lung (Bahmed, Messier et al. 2016), kidneys (Eltoweissy, Dihazi et al. 2016). The lung is 
highly susceptible to the effects of oxidative stress, particularly in the context of CS. 
Bahmed et al showed that primary alveolar type II cells isolated from heavy smokers 
have attenuated DJ-1 expression as compared to those isolated from non-smokers. They 
also that Nrf2 expression and Nrf2-dependent transcripts are restored in cells by the 
overexpression of DJ-1. DJ-1 regulates antioxidant responses through a number of 
pathways. DJ-1 has been shown to play a role in regulating oxidative stress through the 
induction or stabilization of Nrf2. Clements et al demonstrated that DJ-1 necessary for 
Nrf2 stability in non-small cell carcinoma H157, and its ablation significantly attenuates 
Nrf2 protein expression. Furthermore, it also decrease ARE activity, as well the Nrf2-
dependent transcript, NQO1 (Clements, McNally et al. 2006). In addition to Nrf2 
stability, DJ-1 induced Nrf2 activation and translocation in cardiac cells under condition 
of hypoxia re-oxygenation (Yan, Yang et al. 2015). While many models have 
demonstrated the effects of DJ-1 on Nrf2, some models have revealed that it promotes 
cell viability under conditions of oxidative stress independent of Nrf2 (Gan, Johnson et 
al. 2010, Ismail, Abdel Shakor et al. 2015).. It can potentially do so through its ability to 
sense and scavenge for ROS, thereby serving as redox buffer (Eltoweissy, Dihazi et al. 
2016).  
 
6.2.2 DJ-1 is an Oncogenic Protein that Inhibits Apoptotic Pathways  
Oxidative stress can induce DNA damage leading to p53 activation and apoptosis. 
Numerous studies have demonstrated DJ-1’s capacity to antagonize oxidative stress-
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induced apoptosis. ASK1 is a stress responsive member of the MAPK family of proteins. 
ASK1 activates c-Jun N-terminal kinase and p38 signaling cascades important in stress 
response (Ichijo, Nishida et al. 1997). DJ-1 can inhibit ASK1 activation via direct 
interaction mediated by Cys106, which is necessary for this interaction to occur as 
demonstrated by site directed mutagenesis (Waak, Weber et al. 2009). ASK1 activation is 
inhibited by the oxidoreductase protein, thioredoxin (Trx), which binds to ASK1 via its 
N-terminal domain. The Trx-ASK1 interaction is disrupted by presence of ROS, which 
oxidize Trx inhibiting its capacity to bind ASK1 (Saitoh, Nishitoh et al. 1998). DJ-1 can 
also indirectly inhibit the ASK1 pathway by the induction of Trx in an Nrf2-dependent 
transcriptional mechanism (Im, Lee et al. 2012). In addition to the ASK1 pathway, DJ-1 
enhances cell viability via antioxidant upregulation and activation of pro-survival 
pathways, such as the Akt pathway (Yang, Gehrke et al. 2005, Tong, Katoh et al. 2006, 
Wang and Gao 2016). Finally, there is some evidence to implicate DJ-1’s ability to 
negatively regulate the pro-apoptotic transcription factor, p53. DJ-1 was demonstrated to 
bind directly to the DNA-binding region of p53, preventing its interaction with the 
promoters of its downstream genes (Kato, Maita et al. 2013). Taken together, these 
demonstrate that DJ-1 is important in antagonizing apoptosis via direct effects on pro and 






























2.1 Experimental Models 
  
2.1.1 Animal Models  
 
All animal protocols were conducted as approved by the Johns Hopkins 
University Institutional Animal Care and Use Committee. MIF knockout were generated 
in a C57BL/6 as described in (Bozza, Satoskar et al. 1999). Wild type and MIF deficient 
8-10 week old mice were exposed to filtered air or CS. Mice were exposed to CS for 5 
hours/day, 5 days/week for either 3 days (acute) or 6 months (chronic). CS exposure was 
completed in the manner previously described (Sussan, Rangasamy et al. 2009). CS 
exposure was achieved by using a smoke machine (Model TE-10, Teague Enterprises) 
that burned 2R4F reference cigarettes (Tobacco Research Institute, University of 
Kentucky). The machine was adjusted to produce a mixture of side stream and 
mainstream smoke also as previously described (Rangasamy, Cho et al. 2004). 
 
2.1.2 In vitro models & Treatments 
 Human microvascular pulmonary endothelial cells were purchased from Lonza 
(HMVEC-L, CC2527, Lot number: 000441097, Lonza, MD) and were maintained in 
endothelial growth medium (EGM-2, Lonza, MD) supplemented with EGM-MV Bullet 
Kit (Lonza, MD). Cells were utilized for experiments from passages 4 to 9. Rat 
pulmonary microvascular endothelial cell (RMVEC-L, RA6011, Cell Biologics, IL) were 
maintained in complete endothelial cell medium (Cell Biologics, IL) from passages 4 to 
9. Cell cultures were maintained at 37°C and 5% CO2. Cigarette smoke extract (CSE) 
was prepared as described in (Damico, Simms et al. 2011) in a 20% solution (v/v) in 
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complete media. In our recombinant MIF (rMIF) treatment experiments, HMVEC-L and 
RMVEC cells were treated with recombinant MIF (rMIF, (#289-MF (human) and 1978-
MF (mouse), respectively R&D Systems, Minneapolis, MN) was dissolved in 0.1% 
bovine serum abumin in PBS. Cells were treated with a final concentration of 100ng/mL. 
The ROS-sensitive dye, 2’,7’-dichlorodihydrofluorescin (H2DFCDA, D-399, Life 
Technologies, Carlsbad, CA) was utilized to assess intracellular ROS. HMVECs were 
incubated with H2DFCDA for 45 mins, then treated wuth either, vehicle (0.1% BSA), 
rMIF (100ng/mL) or N-acetylcysteine (2mM) after CSE exposure (20% v/v). H2DCFDA 
becomes oxidized into a fluorescent DCF indicator of ROS which was measured every 5 
minutes (495/520nm). Delta fluorescence is defined as the ratio of post-stimulus 
fluorescence over baseline.  
 
2.2 RNA Isolation & RT-PCR 
 Total RNA was isolated from lung homogenized in TRIzol (Invitrogen/ Life 
Technologies, Carlsbad, CA). RNeasy kit (Qiagen, Valencia, CA) was then used to 
further purify the RNA. Purified RNA was then reversed transcribed into complementary 
DNA (cDNA) by RT2 FirstStrand cDNA kit (SAbioscience/ Qiagen, Valencia, CA). 
SYBR Green Dye (Qiagen, Valencia, CA) based Real-Time Quantitative PCR was 
completed to measure gene expression of NADPH dehydrogenase quinone 1 (NQO1) (5’ 
AGCCAATCAGCGTTCGGTAT-3’,5’-GTAGTTGAATGATGTCTTCTCTGAAT-3’), 
glutathione peroxidase 2 (GPX2) (5’-CCCTTCCGTCGCTACAGCCG-3’, 5’-
TCCCAGGGTCTCCCGAGGGTA-3’) beta actin (5’ACGGCTCCGGCATGTGCAAA-
3’, 5’-ACCATCACACCCTGGTGCCT-3’) (IDT San Jose, CA).  
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2.3 Western Blot 
 For protein isolated from tissues, lungs were washed cold PBS and homogenized 
using tissue lysis beads (Next Advance, NY, USA; PINKE5) in 1x cell lysis buffer (Cell 
Signaling, Boston, MA) that contained proteinase inhibitor cocktail and other inhibitors  
(Sigma Chemical Co., St. Louis, MO; P8340). For protein-derived from cells, media was 
aspirated from wells and cells were rinsed with PBS. Cells were then lysed with 1x cell 
lysis buffer. All protein lysates were centrifuged and quantified with BCA assay (Thermo 
Scientific, Waltham, MA). Proteins were then separated by an SDS-PAGE gel (Thermo 
Scientific, Waltham, MA) and electrophorectically transferred to a polyvinylidene 
difluoride membrane (Millipore Corp., Billerica, MA). After blocking for at least 1 hour 
in 5% dry milk, proteins were detected by the following antibodies: actin-HRP (#5125), 
JAB1 (#6895), cullin 3 (#2759), Myc-tag (#2276), HA-Tag (#3724), DJ-1 (5933) were all 
purchased from Cell Signaling (Boston, MA) and MIF (#20121, Santa Cruz 
Biotechnology, Santa Cruz, CA). Membranes were then incubated with secondary 
antibody conjugated to HRP (#5571, Cell Signaling, Boston, MA). Chemiluminescent 
substrate was then used to detect the protein-antibody complexes (ECL; Amersham 
Pharmacia Biotech, Piscataway, NJ). 
 
2.4 Plasmid Preparation & Isolation 
Ampicillin-resistant E. coli containing pcDNA, Nrf2-myc, JAB1-myc, UBC12-
myc, dnUBC12, CAND1-myc, DJ-1-myc were spread on agar one bacterial colony was 
then selected and expanded in ampicillin LB broth. Bacteria was then centrifuged and 
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pelleted within 24 hours of inoculation and plasmids were purified using a Maxi-prep kit 
(Qiagen, Valencia, CA). DNA sequence was subsequently confirmedpcDNA3-FLAG-
HA was a gift from William Sellers (Addgene plasmid #10792), pcDNA-Myc3-Nrf2 and 
pcDNA-Myc3-CAND1 were gifts from Yue Xiong (Addgene plasmid #21555 and 
#19948). FLAG-HA-COPS5 was a gift from Wade Harper (Addgene plasmid #22541), 
pGW1-Myc3-DJ-1 was gifted from Mark Cookson (Addgene plasmid #29347), UBC12-
HA was a gift from Rachel Klevit (Addgene plasmid #31423) and pcDNA-HA-dnUBC12 
were all obtained from (Addgene, Cambridge, MA) 
 
2.5 Transfections 
 2.5.1 Transfection of siRNA 
 For gene-silencing experiments, cells were about 80-90% confluent and siRNA 
knockdowns of JAB1 and DJ-1 (GE Dharmacon, Lafayette, CO) were achieved using 
Geneporter 2 lipid-based transfection reagent (Genlantis, San Diego, CA). Complete 
media was removed and serum-free media was used to for transfections. Complete media 
was added 4 hours post-transfection. Media containing transfection reagent was removed 
and complete media was added 24 hours post-transfection. Cells were harvested with 1x 
cell lysis buffer (Cell Signal Technology, Danvers, MA) 48 hours and 72 hours post-
transfections to ensure significant of JAB1 and DJ-1 knockdowns, respectively.  
 
2.5.2 Plasmid Transfection 
Cells were plated to achieve 70-80% confluency within 24 hours of plating and 
overexpression of plasmids was completed in serum-free media by the lipid-based 
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transfection reagent, Lipofectamin 2000 (Thermo Scientific, Waltham, MA). Cells were 
harvested within 24 hours for analysis of ectopically expressed proteins. In Nrf2 stability 
experiments, cells were treated rMIF (100ng/mL) for 24 hours and with and without the 
protease inhibitor, 50μM MG-132 (Cell Signal Technology, Danvers, MA) for 1.5 hours.  
 
2.6 Dual Luciferase Assay 
Cells were transfected with 1 μg of a mixture of an Nrf2-responsive luciferase 
construct under the control of the antioxidant response element (ARE) and a 
constitutively expressing renilla construct, that served as an internal transfection control 
in a (40:1) using Lipofectamin 2000 as described above. For rMIF treatment experiments, 
cells were treated with 100ng/mL of rMIF within 24 hours post-transfection and 
harvested at 0, 12 and 24 hours with passive lysis buffer. For co-transfection experiments, 
the total amount of DNA transfected into cells on a 6-well plate was maintained at 1 μg 
by co-transfecting about one-third of the ARE-luciferase construct with remaining 
alternative plasmid. To ensure complete lysis, lysates were subject to one freeze-thaw 
cycle. Luciferase assays were completed in white opaque 96-well plates as outlined by 
the manufacturer of the Dual-Luciferase Reporter Assay System (E1910 Promega, 
Madison, WI) and luciferase activity was measured by using a luminometer.  
 
2.7 Caspase 3 Activity Assay 
 For the DJ-1 knockdown experiment, cells were transfected with DJ-1 siRNA, as 
described in section 2.5 and treated with CSE 72 hours post-transfection for 0, 2, 4, 6 and 
8 hours. Cells were then harvested with diluted 1x cell lysis buffer and probed for 
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caspase3 activity using the Caspase-Glo 3/7 assay (G8091, Promega, Madison, WI) 
according to manufacturer’s protocol. The caspase substrate with reconstituted in buffer 
prior to use and equal volumes of cell lysates and caspase 3 buffer were added in a white 
opaque 96-well plate. The cleavage of the substrate by the caspase produces a 
luminescent signal that is measured by a luminometer. All luminescent data were then 
normalized to cell lysate concentrations, determined via a bicinchoninic acid (BCA) 
assay.  
 
2.8 Statistical Analysis 
For comparisons among groups of normally distributed data sets, Student's t test 


































The Effects of MIF on the Nrf2-









3.1 Abstract  
 
 CS is the leading cause of, emphysema, a major type of COPD that is 
characterized by enlargement of the airspaces distal to the terminal bronchioles, 
permanent destruction of alveolar walls, and airflow limitation, ultimately leading to gas 
exchange impairment (Rodgers, Ezzati et al. 2004). CS contains over 4,000 chemicals 
and many of its toxic ingredients include carcinogens, unstable free radicals, particulate 
matter and volatile organic compounds (Talhout, Schulz et al. 2011). These chemicals 
contribute to increased ROS production, DNA damage and ultimately lead to EC 
apoptosis (Damico, Simms et al. 2011, Fallica, Varela et al. 2016). Under conditions of 
oxidative stress, such as in the case of CS exposure, cells respond by up-regulating 
proteins that scavenge and inhibit the effects of excess pro-oxidants. Nrf2 is a 
transcription factor that binds to the ARE and upregulates the transcription of many 
antioxidant genes that work to scavenge and neutralize ROS (Itoh, Chiba et al. 1997). 
There is evidence that the antioxidant pathway is compromised in COPD, leading to 
diminished antioxidant capacity and disease progression, implicating Nrf2’s necessary 
role in preventing oxidant-mediated lung disease (Suzuki, Betsuyaku et al. 2008, Zhao, 
Eguchi et al. 2017).  
 MIF is a pletropic cytokine that has been shown to antagonize CS-induced EC 
apoptosis in vitro (Damico, Simms et al. 2011) and in vivo (Fallia, Varela et al. 2016). 
MIF’s has been implicated in positively regulating antioxidant responses the context of 
oxidant-mediated injury. Aged MIF
-/-
 mice have increased susceptibility to radiation-
induced lung injury (RILI) and associated decreased Nrf2-expression and antioxidant 
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responses to ROS (Mathew, Jacobson et al. 2013). We used in vitro and in vivo models to 
test the hypothesis that MIF is a regulator of antioxidant responses during CS exposure. 
We have shown that exogenous recombinant MIF protein (rMIF) is sufficient to attenuate 
ROS accumulation in primary human microvascular endothelial (HMVECs) cells after 
CS exposure. Further, recombinant rMIF is sufficient to drive both Nrf2 protein 
expression and ARE activity in both HMVECs and rat microvascular endothelial cells 
(RMVECs). We also demonstrated MIF is a necessary mediator of antioxidant responses 
in the context of CS-induced oxidative stress in vivo. MIF deficient (MIF
-/-
) mice are 
unable to upregulate Nrf2-dependent transcription in response to acute CS-exposure. 
Taken together, we show that MIF is a positive regulator of Nrf2, which confers its 















Cells are constantly subject to various sources of ROS and other forms of pro-
oxidants. Endogenous ROS sources are the by-products of normal physiological 
mitochondrial metabolism (Barrett, DeGnore et al. 1999, Marnett 1999, Valko, Rhodes et 
al. 2006, Valko, Leibfritz et al. 2007). Cells are also susceptible to exogenous sources of 
ROS, which due to exposures to heavy metals (Lodovici and Bigagli 2011, Jan, Azam et 
al. 2015), components in CS (Asami, Manabe et al. 1997, Valavanidis, Vlachogianni et 
al. 2009) and particulate matter (Lodovici and Bigagli 2011). Increased exposure to pro-
oxidants can perturb the sensitive redox state of the cell. They are therefore equipped 
with mechanisms to combat the effects of these pro-oxidant exposures through the 
upregulation of antioxidants (Nguyen, Nioi et al. 2009). Oxidative stress is caused by the 
imbalance between the production of oxidants and the cell’s capacity to detoxify and 
neutralize them. While some endogenous sources of oxidants are important in cell 
signaling pathways (Banki, Hutter et al. 1999, Barrett, DeGnore et al. 1999), excessive 
presence of oxidants can cause damage to biological macromolecules (Thannickal and 
Fanburg 2000). Oxidative stress leads to DNA damage via strand breaks and promotion 
of adduct formation. It also causes lipid peroxidation (Wills 1966) and oxidation of 
proteins, which can ultimately lead inappropriate DNA damage repair or cell death (Pero, 
Roush et al. 1990, Asami, Manabe et al. 1997). This imbalance between ROS and anti-
oxidants can have many detrimental effects on cell biology, eventually leading to chronic 
inflammation and disease.  
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COPD is an irreversible lung disease that is characterized by the progressive 
chronic obstruction of the airways that interferes with normal breathing. COPD is the 
result of the complex interplay between genetics and the environmental irritants 
(reviewed in (Mannino and Buist 2007)). One established risk factor is the lifetime toxic 
burden associated with the chronic inhalation of noxious oxidants and particles (Kirkham, 
Caramori et al. 2011). In the United States, chronic exposure to CS is the leading cause of 
emphysema, a major type of COPD (Ezzati and Lopez 2004), contributing to about 80-
90% of all cases (Mannino and Buist 2007). Emphysema is a type of COPD that is 
characterized by irreversible enlargement of airspaces distal to the terminal bronchiole 
and progressive airflow limitation (Hogg, Chu et al. 2004). This enlargement is due to 
increased alveolar wall destruction, which markedly reduces the surface area for adequate 
gas exchange (Hogg 2004). Links between markers of oxidative stress and severity of 
COPD have been previously established. Klchova et al. showed that the severity of 
COPD is associated with increased levels of the lipid peroxidation product, 
malondialdehyde (MDA) (Rahman 2005, Kluchova, Petrasova et al. 2007). Furthermore, 
CS-induced COPD was correlated with enhanced DNA damage as well as oxidation of 
proteins resulting in the formation of protein carbonyl groups (Ceylan, Kocyigit et al. 
2006).   
The transcription factor and master regulator of the anti-oxidant response 
pathway, Nrf2 (Itoh, Chiba et al. 1997, Chan and Kan 1999, Itoh, Ishii et al. 1999) is 
responsible for the control of over 200 antioxidants (Kobayashi and Yamamoto 2006). 
Once activated, Nrf2 translocates to the nucleus where it binds to the ARE, located in the 
promoter of many antioxidant genes. The protective role of the Nrf2 antioxidant response 
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pathway has been well characterized in the context of the lung. Many studies have 
reported the protective role of the Nrf2-antioxidant pathway in the context of ROS-
induced injury in thecontext of the lung (reviewed in (Boutten, Goven et al. 2011)). They 
have also shown that it antagonizes the effects of CS exposure, an established 
determinant of COPD. The importance of Nrf2 in the setting of CS-induced emphysema 
was demonstrated by Rangasamy and colleagues, who showed that emphysematous 
tissue remodeling is exacerbated in Nrf2 deficient mice (Nrf2
-/-
). They also showed that 
Nrf2
-/-
 mice have increased oxidative stress markers, inflammation, EC and EpiC 
apoptosis after chronic exposure to CS for 6 months (Rangasamy, Cho et al. 2004). 
Interestingly, Nrf2 expression is also altered with chronic smoke. Its expression is 
attenuated in lavaged macrophages obtained from aged smokers as compared to non-
smoking age-matched individuals, suggesting that chronic exposure to CS downregulates 
Nrf2 in the aging lung (Suzuki, Betsuyaku et al. 2008), thereby conferring greater 
oxidative injury.  
The lung microvasculature is critical for maintaining homeostasis, gas exchange 
and proper function of the alveolar septa (Sirianni, Chu et al. 2003). ECs are critical for 
the integrity of the capillary network as well as alveolar structure (Le Bot, 2015). EC 
apoptosis has been demonstrated to be a necessary and sufficient mechanism that drives 
emphysematous tissue remodeling (Kasahara, Tuder et al. 2000, Tuder, Zhen et al. 2003, 
Gordon, Gudi et al. 2011). Specifically targeting EC for apoptosis by either a peptide-
directed method or via the pharmacological inhibition of the vascular endothelial growth 
factor (VEGF) receptor is sufficient to drive emphysematous tissue destruction in rodent 
models (Kasahara, Tuder et al. 2000, Giordano, Lahdenranta et al. 2008). Circulating 
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endothelial microparticles  (EMPs), which are markers of EC apoptosis are elevated in 
individuals with COPD with normal lung function. This implies that EC apoptosis is an 
early phenomenon that occurs prior to emphysematous tissue remodeling and pulmonary 
dysfunction (Gordon, Gudi et al. 2011). Therefore, elucidating the molecular mechanisms 
that regulate EC apoptosis in the context of CS exposure provides important insight into 
the pathogenesis of emphysema and potential insight into the well-recognized clinical 
heterogeneous responses to smoke exposure in humans.  
While MIF is long recognized as an important cytokine that regulates the innate 
immunes system, our understanding of its molecular and cell biologic properties have 
expanded substantially in more recent years. It is elevated under conditions of 
inflammation, its functions have been linked to promoting cell survivorship and 
inhibiting apoptosis (Wistow, Shaughnessy et al. 1993, Fingerle-Rowson, Petrenko et al. 
2003). Fallica et al showed that MIF is altered in patients with COPD. Serum levels of 
MIF are decreased in patients with advanced COPD as compared to non-smokers. Further 
stratifying the COPD cohort revealed that MIF is marked reduced in patients with 
advanced stage COPD. Thus, reduction in circulating MIF is associated with worse 
disease in humans (Fallica, Boyer et al. 2014). Similar findings were observed in a 
second independent cohort, which showed that MIF is not only deficient in patients but 
also declines in the BAL of aged mice exposed to chronic CS (Sauler, Leng et al. 2014).. 
Chronic CS exposure also decreases MIF expression in the lung tissue of mice, 
suggesting CS directly or indirectly antagonizes MIF expression in vivo.. Furthermore, 
MIF deficiency in chronic CS exposure results in increased ROS, markers of DNA 
damage, and EC apoptosis, ultimately driving emphysematous tissue damage (Fallica, 
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Boyer et al. 2014, Sauler, Leng et al. 2014, Fallica, Varela et al. 2016). This demonstrates 
a critical role for MIF in antagonizing ROS-mediated injury in the lung. The observed 
increases in sensitivity of pulmonary ECs in the setting of MIF deficiency in vivo, 
suggests that this cell type is particularly dependent on MIF in the context of CS 
exposure. Similar studies demonstrate that knockout of either MIF or one of its receptor, 
CD74, potentiates spontaneous emphysematous tissue remodeling in aging mice (Sauler, 
Leng et al. 2014) implicating MIF’s role in maintaining lung homeostasis during aging, 
although the molecular mechanism(s) of cytoprotection in the aging model remain to be 
defined experimentally.  A role for MIF in cytoprotecting against ROS-mediated injury in 
other injury models in the lung and in other organs have also been demonstrated. Studies 
of MIF knockout mice demonstrate a protective role for MIF in radiation-induced lung 
injury, a model characterized by increased markers of oxidative injury. MIF
-/-
 mice had 
increased BAL protein-a marker of lung permeability, enhanced histological markers of 
pulmonary inflammation and attenuated antioxidant capacity (Mathew, Jacobson et al. 
2013). Aged MIF
-/-
 mice exposed to ionizing radiation-induced disease phenotype was 
rescued via the administration of the antioxidants, implicating that injury is driven by 
oxidative stress and that MIF is a necessary mediator normal of antioxidant defenses 
(Mathew, Jacobson et al. 2013). In another ROS-mediated injury model of ischemic-
reperfusion within the heart, MIF
-/-
 mice have enhanced cardiac dysfunction associated 
with increased activation of the stressed-responsive kinase, JNK and its downstream 
target, BCL2-associated agonist of cell death (BAD) (Qi, Hu et al. 2009). In contrast to 
the work in the heart, MIF-mediated antagonism of another stress-response kinase p38 
MAPK, not JNK, has been linked to its ability to antagonize CS-induced injury in vitro 
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and in vivo (Fallica, Boyer et al. 2014, Fallica, Varela et al. 2016). There is a growing 
body of literature that characterizes MIF’s role is cytoprotective in models of injury 
characterized by increase ROS, yet the molecular mechanisms responsible for its 
biological properties remain to be defined.  
Given Nrf2’s critical role in inducing enzymes important in the detoxification of 
oxidants and the expanding data that MIF antagonizes ROS-mediated injury including 
CS-induced emphysema, we postulated that MIF plays a role in mediating antioxidant 
responses in the context of CS (Qi, Hu et al. 2009, Fallica, Boyer et al. 2014, Sauler, 
Leng et al. 2014, Fallica, Varela et al. 2016). Taken together, we hypothesize that MIF is 
inhibiting oxidant-mediated injury, in part, through its capacity to induce antioxidant 
responses. We therefore utilized in vitro and in vivo models to understand MIF’s effects 
on ROS production, Nrf2 activity and protein expression and Nrf2-dependent responses. 
Here we provided data that MIF is required for optimal antioxidant responses in the lung 
context of CS exposure and is sufficient to positively regulate Nrf2 via a proteasome-





3.3.1 MIF is Necessary for CS-Induced Antioxidant Transcripts in the Lung in vivo 
 It is well-established that CS, a composite of over 4,000 chemicals, induces ROS 
production in animal and cell models (Church and Pryor 1985). Chronic CS exposure 
also significantly blunts MIF expression in the lungs of mice chronically exposed to CS 
(Fallica, Boyer et al. 2014, Sauler, Leng et al. 2014). Furthermore, MIF loss is associated 
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with an increase in ROS accumulation in the lung, as well as increased emphysematous 
tissue remodeling (Fallica, Varela et al. 2016).  Given MIF’s role in antagonizing ROS in 
vivo and as well oxidant-mediated injury, we predict that MIF antagonizes ROS 
accumulation through its effects on antioxidant and detoxifying genes.   




 mice for 3 days with either 
filtered air or CS as previously describe (Fallica, Varela et al. 2016). Next, we utilized 
quantitative RT-PCR (qPCR) to characterize the effects on antioxidant gene expression in 
total RNA isolates from whole lung lysates. NAD(P)H Quinone Dehydrogenase 1 
(NQO1) and Glutathione Peroxidase 2 (GPX2) are two established Nrf2-dependent 
antioxidant genes. The expression of each transcript increased 2 and 7-fold, respectively 
in MIF
+/+
 exposed to CScompared to their air-exposed counterparts (p<0.01) (Fig. 3-1A 
and 3-1B). CS exposure failed to induced these transcripts in MIF
-/-
 mice despite the fact 
that these animals have increased lung ROS accumulation (data not show, reference 
JON). This implicates MIF as a necessary mediator of Nrf2-dependent responses during 
CS-exposure in vivo (n=3) (Fig 3-1A and 3-1B). 
 
3.3.2 Recombinant MIF (rMIF) Decreases CS-Induced ROS Accumulation in vitro 
MIF deficiency potentiates ROS and ROS-driven injury (Mathew, Jacobson et al. 
2013, Fallica, Varela et al. 2016), which is associated with the failure to express Nrf2-
dependent antioxidant transcripts (Mathew, Jacobson et al. 2013). This supports a model 
in which MIF inhibits ROS-mediated injury by promoting antioxidant gene expression in 
vivo. To determine if MIF is sufficient to alter ROS accumulation, we used an in vitro 
model. 
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We therefore, sought to investigate if exogenous MIF was sufficient to blunt the 
effects of CS-induced ROS accumulation in HMVECs. We utilized fluorogenic ROS-
sensitive dye, 2’,7’–dichlorofluorescin diacetate (DCFDA), which becomes oxidized to 
the fluorescent marker, DCF in the presence of ROS.  Based on previously published 
evidence on the efficacy of rMIF in protecting HMVEC’s from CS-induced apoptosis, we 
utilized a dose of 100ng/mL (Damico, Simms et al. 2011). Cells were pre-treated with 
vehicle control (0.1% bovine albumin serum (BSA) in PBS), rMIF (100ng/mL) or N-
acetyl cysteine (NAC), an antioxidant that served as a positive control for this study, 4 
hours. We then challenged cells with cigarette smoke extract (CSE) at a concentration 
2x10
-2
 cigarette per 1 mL of PBS to generate 20% (v/v) as previously described in 
Chapter 2. This dose was chosen based on prior dose-response curved for CSE-induced 
EC apoptosis. Fluorescence was assessed at baseline and after exposure to CSE and 
reported as the change in fluorescence over baseline (ΔF/F0) of each biological sample. 
CSE induced over 1.2-fold increase in ROS accumulation in HMVECs in cells treated 
with the BSA control. Pre-treatment of cells with rMIF significantly antagonized 
intracellular ROS, implicating its role in inhibiting CS-induced ROS production in ECs. 
NAC treatment suppressed the change in DCF fluorescence, demonstrating specificity 
(Fig 3-2). Thus, exogenous MIF had the capacity to blunt CSE-induced intracellular ROS 
accumulation in EC in vitro.  
 
3.3.3 MIF Drives ARE Activity in Pulmonary ECs  
MIF antagonizes the accumulation of CSE-induced ROS, implicating MIF as a 
negative regulator of CSE-induced oxidant formation. We have also previously observed 
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that MIF deficiency in vivo potentiates CS-induced ROS in the lung (Fallica, Boyer et al. 
2014), which is associated with a significant attenuation in antioxidant gene expression 
(Fig 3-1A & 3-1B). Thus, we predict that MIF directly or indirectly promotes antioxidant 
gene expression accounting for its effects on ROS concentrations. Therefore, then sought 
to identify the effects of MIF directly on the ARE, a DNA element within the promoter of 
many antioxidant genes responsive to the Nrf2 transcription factor.  
We transfected HMVECs with a dual ARE reporter system, which is a mixture 
comprised of an ARE-responsive firefly luciferase construct and a Renilla construct 
under the control of the constitutive active CMV promoter, in a 40:1 ratio. Renilla served 
as an internal transfection control. After about 24 hours post-transfection, we treated cells 
with rMIF for 0, 12 and 24 hours (Fig. 3-2a). ARE activity was then determined by a 
luciferase assay that was performed under the manufacturer’s protocol. We found that 
treatment with rMIF significantly drives ARE-activity by about 1.5 fold 24 hours post-
treatment (p<0.01). Given this data, MIF’s ability to drive antioxidant responses, as 
demonstrated by other models, may be through its ability to positively regulate ARE 
activity and downstream antioxidant gene transcription.  
 
3.3.4 MIF is Necessary for Optimal ARE Activity Under Conditions of Oxidative 
Stress 
 We have demonstrated that MIF is able to inhibit CS-mediated ROS accumulation 
both in vivo and in vitro and have postulated that it may antagonize ROS propagation via 
its capacity to induce antioxidant responses. We therefore studied the effects of 
exogenous MIF on ARE activity and found that it positively regulates its activity. We 
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then aim to understand if MIF is a necessary mediator of CS-induced ARE activity. In 
other words, we ask if the loss of MIF would blunt  CS-induced ARE activity.  
In order to address this question of necessity, we utilized MIF siRNA to abrogate 
MIF in vitro. We co-transfected cells with either on-target control (OT) siRNA or MIF 
siRNA and the same dual ARE luciferase constructs (as described previously). Cells were 
then treated with vehicle control 20% PBS (v/v) or cigarette smoke extract (CSE) (2x10
-2
 
cigarette/mL) 24 hours post-transfection. While we have successfully knocked down MIF 
(data not shown), we found no difference in basal ARE activity in cells that were 
transfected with OT siRNA or MIF siRNA, suggesting that MIF is not necessary 
mediator of ARE under basal conditions. CSE was sufficient to significantly drive ARE 
activity by nearly 9-fold in cells co-transfected with OT. The ARE activity response to 
CSE was significantly blunted in cells that were transfected with MIF siRNA, 
demonstrating, MIF as a necessary mediator of optimal CSE-induced ARE activity in EC 
in vitro (p=0.057) (Fig. 3-3).  
 
3.3.5 rMIF Promotes Stabilization of Nrf2 in a Proteasome-Dependent Manner  
 Provided that we have demonstrated that MIF is both a necessary and sufficient 
regulator of ARE activity in vitro and that Nrf2 is the master regulator of the ARE, we 
proceeded to investigate the effects of MIF on Nrf2 expression. We predicted that MIF is 
enhancing antioxidant responses via its capacity to positively regulate Nrf2. In order to 
test the hypothesis that exogenous MIF is impacting Nrf2 protein expression, we treated 
HMVECs with either vehicle control (0.1% BSA) or rMIF (100ng/mL). Cells were then 
lysed 24 post-treatment, which was the amount of time required to significantly drive 
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ARE activity. Endogenous Nrf2 expression was evaluated by western blotting whole cell 
lysates. Results reveal that rMIF was sufficient to significantly increase Nrf2 protein 
expression by approximately 2-fold (Fig. 3-4).  
 While we have demonstrated that MIF increases Nrf2 protein expression, it is 
unclear if MIF is doing so by upregulating its expression or by impeding its degradation. 
Nrf2 is a tightly regulated molecule with a high rate of turnover. Under basal conditions, 
Nrf2 interacts with the redox-sensitive molecule KEAP1, which adapts Nrf2 to the cullin-
RING ligase complex (CRL3), machinery required to target it for ubiquitination and 
subsequently, degradation by proteasome (Itoh, Chiba et al. 1997). We therefore, 
hypothesize that MIF is inducing Nrf2 stability by interfering with its proteasomal-
mediated degradation. To test this, we over-expressed myc-tagged Nrf2 under the 
influence of the constitutively expressed CMV promoter in RMVECs using transient 
transfection. This allowed us to overcome technical limitations inherent in detecting 
endogenous Nrf2 with the commercially available antibodies in these cells. Further, it 
eliminated any effect of MIF on the endogenous Nrf2 promoter. Ectopic Nrf2 protein was 
detected with the myc- epitope tag. Twenty hours post-transfection, we treated cells with 
either 0.1% BSA (vehicle (Veh) control) or rMIF (100ng/mL). In order to investigate the 
effects of MIF on the proteasomal-mediated degradation of Nrf2, we utilized an 
established chemical inhibitor of the proteasome, MG-132. MG-132 inhibits the 
proteasome-mediated degradation, thereby allowing for the accumulation of Nrf2. About 
24 hours post-treatment of either Veh or rMIF, we then treated cells with either, the 
vehicle control, DMSO or MG-132 (50μM) for an additional 90 minutes. This dose and 
time have been extrapolated from previous experiments and been shown to effectively 
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block the proteasome (data not shown). Cells were lysed 24 hours post-treatment and 
whole cell lysate were analyzed by western blot for ectopic myc expression. We found 
that rMIF treatment significantly upregulated Nrf2 expression by approximately, 3-fold 
as compared to Veh control in the DMSO-treated arm (p<0.01). As expected, the 
inhibition of the proteasome by the chemical, MG-132 was also sufficient to drive Nrf2 
expression by a similar increase (Veh+MG-132) (p<0.01). Interestingly, the treatment of 
both rMIF and MG-132 did not potentiate a further increase in Nrf2 expression when 
compared to either the rMIF+DMSO and Veh+MG-132 arms, implicating MIF’s ability 
to increase Nrf2 expression is mediated through a proteasome-dependent mechanism 
(Fig. 4-5). These provide evidence for MIF’s ability to enhance Nrf2 expression by 
impeding its degradation.  
 
3.4 Discussion & Conclusion 
 
Maintenance of redox status within the cell is critical to its survival. Oxidative 
stress is defined as a state in which the amount of oxidants and pro-oxidants overwhelm 
the antioxidant capacity in a cell, thereby leading to changes in the redox status and 
damage to macromolecules (Wills 1966). In order to combat the effects of excess ROS, 
cells express Nrf2, a transcription factor critical in regulating anti-oxidant gene 
expression (Nguyen, Nioi et al. 2009). Our data provides evidence for the role of the 
cytokine, MIF in mediating antioxidant responses in the context of CS-induced oxidative 
stress.   
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Chronic CS exposure remains to be a leading risk factor in developing COPD in 
the Unites States, attributing to approximately 80-90% of cases (Sethi and Rochester 
2000). COPD is heterogeneous disease and one of the established contributors of disease 
pathogenesis is oxidant and antioxidant imbalance. Patients with COPD have not only 
increased markers of inflammation, that correlate with disease severity but they also have 
a greater imbalance between oxidant and antioxidants, which results in enhanced oxidant 
burden in patients with COPD (Marsh, Zaiser et al. 2017). In addition to an imbalance of 
oxidants and antioxidant, there is growing body of literature that demonstrates Nrf2’s role 
in protecting the lung from pathogenesis of the COPD (Cho, Reddy et al. 2006). The loss 
of Nrf2 was shown to drive emphysematous tissue remodeling in mice chronically 
exposed to CS (Iizuka, Ishii et al. 2005). Furthermore, Nrf2 expression is attenuated, 
while KEAP1 expression is significantly increased in alveolar macrophages isolated from 
patients with emphysema as compared to those without disease (Goven, Boutten et al. 
2008). We provide evidence that MIF is a necessary mediator of Nrf2 responses in the 
context of CS exposure. Acute exposure to CS induces the Nrf2-dependent genes, NQO1 
and GPX2 in wild-type mice. This induction is lost however, in MIF-deficient mice, 
implicating MIF as a necessary mediator of antioxidant responses in the context of CS.  
Emphysema, a major type of COPD is characterized by permanent enlargement of 
the alveolar walls. EC apoptosis has been shown to be both a necessary sufficient 
mechanism to induce emphysematous tissue remodeling (Yokohori, Aoshiba et al. 2004, 
Demedts, Demoor et al. 2006). Segura-Valdez and colleagues showed that EC apoptosis 
was elevated in the lungs of patients with COPD as compared to their controls (Segura-
Valdez, Pardo et al. 2000). Furthermore, Giordano et al showed that specifically targeting 
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ECs for apoptosis was sufficient to induce emphysematous tissue remodeling in mice 
independent of CS exposure (Giordano, Lahdenranta et al. 2008). Clinical data shows 
that circulating EMPs, indicative of EC apoptosis is an early phenomenon that predates 
emphysematous remodeling. MIF has been proven to be an important in maintain EC 
homeostasis by antagonizing p53-dependent apoptosis in the context of CS (Damico, 
Simms et al. 2011). Furthermore, its loss is associated with increased ROS production 
and ROS-induced injury (Fallica, Boyer et al. 2014). Here, we provide evidence that one 
of the mechanisms by which MIF is conferring cytoprotection is through its capacity to 
impact Nrf2 stability and mediate antioxidant responses. 
Previous studies have shown that MIF is altered in patients with COPD and that 
MIF is significantly depressed in advanced-stage COPD (Sauler, Leng et al. 2014, 
Fallica, Varela et al. 2016). It remains uncertain if this phenomenon is causative or the 
result of disease in humans. MIF however, is a necessary inhibitor of emphysematous 
tissue remodeling in a well-established preclinical model of CS-induced lung injury, as 
MIF
-/-
 mice have increased emphysematous tissue remodeling after chronic exposure to 
CS (Fallica, Boyer et al. 2014). Furthermore, MIF
-/-
 mice also have increased activity of 
the endothelial ROS-producing enzyme, xanthine oxidoreductase (XOR), which was 
accompanied by an increase in ROS production in the lung tissues (Fallica, Varela et al. 
2016).These findings establish the importance of MIF in inhibiting not only 
emphysematous tissue remodeling, but also in attenuating ROS production in vivo. Given 
evidence of MIF-suppressed ROS production, we sought to determine MIF’s effects on 
antioxidant responses. We found that pre-incubation of HMVECs was sufficient to blunt 
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ROS accumulation after CSE exposure, implicating its role in blunting ROS production 
both in vivo (Fallica, Varela et al. 2016) and in vitro (Fig. 3-1). 
There is sufficient evidence to suggest that MIF is impacting the redox statues of 
the cell, we therefore asked if MIF is impacting the antioxidant response element activity. 
The ARE is a redox sensitive cis-acting DNA element located in the promoter region of 
many antioxidant genes (Rushmore, Morton et al. 1991). We demonstrated that rMIF was 
sufficient to induce ARE activity within 24 hours of EC treatment, independent of CSE 
exposure (Fig. 3-3b). Furthermore, we also showed the abrogation of MIF in vitro by 
siRNA, was sufficient to attenuate CS-induced ARE activity, implicating MIF’s 
necessary role in mediating optimal ARE activity under conditions of oxidative stress 
(Fig. 3-3). The ARE is primarily regulated by Nrf2 (Moi, Chan et al. 1994), we therefore 
postulated that MIF is impacting the ARE via its capacity to impact Nrf2 expression. We 
found that treatment of ECs with rMIF for 24 hours was sufficient to increase 
endogenous Nrf2 protein expression (Fig. 3-3a). This suggests that MIF is impacting 
Nrf2 expression potentially via its capacity to either increase its expression or impede its 
degradation.  
Nrf2 controls the expression of many genes, making its tight regulation crucial for 
normal cell function. Nrf2 is negatively regulated by KEAP1, which serves to adapt Nrf2 
to the ubiquitination machinery and target it for proteasomal-mediated degradation 
(Taguchi, Motohashi et al. 2011). In order to elucidate the mechanism by which MIF is 
impacting Nrf2 expression, we investigated the effects of the proteasome on MIF-induced 
Nrf2 expression. By chemically inhibiting the proteasome with the drug MG-132, we 
provide evidence that MIF is increasing Nrf2 in a proteasomal-dependent mechanism in 
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Nrf2-myc transfected RMVECs. We show for the first time that MIF is impacting Nrf2 
expression at the level of protein degradation. This may be achieved through MIF’s 
capacity to either impact either KEAP1 or a component of the ubiquitination machinery, 
Cullin-RING ligase 3 (CRL3). It has been established that MIF binds to c-Jun activation 
domain binding protein-1 (JAB1)/subunit 5 of the COP9 signalosome (CSN5) and 
inhibits its ability to activate downstream signaling pathways (Kleemann, Hausser et al. 
2000). JAB1 has ispopeptidase activity that serves to remove a uqiquitin-like molecule  
(NEDD8), which ultimately regulates the activity of the KEAP1-CUL3 ligase complex 
(Cope, Suh et al. 2002). Given that JAB1 interacts with and negatively regulated by MIF 
and is an established mediator of the deneddylation of CRL3, it serves as an attractive 
target to elucidate the mechanism by which MIF is impacting Nrf2 degradation. 
Understanding how MIF is impacting KEAP1 and CRL3 would provide important insight 
into MIF antioxidant-mediating capacity.  
In conclusion, we have established that MIF is a necessary mediator of 
antioxidant responses in the context of CS in our in vivo and in vitro models. The loss of 
MIF increases the susceptibility to CS-induced injury through the increase of oxidative 
stress and the loss of the antioxidant responses. Furthermore we provide evidence for 
MIF regulating antioxidant responses by inhibiting proteasomal-mediated degradation of 
Nrf2. Antioxidant responses are important in the impeding the pathogenesis of COPD.   
These responses are altered in patients with COPD and are associated with increased 
oxidative burden and disease pathogenesis. In recognizing the importance of antioxidants 
in the context of increased oxidative burden during CS, our data provides insight for 
MIF’s role in antagonizing CS-induced emphysematous remodeling. Finally, these results 
 78 
demonstrate that MIF is a necessary mediator of antioxidant responses in vivo and a 





















                  
 
 
Figure 3-1: MIF is necessary for CS-induced antioxidant transcription in vivo. 
Wildtype (MIF
+/+
) and MIF knockout (MIF
-/-
) that were exposed to either filtered air or CS for 3 
days as previsouly described (Fallica, Varela et al. 2016) and total RNA was isolated from lung 
homogenates and analyzed by real time quantitative (RT-qPCR). Nrf2-dependent transcripts 
NQO-1 (A) and GPX2  (B) were quantified using Actin mRNA as a referene transcript. CS 
exposure induced significant changes in NQO1 and GPX2 mRNA in MIF+/+ animals while there 




















               
 
Figure 3-2: rMIF decreases CS-induced ROS accumulation in vitro. Primary HMVEC 
cells were loaded with the ROS-sensitive dye, DCFDA for 45 minutes. Cells were then pre-
incubated with either carrier, rMIF(100ng/mL) or N-acetyl cysteine (NAC) for 4 hours prior to 
exposure to 20% CSE. Relative change in fluorescence from baseline (delta F/F0) was used to 
evaluate the CSE-induced ROS accumulation within the cells. Pre-treatment with rMIF 






























Figure 3-3: rMIF induces ARE-activity in vitro. HMVEC were transfected with a plasmid 
encoding the luciferase gene under the control of the ARE protomer and renilla gene 
constitutively expressed under the CMV promoter. Cells were then exposed to rMIF and lysed at 
0, 12 and 24 hours. Luciferase activity was measured according to manufacturer’s protocol, 
normalize to renillin and expresssed as relative light units per microgram protien (RLU/ug). rMIF 
is sufficient to significantly increase ARE promoter activity in EC in vitro. Results based on 3 






















Figure 3-4: MIF loss attenuates CS-induced ARE activity. A. HMVECs were co-transfected 
with the ARE-luciferace reporter plasmid and either on-targeting control siRNA (OT) or MIF 
siRNA, conditions demonstrated to efficiently suppress MIF protein expression (data not shown). 
Cells were subsequently challenged with vehicle or 20% CSE for 24 hours and an assay to assess 



















































Figure 3-5: MIF-induced Nrf2 expression in ECs is proteasome-dependent. A. HMVEs were 
incubated with either carrier control or rMIF (100ng/mL). At 24 hours post-treatment, whole-cell 
lysates were prepared and were subject to western blot analysis as described in methods and 
materialsand probed with anti-Nrf2 antibody and housekeeper, anti-GAPDH. Representative blot 
demonstrating increased Nrf2 protein in rMIF-treated EC. B. Quantification of the western by 
densitometric analysis  (p<0.05). C. rMIF increases expression of ectopic of Nrf2-myc in a 
proteasome-dependent manner. RMVECs were transfected with a myc-tagged Nrf2 plasmid and 
then treated with either vehicle control or rMIF (100ng/mL) for 24 hrs. They were then exposed 
to either DMSO or the proteasome-inhibitor, MG-132 (50μM) for 1 hr. Cells were then lysed and 
whole-cell lysates were prepared for western blot analysis and probed with for myc epitope actin. 






























rMIF induced a significant increase in Nrf2 protein. The ability to rMIF to further augment Nrf2 

























MIF Inhibits Proteasomal-Mediated 














The transcription factor, Nrf2 is the established master regulator of the antioxidant 
pathway. It is important in activating over 200 antioxidant genes that detoxify and 
neutralize ROS, thereby attenuating their detrimental biological effects (Itoh, Chiba et al. 
1997). MIF is a proinflammatory cytokine that has many important biological functions, 
among which include the promotion of cell survival by inhibiting apoptosis (reviewed in 
(Bloom, Sun et al. 2016)). MIF deficient mice have increased ROS accumulation and 
emphysematous tissue remodeling in the lung after exposure to CS (Fallica, Boyer et al. 
2014, Fallica, Varela et al. 2016). We have also previously shown that MIF may confer 
cytoprotection by positively regulating Nrf2 stability in a proteasomal-dependent 
mechanism (Chapter 3). Under basal conditions, Nrf2 is constantly targeted for 
proteasomal-mediated degradation by the KEAP1-CUL3 ligase complex (CRL3) 
(Villeneuve, Lau et al. 2010). KEAP1 serves as an adaptor molecule, connecting Nrf2 to 
the ubiquitination machinery, CRL3. CRL3 activity is regulated by the assembly and 
disassembly of its components, which are regulated by the cyclic addition and removal of 
the NEDD8 molecule, as well as the CRL negative regulator, CAND1. The process of 
neddylation/dennedylation is catalyzed by two enzymes the neddylase, UBC12 and the 
deneddylase, JAB1(Gong and Yeh 1999, Muromoto, Nakajima et al. 2013). Furthermore, 
MIF binds and negatively regulates JAB1 (Burger-Kentischer, Finkelmeier et al. 2005). 
Given MIF’s ability to stabilize Nrf2 in a proteasomal-dependent mechanism and its 
negative regulatory effects on JAB1, we hypothesize that MIF is impacting Nrf2 stability 
via its effects on the KEAP1-CUL3 ligase complex.   
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Our results reveal that chronic CS exposure increased neddylation of CUL3 in the 
lung of wild type mice as compare to those exposed to air. This observation is lost in MIF 
deficient mice, implicating a MIF-dependent mechanism of CUL3 modification. 
Furthermore, MIF
-/-
 mice have increased JAB1 expression during CS exposure, which is 
coincident with decreased neddylation of CUL3, as well as depressed Nrf2-dependent 
responses and enhanced oxidant-mediated injury. Given that deneddylated CUL3 is 
associated with worse disease outcomes, we sought to test the hypothesis that driving the 
neddylation of CUL3 would lead to increase Nrf2 stability in vitro. We induced the 
neddylation of CUL3 in vitro by overexpressing the neddylase, UBC12. We found that 
increased neddylation was associated with an increase in Nrf2 protein expression and 
ARE activity. We also tested the hypothesis that MIF was a negative regulator of JAB1 in 
our model. MIF was not sufficient to impact JAB1 expression in EC in vitro, indicating 
that MIFs ability to modify ROS and Nrf2 expression in vitro are independent of direct 
effects on JAB1 expression. Finally, we found that exogenous MIF was sufficient to 
induce the expression of the negative regulator of CLR3, CAND1. CAND1 binds and 
inhibits CRL3 activity, thereby promoting the stabilization of the CRL’s target substrate 
molecule. Overexpression of CAND1 in our model induced Nrf2 stability. Taken 
together, we demonstrate MIF’s capacity to induce Nrf2 via its ability to upregulate the 








There is growing evidence demonstrating MIF’s role in blunting ROS-induced 
injury, functioning in part to promote antioxidant responses in vitro and in vivo. Mathew 
et al showed that MIF is a necessary regulator of antioxidant gene expression in age-
related susceptibility in radiation-induced lung injury. Aged MIF
-/-
 mice have enhanced 
susceptibility to oxidant-mediated lung injury, which was associated with significantly 
attenuated Nrf2 protein expression and its downstream antioxidant gene transcription 
(Mathew, Jacobson et al. 2013). We have previously demonstrated that MIF antagonizes 
CSE-induced ROS accumulation in EC in in vitro (Fig. 3-2). We have also found that 
MIF positively regulates the master regulator of the ARE, Nrf2, by interfering with its 
proteasome-mediated degradation (Fig. 3-5).  
Nrf2 is a tightly regulated transcription factor that can be controlled both at the 
level of transcription and post-translation (Miao, Hu et al. 2005, Taguchi, Motohashi et 
al. 2011). It is important in the transcription of many genes involved in electrophilic 
stress, xenobiotic metabolism and glutathione synthesis (Okawa, Motohashi et al. 2006, 
Malhotra, Portales-Casamar et al. 2010). Under basal conditions, Nrf2 is rapidly turned 
over with a half-life of <20 minutes (Katoh, Iida et al. 2005). It is sequestered in the 
cytoplasm by KEAP1, an adaptor molecule and sensor of redox changes in the cell. 
KEAP1 assists in the polyunbiqutination and degradation of Nrf2. Under conditions of 
oxidative stress however, KEAP1’s reactive cysteine residues become oxidized, form 
disulfide bridges that induce its conformational changes and through mechanisms not yet 
fully elucidated, perturb its interaction with Nrf2 and thus stabilizes Nrf2 (Holland, 
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Hawkins et al. 2008). KEAP1 connects Nrf2 to the CRL3 (Kobayashi, Kang et al. 2004), 
the complex responsible for ligating ubiquitin to Nrf2 and targeting for degradation by 
26S-mediated proteasome (Kirisako, Kamei et al. 2006). 
This process generally occurs via three major classes of enzymes, ubiquitin 
activating enzymes (UAE or E1), ubiquitin-conjugating enzymes (E2) and finally, 
ubiquitin-protein ligases (E3) (Pickart 2001, Markson, Kiel et al. 2009). RING make up 
the largest group of E3 enzymes. RING E3 ligases bind a family of proteins known as 
cullin, which serve as molecular scaffolds by which other molecules can dock and form 
CRLs, the multisubunit complexes responsible for targeting a substrate molecule for 
ubquitination (Hua and Vierstra 2011). CRLs differ in the types of cullins they form 
around and their constituents, but have they all have share the same general types of 
components. The basic components of the CRL consist of a scaffold (cullin), an adaptor 
molecule (i.e. KEAP1), E3 ligase, ubiqiuitin-loaded E2 ligase and a RING finger protein 
(RBX1 also known as ROC1). In eukaryotes, there are six different cullins (CUL1-5 and 
CUL7), which recognize different domains of adaptor molecules. CRL3, comprised of 
CUL3, specifically recognizes and interacts with the BTB/POZ domain (Genschik, 
Sumara et al. 2013), which is the characteristic domain found in KEAP1 (Furukawa, He 
et al. 2003, Geyer, Wee et al. 2003).  
CRL activity is regulated by a number of ways chief among them is the cyclic 
addition and removal of a small ubiquitin-like molecule known as NEDD8. The 
reversible addition of the NEDD8 molecule to CRL leads to the activation of the complex 
and the recruitment of ubiqiuitin-loaded E2. Similar to ubiquintination, neddylation 
involves the mutli-step cascade consisting of activation (NEDD8 E1), conjugation 
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(NEDD8 E2 or UBC12) and ligation (NEDD8 E3) (Gong and Yeh 1999, Leidecker, 
Matic et al. 2012). NEDD8-UBC12 interacts with RBX1 to catalyze the transfer of 
NEDD8 from UBC12 to a lysine residue of the C-terminal domain of a Cullin molecule 
(Ohta, Michel et al. 1999). Neddylation is a reversible process, and NEDD8 can be 
removed by several different proteins with isopeptidase activities. JAB1, also known as 
CSN5, is a member of the COP9 signalsome that regulates neddylation by the enzymatic 
cleavage of NEDD8. It contains the MPN domain metalloenzyme (JAMM) motif, which 
confers the isopeptidease activity responsible for removing the NEDD8 molecule from 
cullin molecule (Schwechheimer and Deng 2001, Wee, Geyer et al. 2005).  
Our previous study reveals that MIF is interfering with proteasomal-mediated 
degradation of Nrf2. We have thus used an in vivo model to specifically characterize the 
effects of MIF on CUL3. Our in vivo data reveals that CS exposure alters the neddylation 
status of CUL13.  This is lost in the absence of MIF coincident with worse remodeling 
and enhanced expression of the deneddylase, JAB1. We then utilized RMVECs as our in 
vitro model to define the potential mechanism by which MIF impacts CUL3 neddylation 
status and Nrf2 stability. Previous in vitro studies indicate that MIF can modify the 
activity of the transcription factor AP-1, via direct binding and functional antagonism of 
JAB1. Kleeman and colleagues showed that MIF directly binds to JAB1 via residues 50-
60, making Cys60 critical for its interaction with JAB1. Furthermore, they found that the 
addition of rMIF reversed the positive regulatory effects of JAB1 on AP-1 activating, it 
also antagonized enhanced JAB-1 mediated c-Jun amino terminal kinase (JNK) activity 
(Kleemann, Hausser et al. 2000).  Given that MIF is an established negative regulator of 
JAB1 as well as our JAB1 findings in vivo, we sought to evaluate the effects of MIF on 
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JAB1 expression in ECs in vitro. Treatment with rMIF did not alter absolute JAB1 
expression nor did it alter the neddylation status of CUL3 in vitro. This implicates 
another mechanism by which MIF is inducing Nrf2 stabilization in ECs in vitro 
(Kleemann, Hausser et al. 2000, Pyle, Korbonits et al. 2003).  Given that deneddylation 
of CUL3 is associated with worse outcomes in vivo in MIF deficient mice, we postulated 
that promoting CUL3 neddylation in our system would be sufficient to stabilize Nrf2. We 
found that overexpression of the neddylase, UBC12 enhanced CUL3 neddylation and 
improved Nrf2 stability and ARE activity. Next we investigated MIF’s effects on the 
negative regulator of the CRL, CAND1. Treatment of cells with rMIF was sufficient to 
upregulate CAND1 expression and forced overexpression of CAND1 induced Nrf2 
expression. We have thus defined a novel mechanism by which MIF regulates Nrf2 
degradation through its ability to positively regulate CAND1. This represents the first 
demonstration that CAND1 expression is responsive to any extracellular stimulus or 
circulating cytokine and provides the molecular framework to investigate aberrant 




4.3.1 MIF Does Not Effect KEAP1 Expression in vivo and in vitro 
 We have previously shown that MIF is necessary for antioxidants responses in 
vivo. Furthermore, treatment of ECs with exogenous MIF significantly upregulated ARE 
activity as well as Nrf2 expression in vitro (Fig. 3-1, 3-3 & 3-4), suggesting the MIF is 
sufficient to drive antioxidant responses in pulmonary ECs. We have also demonstrated 
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MIF’s capacity to stabilize Nrf2 via interference with its proteasome-mediated 
degradation. KEAP1 is the adaptor molecule that serves to bridge the CUL3-E2 ligase 
complex to Nrf2, to enable its poly-ubiquitination and subsequent degradation (Errington, 
Khan et al. 2012). KEAP1 structure responds to changes in cellular redox status, enabling 
it to unlatch from Nrf2, thereby promoting Nrf2 stabilization. Given KEAP1’s key role in 
Nrf2 degradation and MIF’s ability to promote its stability, we predicted that MIF 
antagonizes KEAP1 expression to promote its stability. We treated RMVECs with either 
vehicle control (0.1% BSA) or rMIF (100ng/ml). This dose was selected based on 
previous results that demonstrated its ability to protect ECs from CS-induced apoptosis 
(Damico, Simms et al. 2011) and sufficient to upregulate Nrf2 expression and ARE 
activity. Cells were lysed 24 hours post-transfection and KEAP1 expression was analyzed 
by western blot. We found that rMIF had no effects on KEAP1 expression in vitro (Fig 4-
1). 
 Next, we investigated the effects of MIF on KEAP1 expression in vivo. Wild-type 
and MIF deficient mice were exposed to either air or CS acutely, for 3 days. CS exposure 
for this given time point has been proven to be sufficient to induce antioxidant responses 
in the lung and phenotypical differences are observed between wild type and MIF
-/-
 mice 
at this time point (Fallica, Varela et al. 2016). Total protein was isolated from whole lung 
homogenate. A western blot analysis of total KEAP1 protein expression revealed that 
MIF deficiency does not alter KEAP1 expression in vivo, indicating that MIF-induced 
Nrf2-stabilization is independent of alterations in KEAP1 expression (figure not shown).   
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4.3.2 Chronic CS Exposure Alters CUL3 Neddylation: Impact of MIF Deficiency  
 Given CUL3’s critical role in the assembly of the CRL complex and in Nrf2 
ubiquitination and subsequent degradation, we sought to investigate MIF’s effects on the 




 mice were exposed to either filtered air or 
CS chronically, for 6 months. Previous experiments have demonstrated that 6-month CS 
exposure is sufficient to induce enhanced emphysematous tissue remodeling in MIF 
deficient mice (Fallica, Boyer et al. 2014). Protein was isolated from whole lung tissue 
that was homogenized in cell lysis buffer. Expression of CUL3 was then analyzed by 





 mice exposed at baseline (i.e. air) or following CS.  
 Recognizing that we did not observe MIF-dependent differences in KEAP1-
CUL3 protein, we investigated the effects of MIF on the well-characterized post-
translational modification (PTM) of CUL3, specifically its neddylation status. Given the 
important role of NEDD8 in regulating CRL activity (Kamitani, Kito et al. 1997, Hori, 
Osaka et al. 1999) and MIF’s ability to regulate antioxidants, we investigated the role of 





 at baseline in mice exposed to filtered air. Thus, MIF does not seem to 
be necessary in CUL3 neddylation under basal conditions. Following exposure of MIF
+/+
 
mice to prolonged CS, we observed a significantly increase in the neddylation of CUL3 
by about 1.5-fold (p<0.01) (Fig. 4-2). Interestingly, we found that CS-induced 
neddylation of CUL3 is completely lost in MIF
-/- 
mice and resembles the neddylation 
status of mice exposed to air (Fig. 4-2), implicating MIF’s role in mediating CUL3 
activity under conditions of increased oxidative burden.  
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4.3.3 Chronic CS Exposure Induces Expression of the Deneddylase, JAB1, in the 
Absence of MIF 
 In recognizing that CS increases the CUL3 neddylation, an observation that is lost 
in MIF
-/-
 mice, we sought to determine if this was associated with altered expression of 
the deneddylating enzyme, JAB1 in vivo. MIF is an established negative regulator of 
JAB1 function. To test the effects of MIF on JAB1 in vivo, we investigated the JAB1 




 mice that were chronically 
exposed to either filtered air or CS for 6 months. We would predict that the differences 




 mice could be linked to 
altered JAB1 expression and/or activity. Western blot results reveal that MIF deficiency 
does not alter JAB1 expression under basal conditions (Fig. 4-3). CS exposure itself is 
not sufficient to affect JAB1 expression in MIF
+/+
 mice. In contrast, JAB1 expression is 
significantly upregulated by about 4-fold in MIF deficient mice relative to their MIF+/+ 
counterparts exposed to chronic CS (p<0.01) (Fig. 4-3). Thus, we observe a differential 
effect of CS on CUL3 neddylation status and expression of the deneddylase, JAB1, as a 
function of MIF expression in the intact murine lung. 
 
4.3.4 Exogenous MIF Does Not Alter Expression of Total Cul3 or NEDD8-CUL3 in 
vitro 
 Exogenous MIF has been demonstrated to protect CS-induced EC apoptosis 
(Damico, Simms et al. 2011), attenuate ROS accumulation in cells exposed to CSE 
(Chapter 3, Fig. 3-2), upregulate Nrf2 expression and ARE activity in ECs (Fig. 3-3 & 
Fig. 3-4). Furthermore, MIF
-/-
 mice display greater susceptibility to the CS-induced 
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emphysematous remodeling, which is associated with decreased CUL3 neddylation. 
Taken together, we aimed to investigate the effects of exogenous MIF on CUL3 
neddylation status in EC in vitro. We postulated that treatment of rMIF would increase 
the neddylation of CUL3, leading to enhanced Nrf2 expression.  
  RMVECs were exposed to either vehicle (0.1% BSA in PBS) or rMIF 
(100ng/mL) for 24 hours. This time point has been previously established for significant 
induction of ARE activity and Nrf2 expression (Chapter 3). Cells were then lysed and 
total CUL3 expression in whole cell lysates was analyzed by western blot. We have 
found that rMIF was not sufficient to alter total CUL3 expression. Furthermore, there 
were no differences in neddylated CUL3 (NEDD8-CUL3) (Fig. 4-4), implicating MIF’s 
role in mediating Nrf2 expression in vitro are independent of changes in CUL3 
neddylation status.  
 
4.3.5 Overexpression of the Neddylase, UBC12 Increases NEDD8-CUL3  
 Given our in vivo findings, we postulated that enhanced CUL3 neddylation would 
be associated with increased antioxidant responses. We therefore attempted to drive the 
neddylation of CUL3 by forced expression of the neddylase, UBC12. We predicted that 
overexpression of UBC12 would increase CUL3 neddylation. We transfected RMVECs 
with either pcDNA or hematagglutinin (HA)-tagged UBC12 plasmid under the CMV 
promoter. Western blotting of the HA-tag confirmed expression of the transgene. As we 
predicted, overexpressing a UBC12 plasmid was sufficient to drive the neddylation status 
of CUL3 by approximately, 1.5-fold (p=0.02) (Fig. 4-8).  
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4.3.6 UBC12 Overexpression Induces Nrf2 Expression in vitro 
Chronic CS exposure is associated with enhanced CUL3 neddylation and MIF 
loss results in decreased CUL3 neddylation, absent Nrf2-dependent gene expression, 
increased ROS, increase cytotoxicity and enhanced emphysematous remodeling. In order 
to demonstrate the effects of UBC12-induced CUL3 neddylation on EC antioxidant 
capacity, we co-transfected RMVECs with either pcDNA or UBC12-HA and Nrf2-myc 
plasmids and harvested cells within 24 hours of transfection. Driving the expression of 
UBC12 in our system significantly upregulate CUL3 neddylation (Fig. 4-8), which was 
also associated with a nearly 2-fold increase in Nrf2 expression (p<0.01) (Fig.4-9A, 4-
9B). Next, we investigated the effects of enhanced CUL3 neddylation on ARE activity. 
Either pcDNA or UBC12-HA and a luciferase construct under the control of the ARE (as 
described in Chapter 3) were transfected in RMVECs. Cells were harvested within 24 
hours of transfection and assayed the lysates according to manufacturer’s protocol. Our 
results indicate that UBC12 overexpression significantly up-regulates ARE activity by 
over 2-fold (p=0.021) (Fig. 4-9C). Thus, CUL3 neddylation is sufficient to stabilize 
Nrf2/ARE activity in EC. 
 
4.3.7 JAB1 Does Not Affect the Neddylation of CUL3 in vitro   
 Our in vivo data revealed that MIF loss during CS exposure was associated with 
an increase in JAB1 expression, which was coincident with decreased CUL3 neddylation. 
These observations were also associated with worse emphysematous remodeling (Fallica, 
Boyer et al. 2014).  Previous work from our lab suggests that JAB1 antagonizes Nrf2 
expression, as JAB1 loss led to enhanced Nrf2 expression and ARE activity (data not 
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shown). In order to elucidate the effects of CUL3 neddylation on Nrf2 stabilization, we 
attempted to induce the deneddylation in vitro by the overexpression of JAB1. We 
transfected RMVECs with either an empty pcDNA vector or a myc-tagged JAB1 plasmid 
under the control of the CMV promoter. Cells were then harvested within 24 hours post-
transfection, to ensure expression of the tagged transgene. Whole cell lysates were then 
run on an SDS-PAGE gel for western blot analysis of neddylated-CUL3 expression.  
 We expected that overexpressing the deneddylase, JAB1 would promote CUL3 
deneddylation. Our results however, show that JAB1 overexpression was not sufficient to 
drive the deneddylation of CUL3 in vitro, as there were no observable differences in 
CUL3 neddylation in cells transfected with pcDNA as compared to those transfected with 
the JAB1 overexpressing plasmid (Fig. 4-5). We therefore attempted use an alternative 
approach to address the role of JAB1 in CUL3 neddylation in vitro. HMVECs were 
transfected with either OT or siRNA targeted against JAB1. We then harvested cells 48 
hours post-transfection, to allow for sufficient JAB1 knockdown. Protein was isolated 
from whole cells and lysates were run on an SDS-PAGE gel for western blot analysis. 
We predicted that the abrogation of JAB1 would lead to an increase in the neddylation of 
CUL3. Our results show that while we successfully knocked down JAB1 by about 70% 
(p<0.01) (Fig. 4-6B), it did not affect total or neddylated CUL3 expression, suggesting 
JAB1 does not significantly impact CUL3 neddylation status in vitro (Fig.4-6C & 4-6D).  
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4.3.8 Enhanced Expression of Dominant Negative UBC12 Does not Alter CUL3 
Neddylation in vitro 
 In a parallel experiment, we attempted to overcome challenges of deneddylating 
CUL3 by JAB1 overexpression by using an alternative approach and inhibiting UBC12 
directly via expression of a dominant negative form of the enzyme (dnUBC12). The 
dnUBC12 construct has a specific point mutation (C111S) in the catalytic site of the 
enzyme, inhibiting its function (Wada, Yeh et al. 2000). We therefore transfected 
RMVECs with either pcDNA with an empty vector or plasmid encoding dnUBC12 with 
the hemagglutinin epitope tag (HA) and used western blotting to analyze the effects on 
CUL3 neddylation. Total cell lysates were collected 24 hours post transfection. 
Transgene expression was confirmed with Anti-HA antibodies. We predicted that 
overexpressing dnUBC12, that it would drive the deneddylation of CUL3. Our results 
however, reveal, that while we expressed the dnUBC12-HA plasmid, it did not affect the 
neddylation status of CUL3 in vitro  (Fig. 4-7).  
 
4.3.9 MIF Does Not Alter JAB1 Expression in vitro 
 Prior studies suggest that JAB1 suppresses Nrf2, as demonstrated by increased 
Nrf2 in JAB1 deficient EC in vitro (Fallica Dissertation, 2015). Our data here indicate 
that MIF is sufficient to stabilize Nrf2 suggesting that it may modulate Nrf2 via effects 
on JAB1 expression. In order to test this hypothesis this, we utilized gain of and loss of 
function approaches. HMVECs were transfected with either OT control or MIF siRNA. 
We expected that the loss of MIF would drive JAB1 expression. MIF loss in vitro 
however did not alterJAB1 expression in vitro (data not shown), suggesting that MIF 
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does not negatively regulate JAB1 expression in ECs under basal conditions. We then 
asked if treatment with rMIF would down-regulate JAB1 expression. In order to test this, 
HMVECs were treated with either vehicle control or rMIF (100ng/mL) for 24 hours and 
then lysed. Western blotting was used to evaluate JAB1 expression in whole cell lysate. 
We found that treatment with rMIF was not sufficient to alter JAB1 expression (Fig. 4-
10).  
 
4.3.10 Exogenous MIF Increases the Expression of the CRL Inhibitor, CAND1  
Activity of the CRL is not only dependent on the neddylation status, but also the 
assembly and disassembly of the complex, which is regulated by CAND1. CAND1 binds 
to and inactivates the CRL, preventing the formation of the active CRL-E3 ligase 
complex. We therefore, wanted to test the hypothesis that rMIF is negatively impacting 
CUL3 via effects on the negative regulator, CAND1. RMVECs were treated with either 
vehicle control (0.1% BSA) or rMIF (100ng/mL) for 24 hours. We harvested cells and 
used immunoblotting to analyze MIF’s effects on CAND1 expression. We found that 
rMIF significantly induced CAND1 expression by about 50% (p=0.02) (Fig. 4-11A, 4-
11B). We also show that rMIF is sufficient to alter the ratio of CAND1 to CUL3 by about 
1.5-fold (p=0.03) (Fig.4-11C). We therefore provide evidence for MIF as a novel positive 
regulator of an established CRL inhibitor, CAND1.  
 
4.3.11 CAND1 Overexpression Increases Nrf2 Protein  
 Given CAND1’s role in negatively regulating of the CUL3 ligase complex, we 
predicted that overexpressing CAND1 would be sufficient to drive Nrf2 protein 
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expression in our model. To test this we co-transfected RMVECs with myc-tagged Nrf2 
and either the empty vector, pcDNA or a myc-tagged CAND1 plasmid under the control 
of the CMV promoter. Ectopic CAND1 and Nrf2 have different mobility’s allowing for 
their identification based on molecular weight.  Cells were then harvested within 24 hours 
of transfection. Ectopic Nrf2 and CAND1 expression in whole cell lysates were analyzed 
by western blot. We observed that overexpression of CAND1 was sufficient to drive Nrf2 
expression by nearly 2-fold (p=0.015) (Fig.4-12), potentially via its capacity to inhibit 
activation of CRL3.  
 
4.4 Discussion & Conclusion 
 
The Nrf2-antioxidant pathway is critical in mitigating the effects of oxidative 
stress. It provides the first line of defense against ROS. Once activated, Nrf2 binds to the 
ARE, the DNA element found in the promoter region of over 200 antioxidant genes. Its 
importance in CS-induced lung injury was demonstrated in Nrf2 deficient mice. These 
mice had increased markers of oxidative stress, DNA damage, attenuated antioxidant 
responses and enhanced apoptosis (Iizuka, Ishii et al. 2005). Furthermore, chronic CS 
exposure significantly blunts Nrf2-expression, which is associated with increased 
inflammation (Garbin, Fratta Pasini et al. 2009). Nrf2 is a dynamically regulated 
molecule and under basal conditions and is constitutively generated and targeted for 
degradation by the KEAP1-CUL3 ligase complex. This allows for rapid changes in 
protein expression in responses to environmental stimuli (Chan and Kan 1999, Itoh, Ishii 
et al. 1999). We have previously shown that MIF is a necessary mediator of antioxidant 
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transcriptional responses during acute CS exposure in vivo. It also up-regulates Nrf2 
expression in a proteasomal-dependent manner and ARE activity in vitro (Chapter 3). In 
this study, we have identified MIF as a novel positive regulator of CAND1, an inhibitor 
of the CRL machinery that is required to ubiquitinate and target Nrf2 for degradation 
(Zheng, Yang et al. 2002). Further, we provide evidence that CAND1 expression can 
stabilize Nrf2 expression. 
 Having established MIF as positive regulator of Nrf2, we sought out to determine 
if MIF altered key Nrf2’s regulatory components, KEAP1 and CUL3. This was 
accomplished in both primary cells in vitro and in the intact murine lung. We 
manipulated its expression by utilizing gain and loss-of-function approaches via 
exogenous rMIF treatment and siRNA targeted against MIF in vitro and knockout mice 
in vivo. We first investigated MIF’s effects on KEAP1, the adaptor molecule that serves 
to link Nrf2 to the CUL3 ligase complex. Given KEAP1’s role in suppressing Nrf2, we 
predicted that exogenous MIF would in inhibit KEAP1 expression in vitro. We have 
found that treatment of cells with rMIF failed to suppress KEAP1 expression (Fig. 4-1). 
Our in vivo data reveals that KEAP1 expression is unaffected by the absence of MIF 
(data not shown). Similarly, we tested the effects of rMIF on the scaffold, CUL3 in vitro. 
If MIF functioned via direct effects on CUL3, we would expect that rMIF should alter 
CUL3 expression, but we found that exogenous MIF had no effects on absolute CUL3 
expression in the time point we were investigating (Fig. 4-4). In summary, we have no 
evidence to suggest that MIF is suppressing the expression of key CRL3 components, 
implicating mediating an alternative mechanism.  
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In recognizing that MIF’s capacity to positively regulate Nrf2 is independent of 
changes in absolute expression of KEAP1 and CUL3, we directed our efforts to 
identifying MIF’s effects on established regulators of the CRL complex activity. One 
such mechanism of CRL regulation is via PTM specifically, neddylation (Lyapina, Cope 
et al. 2001, Cope, Suh et al. 2002). We first addressed if MIF deficiency alters the 
neddylation of CUL3 in our in vivo CS-induced emphysema model. Our data reveals that 
CS promotes the neddylation of CUL3 in MIF
+/+
 mice, which was not observed in MIF
-/-
 
mice. This implicates MIF as a positive regulator of neddylation in the context of 
oxidative stress (Fig. 4-3). CS-induced neddylated CUL3 in MIF
+/+
 mice have increased 
antioxidant capacity and decreased emphysematous remodeling. We therefore, aimed to 
test the hypothesis that driving CUL3 neddylation would be associated with increased 
Nrf2 and antioxidant capacity. Overexpression of the neddylase, UBC12, increased 
CUL3 neddylation in vitro. UBC12-mediated CUL3 neddylation was also associated with 
increased Nrf2 expression and ARE activity by nearly 2-fold (Fig. 4-9). Taken together, 
these results suggest that increasing the neddylation of CUL3 is associated with increased 
antioxidant capacity.  
Interestingly, our in vivo data suggests a potential role for JAB1 in the differential 
CUL3 neddylation status observed in wild type and MIF deficient mice. Changes in 
CUL3 occurred in the presence of enhanced expression of the established deneddylase 
and MIF binding partner, JAB1. This led us to speculate that MIF’s ability to positively 
regulate Nrf2 is via JAB1 suppression and promotion of CUL3 neddylation. In order to 
test this hypothesis, we used two complementary approaches to test JAB1’s ability to 
alter CUL3 neddylation. In the first approach, we overexpressed JAB1 in RMVECs to 
 104 
test if it was sufficient to promote CUL3 deneddylation. We observed no differences in 
NEDD8-CUL3 in JAB1 overexpressing cells (Fig. 4-5) indicating that either it the 
kinetics of the deneddylase reaction was either insufficient to observe measure 
differences during the 24 hour reaction or that the transfection efficient was insufficient 
to see measurable differences in the entire population. Next, we knocked down JAB1 
expression in HMVECs using siRNA. This second technique is highly efficient and prior 
studies demonstrate that greater than 95% of the monolayer of cells are transduced 
duplex RNA (Damico, Chesley et al. 2008). We predicted that by knocking down the 
deneddylase we would observe an increase in the neddylation of CUL3. We found no 
differences in CUL3 neddylation in JAB1 deficient cells. Published works suggest that 
changes in the neddylation status of CUL3 can also alter absolute CUL3 expression via 
alterations in auto-ubiquintinate and subsequent degradation (Duda, Borg et al. 2008, 
Fischer, Scrima et al. 2011). Despite these reports, we found that manipulation of the 
deneddylase (directly via JAB1 or indirectly via dnUBC12) did not alter absolute CUL3 
(Fig. 4-6 & Fig. 4-2). In summary, these results suggest that despite the observed increase 
JAB1 in MIF
-/-
 animals exposed to smoke, JAB1 is not responsible for the ability of MIF 
to positively regulate Nrf2 in vitro. 
In a third approach to alter CUL3 neddylation, we attempted to inhibit the 
function of UBC12 by overexpressing a dominant negative form of the protein 
(dnUBC12) with an impaired catalytic site (Wada, Yeh et al. 2000). Our results revealed 
that the overexpression of dnUBC12 was not sufficient to drive alterCUL3 neddylation 
status or alter absolute CUL3 expression (Fig. 4-7). This failure may reflect our inability 
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to transfect the transgene into the majority of cells in the monolayer or be a function of 
kinetics.  
In addition to investigating the role of CUL3 PTM, we studied MIF’s roles on 
another regulator of CUL3 activity, CAND1. Inactivation of cullins is a two-step process. 
First, it requires the activity of JAB1 to remove the NEDD8 molecule and then it requires 
the function of the CRL inhibitor (CAND1). CAND1 is a 120-kDa protein that 
exclusively recognizes deneddylated cullins. After the enzymatic removal of NEDD8 
from the CRL by JAB1, CAND1 is then able to bind both CUL and RING finger protein 
(Yogosawa, Makino et al. 1996, Kawakami, Chiba et al. 2001, Boutten, Goven et al. 
2011). We have found rMIF increased CAND1 protein expression in vitro by about 50% 
(Fig. 4-11). Further, the forced overexpression of CAND1 in RMVECs was sufficient to 
increase Nrf2 expression by over 2-folds (Fig. 4-12). Work from Lo and Hannick 2006 
demonstrates that CAND1 can compete with KEAP 1 for CUL3 binding, thus 
antagonizing Nrf2 degradation.  In cells made deficient of CAND1, KEAP1 
preferentially binds CUL3 increasing KEAP1 ubiquitination and degradation. Thus, 
CAND1 appear to dynamically regulate Nrf2 with increased expression stabilizing via 
direct binding to CUL3 and absolute loss decreasing degradation indirectly by required 
via direct effects on KEAP (Lo and Hannink 2006). CAND1’s role in cellular responses 
to oxidative stress has not been fully elucidated. Taken together, these data demonstrate 
CAND1’s importance in regulating efficient CRL3 activity (Lo and Hannink 2006, Bosu 
and Kipreos 2008).  
 The limited characterization of CAND1 function in the context of oxidative injury 
serves to highlight the novelty of our observation, as MIF-induced CAND1 expression 
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provides a potential mechanism by which Nrf2 is modified in the setting of oxidative 
stress. Additional studies should directed at determining the effects of ROS on CAND1 
expression and function, as well as the identifying effects of CAND1 in potentially 
mitigating CS-induced apoptosis in ECs. It is unclear if MIF’s ability to induce CAND1 
expression is unique to pulmonary ECs, or more it is a more generalizable finding in 
other cell types and species. Future studies may also be designed to identify the effects of 
MIF deficiency on CAND1 expression both in vivo and in vitro. Furthermore, the 
interaction between MIF and CAND1 can further be elucidated with rescue experiments. 
We have previously demonstrated that MIF deficiency enhances CS-induced apoptosis 
(Damico, Simms et al. 2011). Studies can be designed aim to elucidate the effects of 
CAND1 overexpression in the context of CSE-induced apoptosis in MIF deficient cells.  
While more work is required to further characterize the effects of CAND1 in our EC 
model, we provide evidence that MIF is impacting Nrf2 stability in a proteasomal-
dependent mechanism via its capacity to regulate the CRL-inhibitor, CAND1. 
Antioxidant responses are altered in the context of CS-induced emphysema and 
identifying CAND1’s function in our in vitro and in vivo models provides insight into 










Figure 4-1. rMIF does not effect KEAP1 expression in vitro. Western blot of RMVECs that 
were treated with eiher vehicle (0.10% BSA in PBS) or rMIF (100ng/mL), protein was isolated 
24 hours post-treatment. Immunoblot A.) KEAP1 and Actin B.) Densitometric analysis of 







































 mice exposed chronically for 6 months to either filtered air or CS. 
A. Immunoblot of Cul3 and neddylated Cul3. B. Graphical representation of densitometric 
quantification of the neddylation fraction over the deneddylated fraction (n=3/group) (**p<0.01; 


























































mice exposed chronically for 6 months to either air or CS A. Western blot analysis of JAB1 




 mice exposed to either air or CS. Lungs were 
isolated, homogenized (see methods and materials) and whole lung homogenate was immunoblot 
was used to analyze expressions of JAB1 and Actin (**p<0.01). B. Quantification of the 
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Figure 4-4: rMIF does not alter CUL3 neddylation in vitro. RMVECs were treated with either 
vehicle (0.10% BSA in PBS) or rMIF (100ng/mL) and protein was isolated 24 hours post-
treatment. Western blot analysis of whole-cell lysates and analyzed for  A.) CUL3, NEDD8-



























































                                                   
 
     




Figure 4-5: UBC12-mediated CUL3 neddylation. RMVECs were transfected with 1ug of either 
pcDNA or UBC12-HA and then lysed about 24 hours post-transfection. Whole-cell lysates were 
run on an SDS-PAGE gel Western blot analysis of A.) NEDD8-CUL3, actin and ectopic HA-tag 
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Figure 4-6: UBC12-driven Nrf2 protein expression and ARE activity. RMVECs were co-
transfected with 0.5ug of Nrf2-myc and 0.5ug of either pcDNA or UBC12-HA, cells were 
harvested about 24 hours post-transfection. Western blot analysis of A.) myc-tagged Nrf2 and 
HA-tag B.) Graphical representation of immunoblot densitometry of Nrf2-myc (**p<0.01) C.) 
Luciferase activity of cells were co-transfected with a 0.3ug of ARE-luciferase construct and 
0.70ug of either pcDNA or UBC12-HA, then harvested within 24 hours of transfection. 
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Figure 4-7: JAB1 overexpression does not alter CUL3 neddylation pulmonary ECs. 
RMVECs were transfected with 1ug of either pcDNA or myc-tagged JAB1 plasmid in 6-well 
plates, cells were then harvested 20-24 hours post-transfection and whole cell lysates were then 
analyzed by immunoblotting with anti CUL3 and actin antibodies. Densitometric analysis of total 
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C.         D. 
    
Figure 4-8: JAB1 deficiency does not alter the neddylation of CUL3. HMVECs were 
transfected with either OT or JAB1 siRNA and were then harvested 48 hours post-transfection 
and whole-cell lysates were then analyzed by immunoblotting with A.) anti-CUL3, anti-Actin and 






























Figure 4-9: dnUBC12 expression does not alter CUL3 neddylation. RMVECs were 
transiently transfected with 1ug of either pcDNA or dnUBC12 and then harvested approximately 
24 hours post-transfection. Western blot analysis of A.) CUL3, NEDD8-CUL3, actin and ectopic 


















































Figure 4-10: rMIF does not alter JAB1 expression in vitro. RMVECs were treated with either 
0.1% BSA in PBS (vehicle) or rMIF (100ng/ml) for 24 hours, cells were then harvested and 
whole-cell lysates were analyzed by immunoblotting with A.) anti-JAB1 and anti-actin 
antibodies. B.) Quantification of western blot result of cells that were treated with either vehicle 
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Figure 4-11: MIF-induced CAND1 expression. RMVECs were treated with either vehicle 
(0.1% BSA in PBS) or rMIF for 24 hours. Cells were then harvested and analyzed by 
immunoblotting with A.) anti-CAND1 and anti-actin antibodies B.) Densitometric quantification 
of the western blot result of CAND1/Actin in cells treated with either Veh or rMIF. Statistical 
significance is observed between Veh and rMIF treated cells as denoted by * (p<0.05) C.) 


















































                                 
 





Figure 4-12: CAND1-mediated Nrf2 expression. RMVECs were co-transfected with either 0.5 
ug of pcDNA or CAND1-myc and 0.5 ug of Nrf2-myc. Cells were harvested within 24 hours of 
transfection and whole cell lysate was analyzed with western blot A.) with anti-Myc (Nrf2), anti-
CAND1 and anti-actin antibodies. B.) Densitomteric quantification of myc (Nrf2) depicting a 















































We have thus far demonstrated that MIF is an important regulator of the Nrf2-
antioxidant pathway, via its ability to stabilize Nrf2  (Chapter 3) and antagonize the 
effects of CS-induced ROS both in vitro (Fig. 3-2) and in vivo (Damico, Simms et al. 
2011, Fallica, Varela et al. 2016). We have therefore sought to determine the mechanism 
by which MIF is mediating Nrf2 stabilization. Nrf2 is targeted for ubquitination by CRL3 
and we have identified MIF’s effects on the components of CRL3 and established that is 
a positive regulator of CAND1, an inhibitor of CRL3 activity. Nrf2 regulation involves 
the complex interactions between many molecules. DJ-1 is known to positively regulate 
its stability and expression in astrocytes and neuronal cells in the context of oxidative 
stress and Parkinson’s disease (PD). DJ-1 is encoded by the PARK7 gene is an 
established positive regulator of Nrf2 and antioxidant responses in the brain (Bonifati, 
Oostra et al. 2004).  
DJ-1 is a homodimer with oxidoreductase activity that stabilizes Nrf2, upregulates 
Nrf2-dependent transcripts and inhibits apoptosis. Loss-of-function mutation of DJ-1 has 
been associated with increased ROS generation and increased susceptibility of neuronal 
cell death in inherited forms of PD, implicating its role as a necessary mediator of 
antioxidants (Bonifati, Rizzu et al. 2003). DJ-1 inhibits apoptosis by antagonizing the 
effects of ROS and by directly acting on pro-apoptotic pathways. It inhibits ASK1 
activity in the several in vitro models including embryonic fibroblasts and human 
neuroblastoma. ASK1 activates a signaling cascade that ultimately results in apoptosis 
(Ouyang and Shen 2006, Mo, Jung et al. 2010). MIF was also shown to inhibit the ASK1-
p38 pathway in the context of CS-induced oxidative stress (Fallica, Varela et al. 2016). 
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Given these functional similarities, we postulated that MIF may mediate Nrf2-dependent 
responses via DJ-1. We show here that DJ-1 expression is increased in the lungs of MIF 
deficient mice. DJ-1 overexpression however, was not sufficient to upregulate Nrf2 
expression or activity in our pulmonary EC model. Moreover, DJ-1 deficiency did not 
sensitize these cells to the effects of CS-induced oxidative stress. Interestingly, its 
functions appear to be cell-type dependent, even in the context of the lung. Others have 
reported that DJ-1 overexpression in type II alveolar cells isolated from heavy smokers 
improves cell viability and enhances Nrf2-dependent transcription.  We found however 
that DJ-1 does not appear to positively regulate Nrf2 nor antagonize CSE-induced 



















MIF is a ubiquitously expressed cytokine that was originally identified as a 
regulator of innate immune responses, but its functions extend far beyond the immune 
system (Nguyen, Beck et al. 2003, Lue, Thiele et al. 2007, Fan, Kao et al. 2014). One of 
its well-characterized functions is the inhibition of apoptosis by antagonizing p53 
(Nguyen, Lue et al. 2003, Damico, Simms et al. 2011). MIF is cytoprotective in the 
context of CS-induced oxidative stress. Furthermore, there is a growing body of literature 
that demonstrates MIF’s emerging role as a mediator of antioxidant responses (Mathew, 
Jacobson et al. 2013). We have also demonstrated MIF stabilizes Nrf2 by inhibiting its 
proteasomal-mediated degradation, via its capacity to positively regulate CAND1, a 
negative regulator of CUL3 (Fig. 4-11). Given MIF’s effects on Nrf2 as well as its ability 
to antagonize ASK1 activity (Fallica, Varela et al. 2016), we have investigated the 
capacity of MIF to positively regulate antioxidant responses via DJ-1.  
 DJ-1 is a redox-sensitive, 20 kDa molecule homodimeric multifunctional protein 
that is conserved in both prokaryotes and eukaryotes (Hod, Pentyala et al. 1999). It was 
initially discovered as an oncogenic protein that promotes cell proliferation. It positively 
regulates Ras-mediated signaling, which is important in the cell growth and cancer 
development (Nagakubo, Taira et al. 1997). It is highly expressed in many tumors and its 
overexpression is associated with worse tumorigenic outcomes (reviewed in (Cao, Lou et 
al. 2015)). Furthermore, it is has been shown to promote cell proliferation by 
antagonizing the tumor suppressor, PTEN and promoting the activation of the 
phosphatidylinositol-3 kinase (PI3′K)/Akt signaling pathway, which ultimately stimulates 
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cell growth (Kim, Peters et al. 2005). In addition to its anti-apoptotic functions, DJ-1’s 
cytoprotective roles have been ell characterized in neuronal cells and the development of 
PD. It acts as a molecular chaperone, preventing the aggregation of α-synuclein, as well 
as attenuating oxidative stress (Shendelman, Jonason et al. 2004). Furthermore, loss-of-
function of the PARK7 gene has been associated with familial early onset PD. DJ-1 
inhibits PD pathogenesis by antagonizing oxidative stress and mediating antioxidant 
responses (Bonifati, Rizzu et al. 2003). DJ-1 loss also sensitizes cells to the effects of 
hydrogen peroxide in vitro (Taira, Saito et al. 2004). Taken together, DJ-1’s role have 
been elucidate in the context of brain and has been shown to play an important role in 
antagonizing both ROS production and apoptosis.    
In addition to its capacity to directly antagonize ROS, Clements et al showed that 
DJ-1 is indispensable for Nrf2-stability through its ability to inhibit KEAP1-mediated 
Nrf2 degradation in a cancer cell line. They also showed that Nrf2-dependent transcripts 
are attenuated in the absence of DJ-1 (Clements, McNally et al. 2006). DJ-1’s effects on 
Nrf2 have also been shown in the context of smoking. Type II alveolar EpiCs isolated 
from aged smokers showed diminished DJ-1 expression and antioxidant capacity 
including decreased Nrf2 expression as compared to cells isolated from age-matched 
moderate smokers and non-smokers. They were rescued from the effects of CS-induced 
apoptosis by overexpression of DJ-1, implicating DJ-1 as a necessary mediator of 
antioxidants and cytoprotection in context of CS-induced stress in EpiCs (Bahmed, 
Messier et al. 2016). DJ-1’s effects were also demonstrated in the context of the cancer 
cell line, MCF-7. The antitumor drug, BCA induces oxidant-mediated apoptosis, a 
phenomenon that is enhanced in the absence of DJ-1. Interestingly, sensitization of DJ-1 
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deficiency was independent of Nrf2, as these cells showed no changes in Nrf2-dependent 
transcription. Taken together, this implicates that DJ-1’s ability to positively regulate 
Nrf2 is cell-type dependent (Ismail, Abdel Shakor et al. 2015). 
 In addition to its capacity to directly positively regulate Nrf2 stability, DJ-1 also 
regulates the Trx/ASK1 pathway (Mo, Jung et al. 2010). Reduced Trx is able to bind to 
ASK1, thereby inhibiting its activity. However, in the presence of oxidative stress, 
becomes oxidized, thereby interrupting its interaction with ASK1. This leads to 
phosophorylation and activation of p38 MAPK, which may result in apoptosis (Saitoh, 
Nishitoh et al. 1998). DJ1 can inhibit the ASK1 pathway through direct effects on ASK1 
or via effects on ASK1 binding proteins, such as Trx upregulation and DAXX 
sequestration (Hsieh and Papaconstantinou 2006, Ouyang and Shen 2006, Im, Lee et al. 
2012). In summary, while all of the functions of DJ-1 have not been elucidated, its role in 
antagonizing ROS-mediated injury and preventing cell death is becoming well 
established.  
 CS-induced activation of the ASK1-p38 pathway is antagonized by MIF. Fallica 
et al demonstrated that MIF inhibits EC apoptosis by directly antagonizing ASK1 activity 
and inhibiting p38 activity. They also demonstrate that ASK1 functions upstream of p38 
in the context of CS-induced oxidative stress and MIF antagonizes p38 phosphorylation 
and p38-dependent CSE-induced apoptosis (Fallica, Varela et al. 2016). Given the 
functional similarities of DJ-1 and MIF, we hypothesized that MIF may impact 






5.3.1 DJ-1 is Differentially Expressed in the Lung Tissues of Wild-type and MIF 
Deficient Mice 
There is sufficient evidence demonstrating DJ-1’s role in mediating 
cytoprotection in the context of oxidative stress by antagonizing ROS and apoptosis 
(Bonifati, Rizzu et al. 2003, Im, Lee et al. 2010, Bahmed, Messier et al. 2016). We have 
already demonstrated MIF’s ability to positively regulate Nrf2 and downstream 
antioxidant responses. Given DJ-1’s established role in mediating the Nrf2-antioxidant 
pathway, we hypothesize that MIF is mediating antioxidant via DJ-1.  We predict that 
DJ-1 expression would be enhanced in context of CS and that MIF deficiency would 
suppress it. We therefore, investigated DJ-1 expression in the intact lung of WT and MIF
-
/-
 mice exposed to either air or CS for 3 days. Mice were then harvested and the lung was 
homogenized for western blot analysis of DJ-1. Our results showed no differences in DJ-
1 expression in MIF
+/+
 mice exposed to CS as compared to their air-exposed counterparts 
(Fig. 5.3.1), implicating that acute CS exposure is not sufficient to drive DJ-1 expression. 
Interestingly, the MIF deficient mice have enhanced DJ-1 expression as compared to 
their wildtype counterparts (Fig. 5.3.1), implicating that differential expression of DJ-1 is 
genotype-dependent and irrespective of exposure type.  
 
5.3.2 The Loss of DJ-1 Does Not Down regulate MIF Expression  
We predicted that MIF and DJ-1 are linked via their capacity to positively 
regulate Nrf2 we therefore, sought to elucidate DJ-1’s effects on MIF expression, by 
abrogating DJ-1 in vitro. RMVECs were transfected with either on-target control siRNA 
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(OT) or siRNA targeted against DJ-1. We then harvested cells 72 hours post-transfection, 
as a previous time course revealed that this was the optimal time to ensure significant 
knock down of DJ-1.  Whole cell lysates were run on an SDS-PAGE gel and 
immunoblotting was used to analyze the effects of DJ-1 loss on MIF expression. We 
successfully knocked down DJ-1 by about 70% (Fig. 5.3.3) (p<0.01), however we found 
no significant alterations in MIF protein expression (Fig. 5.3.3). 
 
5.3.3 DJ-1 Expression is Not Altered in vitro in Response to Oxidative Stress 
DJ-1 expression is enhanced in the context of ROS, which may be due to its role 
in antagonized oxidant-mediated stress. It can inhibit the effects of ROS both directly and 
indirectly by upregulating pathways that lead to Nrf2 activation (Lev, Ickowicz et al. 
2008, Yanagida, Tsushima et al. 2009, Im, Lee et al. 2012). DJ-1 expression is responsive 
to the effects of ROS in a dose-dependent manner in other in vitro models (Lev, Ickowicz 
et al. 2008). We therefore sought to determine if increased oxidative burden would 
upregulate DJ-1 expression in pulmonary EC in vitro. We exposed RMVECs to 
increasing concentrations hydrogen peroxide (H2O2) assessed DJ-1 expression by western 
blotting. RMVECs were treated to 0, 0.1, 0.2 and 0.5 mMol of H2O2 for 24 hours. These 
doses were derived from a dose-response cell survival experiments. The 24-hour time 
point was extrapolated from previous studies that indicated sufficient time for DJ-1 to be 
upregulated in response to ROS generating compounds (Lev et al 2008, Mendivil-Perez 
et al 2014). Western blot was used to analyze DJ-1 expression in whole cell lysates. Our 
results reveal that 24-hour treatment with increasing H2O2 dose concentration failed to 
induce DJ-1 expression in our EC model (Fig. 5-3). We next asked if CSE would be 
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sufficient to induce DJ-1 expression, postulating that it would increase DJ-1 expression. 
We treated RMVECs with varying concentrations of cigarette smoke extract (0%, 2.5%, 
5%, 7.5%, 10% and 20%) and there were no differences in DJ-1 expression in response to 
CSE (data not shown). Thus, exposure to H2O2 and CSE had no effects on absolute DJ-1 
expression in EC in vitro. 
 
5.3.5 DJ-1 is not Sufficient to Increase Nrf2 Expression or Activity in vitro 
 There is mounting evidence to show that DJ-1 modulates oxidative stress by 
mediating Nrf2 and ARE-dependent responses. DJ-1 overexpression has been shown to 
promote the disassociation of Nrf2 from its repressor, KEAP1(Yan, Yang et al. 2015). 
Furthermore, Clements et al. showed that DJ-1’s has an necessary role in stabilizing Nrf2 
in a hepatocarcinoma cells. DJ-1 knockdown led to decreased Nrf2 stabilization and 
Nrf2-dependent transcripts (Clements, McNally et al. 2006). Furthermore, overexpression 
of DJ-1 restored blunted Nrf2 protein expression and Nrf2-dependent transcription in 
type II alveolar cells derived from aged smokers (Bahmed, Messier et al. 2016).Taken 
together, we postulated that overexpression of DJ-1 may be sufficient to drive both Nrf2 
expression and activity in EC. We therefore, co-transfected RMVECs with Nrf2-myc 
plasmid and either pcDNA or myc-tagged DJ-1 plasmids under the control of the CMV 
promoter. Cells were harvested within 24 hours of transfection and whole cell lysates 
were analyzed via western blot to investigate the effects of DJ-1 on Nrf2 expression. 
While our cells express the DJ-1 transgene, it was not sufficient to drive Nrf2 expression 
in our pulmonary ECs, as there were no differences in Nrf2 expression in control cells as 
compared to those over expressing DJ-1 (Fig. 5-4A & 5-4B).  
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In a parallel experiment, we co-transfected an ARE-luciferase construct and either 
a pcDNA or myc-tagged DJ-1 plasmid. We then harvested cells within 24 hours and 
completed a luciferase assay as per manufacturer’s protocol. We found no differences in 
ARE activity in DJ-1 overexpression as compared to empty vector transfected cells, 
indicating that DJ-1 is not sufficient to drive Nrf2 protein expression or ARE activity in 
EC in vitro (Fig. 5.4C).  
 
5.3.6 DJ-1 Deficiency does not Sensitize ECs to the effects of CSE  
 Multiple in vitro models have demonstrated DJ-1’s necessary role in mediating 
antioxidant responses and inhibiting apoptosis during oxidative stress (Clements, 
McNally et al. 2006, Bitar, Liu et al. 2012, Bahmed, Messier et al. 2016). The loss of DJ-
1 sensitized cells to the effects of ROS-generating agents, increased ROS accumulation 
and inhibited antioxidant capacity (Ishiwatari, Takahashi et al. 2015, Bahmed, Messier et 
al. 2016). Furthermore, DJ-1 loss in types II alveolar cells derived from heavy smokers 
had increased markers of oxidative stress and apoptosis and decreased Nrf2-dependent 
transcripts. Overexpression of DJ-1 in their model decreased apoptosis and restored Nrf2-
dependent responses (Bahmed et al. 2016). We therefore, postulated that the ablation of 
DJ-1 would sensitize RMVECs to the effects of CS. We utilized caspase 3 activity, as a 
marker of apoptosis. We have transfected RMVECs with either on-target control siRNA 
(OT) or DJ-1 siRNA and then waited 72 hours post-transfection, to ensure efficient DJ-1 
knockdown treated. Cells were then treated with 20% CSE (v/v) for increased duration of 
time. After harvesting cells at indicated times, we assayed whole cell lysate s for caspase-
3 activity according to manufacturers protocol. Our results show that CSE treatment 
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induces a 2.5-fold increase in caspase-3 activity that peaks at around 6 hours (p<0.01). 
Interestingly, DJ-1 knockdown did not enhance CSE-induced apoptosis, as DJ-1 deficient 
cells showed no induction of caspase 3 activity 6 hours post-treatment (Fig. 5-5). These 
findings demonstrate that DJ-1 loss does not sensitize RMVECs to the effects of CSE, 
implicating its role is independent of antagonizing apoptosis in our ECs model in the 
context of oxidative stress.   
 
5.4 Discussion & Conclusion 
 
While we have shown that DJ-1 expression is altered in MIF deficient mice, its 
functions are less clear in vivo. We have however, determined that DJ-1 is insufficient to 
upregulate Nrf2 expression and ARE activity in vitro. Further, its loss does not enhance 
sensitize EC to CSE-induced apoptosis. Like MIF, DJ-1 has been demonstrated to 
antagonize the ASK1 pathway, which ultimately leads to p53 activation under conditions 
of oxidative stress (Karunakaran, Diwakar et al. 2007, Im, Lee et al. 2010, Fallica, Varela 
et al. 2016). Given the similarities in function, antioxidant capacities and negative 
regulation of the ASK1 pathway, we hypothesized that MIF and DJ-1 are interacting to 
inhibit EC apoptosis in the context of CS-induced oxidative stress.  
Bonifati et al drew the connection between loss-of-function mutations of the 
PARK7 gene and familial inherited PD (Bonifati, Rizzu et al. 2003). Loss of DJ-1 
function is associated with increased oxidative stress, decreased antioxidant capacity and 
increased mitochondrial dysfunction in the context of PD (Irrcher, Aleyasin et al. 2010, 
McCoy and Cookson 2011). Moreover, DJ-1 is an established positive regulator of Nrf2 
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in other cells types and has been demonstrated to increase Nrf2 expression, as well as 
downstream transcription of Nrf2-dependen targets (Yan, Yang et al. 2015, Bahmed, 
Messier et al. 2016). DJ-1-mediated upregulation of Nrf2 has been linked to multiple 
molecular mechanisms. Clements and colleagues showed that DJ-1 is necessary for Nrf2 
stability and induction of Nrf2-dependent transcripts in the non-small lung cancer cell 
line, H157 cells (Clements, McNally et al. 2006). We therefore investigated the effects of 
rMIF in our cell model. Due to MIF’s capacity to increase Nrf2 expression, we postulated 
that MIF is impacting Nrf2 stability via increased DJ-1 expression. We have shown that 
DJ-1 expression was upregulated in MIF
-/-
 mice, however this was not sufficient to drive 
the expression of Nrf2-dependent transcripts in vivo, as MIF
-/-
 mice had attenuated 
antioxidant responses to CS-induced oxidative stress that was associated with an increase 
in ROS accumulation in the intact lung (Fig. 3-1). Data from our lab revealed that p38 
signaling is upregulated in MIF
-/-
 mice in the context of CS, which was associated with 
increased ROS in the intact lung (Damico, Simms et al. 2011, Fallica, Varela et al. 2016). 
Intriguingly, DJ-1 expression is also upregulated in these mice, which may be a 
phenomenon of compensation in whole body knockout of MIF. We also recognize that 
the lung is comprised of many different cell types, thus differential expression of DJ-1 in 
MIF-/- may not be EC driven.   
We attempted to further elucidate the potential interaction between DJ-1 and MIF 
by successfully knocking down DJ-1 and studying its effects on MIF expression. We 
found that the ablation of DJ-1 did not alter MIF expression in ECs. We have previously 
established that MIF antagonizes CS-induced EC apoptosis in vitro (Damico, Simms et 
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al. 2011) and in vivo (Fallica, Boyer et al. 2014), we asked if DJ-1 alters EC sensitivity to 
CSE. We also found that DJ-1 loss fails to sensitize ECs to CSE-induced apoptosis.   
Previous studies have also established that DJ-1 expression is upregulated in the 
context of increased ROS (Lev et al 2008, Mendivil-Perez et al 2014). We therefore 
sought to determine if DJ-1 expression is altered by ROS in ECs in vitro. We found no 
changes in DJ-1 expression in response to increasing concentrations of H2O2, 
(concentrations 0-0.5mM) (Fig. 5-3) or CSE (data not shown). It is possible that DJ-1 
represents an early redox-responsive protein and that ROS-induced DJ-1 expression is 
very transient or requires prolonged exposure. Given DJ-1’S role in mitigating the effects 
of ROS, we postulated that driving DJ-1 expression would upregulate Nrf2 expression in 
ECs. Our results reveal that DJ-1 overexpressing cells failed to upregulate Nrf2 
expression and ARE activity. We then asked if DJ-1 was sufficient to drive both Nrf2 
expression and activity in vitro. In a co-transfection experiment in which we 
overexpressed both myc-tagged Nrf2 and either an empty vector or a DJ-1 encoding 
plasmid, DJ-1 overexpression was not sufficient to drive Nrf2 protein expression. We 
also found no differences in ARE activity in DJ-1 overexpressing cells as compared to 
their control counterparts. Thus, in contrast to the observed effect of DJ-1 in type II 
EpiCs, (Bahmed, Messier et al. 2016), we have not observed a role for DJ-1 in Nrf2 
and/or cytoprotection in pulmonary ECs in vitro. 
In addition to inhibiting oxidative stress via Nrf2-dependent mechanisms, DJ-1 
also inhibits the NF-κB and MAPK signaling, thereby inhibiting phosphorylation and 
activation of p38 and potentiation of ROS and its downstream targets (Jo, Yeo et al. 
2017). More importantly, DJ-1 expression is upregulated in many cancers, which has the 
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potential to drive worse disease outcomes due to its ability to promote cell viability and 
inhibit apoptosis (reviewed in (Cao, Lou et al. 2015)). Due to its tumor-promoting 
functions, serum levels of DJ-1 have the potential of being utilized as diagnostic markers 
for certain cancers (Benati, Montagnana et al. 2017). DJ-1’s ability to inhibit apoptosis 
has been demonstrated in several pathways that result in the activation of the PI3K/Akt 
pathway (Jaramillo-Gomez, Nino et al. 2015). We therefore asked if knockdown DJ-1 
would increase CS-induced apoptosis. We utilized caspase 3 activity to measure CSE-
induced apoptosis. CSE significantly induced 2.5-fold increase in caspase 3 activity that 
was characterized by a peaked at about 6 hours post-treatment in OT transfected cells 
(p<0.01). Interestingly, this was not seen in DJ-1 deficient cells, as they were not further 
sensitized to the effects of CSE in the absence of DJ-1  (Fig. 5.3.6). Collectively, these 
data do not support a role for DJ-1 as a mediator of cytoprotection in ECs. There is a 
limited understanding of DJ-1’s role in the lung in the setting of CS, as there is a dearth 
in literature about the DJ-1’s function in this context. Only one study by Bahmed et al 
demonstrated DJ-1’s cytoprotective and antioxidant-mediating capacity in epithelial type 
II alveolar cells (Bahmed, Messier et al. 2016). These disparate results in their in vitro 
system would suggest that DJ-1’s functions are cell type-dependent.  
In conclusion, we have determined that MIF can stabilize Nrf2 in ECs 
independent of changes in DJ-1 expression. We have also found that DJ-1 is not 
sufficient to increase Nrf2 expression or ARE activity, nor does its abrogation sensitize 












Figure 5-1: DJ-1 is upregulated in MIF
-/-
 Mice. Western blot analysis of DJ-1 protein 
expression in wild-type (MIF
+/+
) and MIF deficient (MIF
-/-
) mice exposed to either air or CS  for 
3 days. Right lung with excised, homogenized in cell lysis buffer and run an SDS-PAGE gel and 
probed with A.) anti-DJ-1 and anti-actin. B.) Densitometric analysis of western blot results. DJ-1 
protein expression is increased in MIF
-/-
















Figure 5-2: The loss of DJ-1 does not impact MIF protein expression. RMVECs were 
transfected with either OT siRNA or DJ-1 siRNA and were harvested 72 hours post transfection. 
Whole cell lysates were run an SDS-PAGE gel and probed using antibodies against A. MIF, DJ-1 













Figure 5-3: H2O2 does not alter DJ-1 expression in pulmonary ECs. Western blot analysis of 
RMVECs challenged with H2O2. Cells were exposed to varying concentrations of H2O2 (0-0.5 
mM) for 24 hours, lysed and whole cell lysates were analyzed for A. DJ-1 and actin proteins 
















Figure 5-4: DJ-1 overexpression does not alter Nrf2 expression or ARE activity in EC in 
vitro. RMVECs werer co-transfected with a plasmid encoding Nrf2-myc and either OT non-
targeting siRNA or DJ-1 siRNA. Cells were harvested 72 hours -transfection. A. MIF expression 
was analyzed and DJ-1 knockdown was confirmed by western blot. B. Densitometric 








































































Figure 5-5: CS-Mediated Caspase 3 activity. RMVECs were transfected with either OT control 
or DJ-1 siRNA for 72 hours. Cells were treated with 20% CSE complete media (v/v) and 
harvested at 0, 2, 4, 6 and 8 hours. Caspase 3 activity assay was completed according to 
manufacturer’s protocol A. Caspase 3 activity of cells transfected with OT (*p<0.05) B. and cells 


























6.1 Summary of Thesis 
 
 COPD remains to be an important public health concern that is the third leading 
cause of death globally (Raherison and Girodet 2009). Emphysema, a type of COPD is 
characterized by permanent damage to the alveoli, leading to increased airspace size. It is 
a multifactorial disease that caused by many different cellular and molecular events 
(Sharafkhaneh, Hanania et al. 2008). EC apoptosis has been gaining recognition as an 
important mediator of pathogenesis. The pulmonary microvasculature is important in 
maintaining the structure and function of the alveolar septa. Furthermore, EC apoptosis 
has been identified as both a necessary and sufficient phenomenon of emphysematous 
tissue remodeling (Kasahara, Tuder et al. 2000, Giordano, Lahdenranta et al. 2008). 
Previous work from our lab has demonstrated that CS induces EC apoptosis, which is 
antagonized by the presence of MIF, implicating MIF’s role as a necessary inhibitor of 
oxidant-mediated apoptosis (Damico, Simms et al. 2011). MIF serum levels as also 
significantly blunted in patients with advanced stage COPD, suggesting that MIF loss is 
associated with worse disease. Fallica et al. also showed that MIF
-/-
 mice had more severe 
emphysematous tissue remodeling after chronic CS exposure as compared to their wild-
type counterparts (Fallica, Boyer et al. 2014). CS induces activity of the ROS-promoting 
enzyme, xanthine oxidoreductase (XOR) in the murine lung. Enhanced XOR activity 
potentiates ROS, which induces DNA double strand breaks, increased p53 activation, 
ultimately leading to EC apoptosis (Kim, Serebreni et al. 2013). This phenomenon is 
enhanced with the loss of MIF, as MIF
-/-
 mice have enhanced XOR activity during CS 
exposure in an ASK1-p38-dependent manner. Interestingly, in spite of displaying similar 
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levels of XOR activity, staining with the lipophilic ROS-sensitive dye, dihyroethidium 
(DHE) suggests that qualitative assessment of basal ROS maybe different in the absence 
of MIF. These findings implicate XOR-independent and MIF-mediated mechanisms for 
ROS generation in the lung (Fallica, Varela et al. 2016). Taken together, we sought to 
understand the mechanisms by which MIF is mitigating CS-induced ROS production in 
pulmonary ECs. 
 Oxidative stress is a critical driving force in the initiation and promotion of 
COPD and oxidant/antioxidant homeostatic balance is disrupted in the context of disease, 
thus we investigated MIF’s effects on antioxidant responses during CS-induced oxidative 
stress. We have demonstrated that MIF
-/-
 mice failed to upregulate antioxidant genes in 
response to acute CS exposure, demonstrating MIF’s role as a necessary mediator of 
antioxidant responses in the lung (Fig. 3-1). We utilized two in vitro models, HMVECs 
and RMVECs to further understand how MIF is mediating antioxidant responses. We 
showed that pretreatment with rMIF was sufficient to antagonize CS-induced ROS 
accumulation in ECs (Fig.3-2). Given MIF’s capacity to drive the upregulation of 
antioxidant gene expression during CS exposure, we postulated that MIFs ability to 
mediate intracellular ROS is via the master regulator of the antioxidant response element, 
Nrf2. We first identified that treatment of ECs with rMIF in vitro was sufficient to drive 
activity of the DNA element, ARE (Fig. 3-3). We then showed that MIF is necessary for 
efficient ARE-driven response to CS exposure in vitro (Fig. 3-4). Given Nrf2’s critical 
role in mediating ARE activity, we shifted our focus to understanding MIF effects on 
Nrf2 protein expression. We have found that rMIF significantly upregulated Nrf2 protein 
expression by about 2.5 fold in a proteasomal-dependent manner (Fig. 3-6). While some 
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mitigation of ROS in vitro and in vitro could be attributed to MIF’s intrinsic 
oxidoreductase activity, we show here that it is a positive regulator of ARE activity, as 
well as the antioxidant transcription factor, Nrf2. The remainder of this thesis is aimed at 
determining the underlying mechanism(s) by which MIF is increasing Nrf2 expression. 
We thus investigated the effects of MIF on established positive and negative regulators of 
Nrf2.  
Nrf2 is a dynamically regulated molecule with a relatively high rate of turnover. 
Under basal conditions, it is targeted for ubiquitination by the CRL3 ligase complex via 
its adaptor molecule, KEAP1 and then subsequently, degraded by the proteasome 
(Furukawa and Xiong 2005). KEAP1 is a redox-sensitive molecule that changes 
conformation in response to changes in cellular redox status (Itoh, Wakabayashi et al. 
1999). Given the established function of the KEAP1-CRL3 complex in mediating Nrf2 
ubiquitination, we postulated that MIF suppresses the expression or activity of 
components of KEAP1-CRL3. We first investigated the effects of MIF on KEAP1 and 
CUL3. We found that the addition of rMIF to EC in culture was not sufficient to reduce 
the absolute expression of either of these two molecules, as initially postulated. These 
data suggest that MIF’s potential role in regulating the complex is independent of their 
expression (Fig. 4-1; 4-4). We therefore investigated MIF’s effects on established 
regulators of CRL activity. The activity of the CRL can be modified by the covalent 
addition of NEDD8 to the cullin scaffold (Boh, Smith et al. 2011). This modification 
affects both the activity and stability of the CRL (Villeneuve, Lau et al. 2010). Our in 
vivo data showed that differential neddylation of Cul3 in lung tissues of wildtype in a 
MIF-dependent manner. CS significantly increased neddylation of CUL3 in the lungs of 
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wild type mice, which not observed in MIF deficient mice. This phenomenon however 
was lost in MIF
-/-
 mice, implicating MIF’s role in regulating the post-translational 
modification of Cul3 (Fig. 4-2).  
The cyclic process of neddylation and deneddylation is regulated by the 
enzymatic abilities of two proteins, JAB1 and UBC12 (Bosu and Kipreos 2008). JAB1, 
the fifth member of the COP9 signalsome has an isopeptidase activity that can cleave 
NEDD8 and deneddylated the complex. JAB1 is also an established binding partner to 
MIF. MIF has been demonstrated to negatively regulate JAB1 activity (Kleemann, 
Hausser et al. 2000). . Given MIF’s role in negatively regulating this deneddylase, we 
predicted that the loss of MIF would potentiate JAB1’s expression or activity. We found 
that MIF
-/-
 mice exposed to CS had significantly elevated JAB1 expression, which was 
coincident with blunted neddylation of Cul3. Furthermore, decreased Cul3 neddylation 
was associated with enhanced emphysematous tissue remodeling (Fallica, Boyer et al. 
2014). Thee knockdown of JAB1 in vitro stabilized Nrf2 expression (data not shown). 
Given that JAB1 overexpression in vivo is associated with decreased neddylation of 
CUL3 and worse outcomes, we predicted that driving neddylation would enhance 
antioxidant responses. We therefore targeted UBC12 as a potential positive regulator of 
CUL3 neddylation and hypothesized that its overexpression would drive neddylation and 
stabilize Nrf2. By transiently overexpressing UBC12 in pulmonary ECs, we were able to 
promote CUL3 neddylation, and upregulate both, ARE activity and Nrf2 expression (Fig. 
4-3). Taken together, this data shows that influencing the neddylation of CRL3 is 
sufficient to drive antioxidant responses both in vivo and in vitro. Changes in neddylation 
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potentially alter the CRL’s activity or stability, ultimately inhibiting the ubiquitination of 
Nrf2.  
Alternatively, we then sought to deneddylate the CRL complex by overexpressing 
a dominant negative form of UBC12 (dnUBC12) or JAB1. dnUBC12 has a point 
mutation that inhibits UBC12’s enzymatic activity and ability to neddylate CRL. 
Interestingly, while we successfully overexpressed the transgene, we were unable to 
detect differences in the neddylation status of cells expressing dnUBC12 as compared 
those transfected with the pcDNA (Fig.4-7). Given that MIF deficient mice 
overexpressed JAB1 under conditions of CS exposure and showed diminished CUL3 
neddylation, we predicted that overexpressing JAB1 in our in ECs would deneddylate 
CUL3. We however did not find that driving JAB1 expression altered CUL3 neddylation. 
Furthermore, while our in vivo data suggests changes in neddylation of CUL3 that may 
be associated with increased JAB1 expression, lung homogenates represent many 
different cells types. In other words, cell type other than microvascular ECs may not be 
driving these changes.  
We have found the treatment of ECs with rMIF does not affect CUL3 
neddylation, nor does it decrease JAB1 expression. We therefore, focused our efforts on 
studying MIF effects on other regulators of CRL3.  CAND1 is an established inhibitor 
and regulator of the CRL3 complex. It binds to cullins, inhibiting the neddylation, 
activation and assembly of the complex (Dubiel, Ordemann et al. 2015). Given CAND1’s 
role in negatively mediating CRL3, it served as an attractive target for understanding 
MIF-mediated regulation of the CRL. Treatment of EC’s with rMIF significantly 
increased CAND1 expression by over 1.5 fold (Fig. 4-10). We then showed that CAND1 
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overexpression was sufficient to upregulate Nrf2. In summary, we demonstrate that MIF 
is novel positive regulator of CAND1 and may provide a mechanism by which MIF is 
altering CUL3 activity, ultimately stabilizing Nrf2.  
This thesis aimed to investigate the effects of MIF on other regulators of Nrf2. 
We have found that MIF is altering the activity of an established negative regulator of 
Nrf2, we have also investigated MIF effects on DJ-1, a positive mediator of antioxidant 
responses. DJ-1 is a redox-sensitive molecule that is important in antagonizing the effects 
of ROS via both, Nrf2-dependent and independent mechanisms. Its role in upregulating 
antioxidant gene transcription has been demonstrated in neuronal cells in the context of 
PD (Bahmed, Messier et al. 2016). In addition to its ability to upregulate Nrf2-dependent 
transcripts, it also acts as a chaperone by directly binding to Nrf2, ultimately facilitating 
its translocation into the nucleus (Clements, McNally et al. 2006, Bitar, Liu et al. 2012). 
Furthermore, loss-of-function of DJ-1 is associated with increased ROS, decreased 
antioxidant capacity and has been linked to familial PD (Bonifati, Rizzu et al. 2003). 
Also similarly to MIF, DJ-1 protects against oxidative stress-induced apoptosis not only 
through Nrf2, but it also inhibits the activation of the ASK1-signaling pathway, which 
results in the activation of p53 (Im, Lee et al. 2010). Given DJ-1’s role in positively 
regulating Nrf2 and functional similarities between MIF and DJ-1, we hypothesized that 
MIF may upregulate Nrf2 via a DJ-1-dependent mechanism. 
 We initially investigated the effects of MIF on DJ-1 expression in vivo. We found 
that DJ-1 is upregulated in the absence of MIF in vivo, independent of CS exposure. 
Given the fact that these two molecules act on the same pathways, we concluded that 
increases in DJ-1 expression may be the result of a compensatory mechanism, or may be 
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driven by other cell types in the lung. However, an increase in DJ-1 expression was not 
sufficient to impact antioxidant responses, because MIF
-/-
 mice still failed to upregulate 
Nrf2-depedent genes. We then wanted to elucidate the functional importance of DJ-1 in 
EC in vitro . We found that siRNA-mediated knockdown of DJ-1 did not further sensitize 
cells to the effects of CSE exposure. Furthermore, DJ-1 overexpression was not sufficient 
to upregulate Nrf2 expression nor ARE activity. Our data suggests that DJ-1 does not 
positively regulate antioxidant responses in primary pulmonary EC.  
 In summary, this project provides insight on MIF as a positive regulator of Nrf2, 
which is mediated through its ability to antagonize its proteasome-mediates degradation. 
We have also found that MIF acts via upregulating CAND1, an established negative 
regulator of CRL3.  
 
6.2 Limitations of Work 
 
 There are several limitations to consider while interpreting these experimental 
results. Inherent physiological and anatomical differences between murine and human 
lungs pose some challenges when extrapolating results from in vivo models to humans, 
especially when attempting to model a human disease that takes decades of exposure to 
manifest. Additionally, the utilization of a single cell type for in vitro models pose 
important limitations as the lung itself is comprised of an interactive network of many 
different types of cells. There are also technical limitations to consider that may also 
influence interpretation of our results.  
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6.2.1 Limitations of In Vitro and In Vivo Models 
 COPD is a progressive irreversible disease with a long latency period, as most 
people who experience symptoms are at least 40 years of age. Given this fact, animal 
models of disease fail to accurately depict disease kinetics (Lokke, Lange et al. 2006), 
they are associated with many inherent limitations. Furthermore, rodent models do not 
demonstrate COPD, but rather show CS-induced emphysematous tissue remodeling. 
There are also fundamental anatomical and physiological differences between the 
pulmonary system of mice and humans. Unlike humans, mice are obligate nasal 
breathers. Therefore, the nasal cavity in humans is less susceptible to the effects of CS 
exposure and that it is unable to scrub the air entering as effectively as mice. This also 
implies that higher concentration of particles from CS exposure will travel further into 
the human bronchioles than in mice. Another important model limitation is involves 
using in vitro models to further elucidate protein function. We have employed a 
reductionist approach to study the effects of MIF on antioxidant responses in pulmonary 
ECs. While the data provides some mechanistic insight on how MIF is regulating Nrf2, it 
is important to recognize that this is not representative of the intact lung due to the 
heterogeneity of cell types that interact with one another. We have focused our studies on 
pulmonary ECs because of their critical role in maintaining not only the lung 
microvasculature, but the integrity of the alveolar septa as well. Additionally, there is a 
growing body of literature that demonstrates enhanced markers of EC apoptosis in 
patients with COPD. It has also been shown to be a determinant of emphysematous tissue 
remodeling in vivo (Giordano, Lahdenranta et al. 2008, Thomashow, Shimbo et al. 2013, 
Liu, Ding et al. 2014, Takahashi, Kobayashi et al. 2014). While EC apoptosis is an 
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important driver of remodeling, apoptosis of other cell types including EpiCs have also 
been implicated in disease progression (Gao, Li et al. 2015).  
 
6.2.2. Technical Limitations  
 We interpret our results with careful considerations of technical limitations that 
may have impacted our results. One challenge that was presented to us was the 
identification of antibody that detects biologically-relevant Nrf2. Nrf2 exists in two 
isoforms, which are differentiated by their molecular weights. Nrf2-bound to ubiquitin 
that is detectable at around ~100 kDa and non-biologically relevant Nrf2 is detected ~70 
kDa (Kemmerer, Ader et al. 2015).  Detection of endogenous Nrf2 in RMVEC was not 
reliable. To overcome this limitation, we overexpressed ectopic Nrf2 with an epitope tag 
allowing us to reliably identify the transgene.   
Another potential limitation is that we have focused is identifying MIF-dependent 
mechanisms in RMVECs in vitro. Although we saw the same effects of MIF on Nrf2 
expression and ARE activity in both species, we have only identified MIF’s effects on 
CAND1 in RMVECs.  The major advantage of using RMVECs is that transfection 
efficiency of plasmid DNA is significantly more when compared to their human-donor 
counterparts (typically 30% vs. 5%). In spite of greater transfection efficiency in 
RMVECs however, the plasmid was unable to transfected in most of the cells in culture. 
We were still unable to deneddylate CUL3 with either JAB1 or dnUBC12 
overexpression. While these findings may be true, they may also be artifacts of 
insufficient transfection efficiencies.  In conclusion, while these models provide critical 
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insight into the molecular processes that regulate antioxidant responses, it is important to 
consider the limitations associated with them as results are interpreted.  
   
 6.3 Implications of Findings and Future Directions 
 
In recognizing that CS, a potent source of ROS (Rennard, Decramer et al. 2002) is 
the leading cause of COPD in the United States, and that MIF  is a determinant of 
emphysema in vivo, we have sought to determine MIF-dependent mechanisms of 
antioxidants regulation. In the present study, we have furthered our understanding of 
MIF’s function in the context of CS-induced oxidative stress. Taken together, our data 
shows MIF’s role as a mediator of antioxidant responses in the context of CS. 
Antioxidant capacity is depressed in patients with COPD and in smokers. Smoking 
cessation allows for the restoration of this protective capacity, but elevated levels of 
oxidative stress persist even in the absence of active CS exposure, implicating the role of 
diminished antioxidant capacity among other molecular processing in driving tissue 
destruction (Corradi, Rubinstein et al. 2003). CS has been shown to inhibit Nrf2 activity 
in mononuclear peripheral cells (Garbin, Fratta Pasini et al. 2009). Given the importance 
of oxidative stress in COPD, identifying the mechanisms that modulate Nrf2 expression 
and activity provides important insight into understanding disease pathogenesis. We have 
already identified MIF deficiency as a determinant of emphysematous tissue remodeling 
via its ability to impede EC apoptosis, but now shed light on its ability to positively 
regulate antioxidant responses in the context of CS.  
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 Future studies should be aimed to at furthering understanding of the mechanism 
by which MIF is positively regulating Nrf2. We have identified MIF’s novel role in 
stabilizing Nrf2 by antagonizing its proteasome-mediated degradation via its ability to 
regulate CAND1, a negative regulator of CRL. To date, expression and activity profiles 
of the CRL have not been well characterized in smokers and individuals with COPD. 
Therefore, future studies should be aimed at investigating the expression and activity 
profiles of these key regulators of proteasome-mediated degradation. Goven and 
colleagues did identify an altered Nrf2-KEAP1-Bach1 equilibrium that was coincident 
with a depressed antioxidant capacity phenotype in alveolar macrophages from patients 
with emphysema (Goven, Boutten et al. 2008).  Oxidative stress is an important driver of 
CS-induced emphysematous remodeling and Nrf2 expression and function are important 
in combating the effects of CS, therefore identifying modulators of antioxidants would 




 In conclusion, we demonstrate that MIF is a mediator of antioxidant responses in 
the context of CS-induced oxidative stress. It positively regulates antioxidant response by 
mediating Nrf2 stability in a proteasomal-dependent mechanism. MIF stabilizes Nrf2 by 
upregulating the CRL complex inhibitor, CAND1 and not through the established 
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